<!DOCTYPE html>
<html lang="en">

  <head>
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, user-scalable=no, initial-scale=0.95, maximum-scale=0.95, minimum-scale=0.95"/>
    <meta http-equiv="x-ua-compatible" content="IE=edge">
    <title>Liverpool HEP Interactions</title>
    <link rel="stylesheet" media="all" href="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/hep_site-0421400019db208b1d106efff149fed9f0abde6b5930375a0418530dea82296a.css" />
    <!--[if IE 8]>
        <script src="//cdnjs.cloudflare.com/ajax/libs/es5-shim/4.0.5/es5-shim.min.js"></script>
        <style>
            .ng-hide {
                display: none !important;
            }
        </style>
    <![endif]-->
    <script src="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/application-558b3c2a3e06dc8db0be037ca1d2b0a8b417b18dfe38e0d45ee242ed38ca7613.js"></script>
    
    <meta name="csrf-param" content="authenticity_token" />
<meta name="csrf-token" content="M1caHgNFjYuW5jTTTWMugwTN2yMW2DsO0D271nta+pTAPfJcyXw4ypkZFq7CGRhFXVpA45U5rQPkugvjkm4fQQ==" />
    
    <link rel="icon" href="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/hep-favicon-0b1de395e29b3378158cf3af166aecaffee33d4b3831cdfe5908d7917c8565ce.ico" sizes="32x32">
    <link rel="apple-touch-icon-precomposed" sizes="152x152" href="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/hep-favicon-152px-1430fb5312ef973e6b119c2b281f90d0208d4b734a435773ac3b59f7797e595b.png">
    <link rel="apple-touch-icon-precomposed" sizes="144x144" href="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/hep-favicon-144px-7d2608d25fd053e2cfeb500ca4a9bce13a8d16558b49fb4eabda5be913b46eed.png">
    <link rel="apple-touch-icon-precomposed" sizes="120x120" href="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/hep-favicon-120px-5b1fb865c26e0e656ddbf12ac38e48e8af3fb4b72c7389acd533780c39e99f53.png">
    <link rel="apple-touch-icon-precomposed" sizes="114x114" href="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/hep-favicon-114px-1a6eb8ec55928fd9ea04c5084b3a1be65ede2e88f81f0fe53b29d78765494a50.png">
    <link rel="apple-touch-icon-precomposed" sizes="72x72" href="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/hep-favicon-72px-f3ceebfb3662783b9d68a1dad0f7441022813b9cac39b26e0b7b4b732991bfde.png">
    <link rel="apple-touch-icon-precomposed" sizes="57x57" href="http://liverpool-web-herokuapp-com.global.ssl.fastly.net/assets/hep-favicon-57px-fa4ef22bdeaefb89df4be075b33c116f6b4c8499bff89c05a76eafb8fd19a7ec.png">
    <link href='http://fonts.googleapis.com/css?family=Varela+Round' rel='stylesheet' type='text/css'>
    <!-- start Mixpanel --><script type="text/javascript">(function(e,b){if(!b.__SV){var a,f,i,g;window.mixpanel=b;b._i=[];b.init=function(a,e,d){function f(b,h){var a=h.split(".");2==a.length&&(b=b[a[0]],h=a[1]);b[h]=function(){b.push([h].concat(Array.prototype.slice.call(arguments,0)))}}var c=b;"undefined"!==typeof d?c=b[d]=[]:d="mixpanel";c.people=c.people||[];c.toString=function(b){var a="mixpanel";"mixpanel"!==d&&(a+="."+d);b||(a+=" (stub)");return a};c.people.toString=function(){return c.toString(1)+".people (stub)"};i="disable time_event track track_pageview track_links track_forms register register_once alias unregister identify name_tag set_config people.set people.set_once people.increment people.append people.union people.track_charge people.clear_charges people.delete_user".split(" ");
for(g=0;g<i.length;g++)f(c,i[g]);b._i.push([a,e,d])};b.__SV=1.2;a=e.createElement("script");a.type="text/javascript";a.async=!0;a.src="undefined"!==typeof MIXPANEL_CUSTOM_LIB_URL?MIXPANEL_CUSTOM_LIB_URL:"file:"===e.location.protocol&&"//cdn.mxpnl.com/libs/mixpanel-2-latest.min.js".match(/^\/\//)?"https://cdn.mxpnl.com/libs/mixpanel-2-latest.min.js":"//cdn.mxpnl.com/libs/mixpanel-2-latest.min.js";f=e.getElementsByTagName("script")[0];f.parentNode.insertBefore(a,f)}})(document,window.mixpanel||[]);
mixpanel.init("cac4e9c0b9aef2c3bc30326ca7d1683f");</script><!-- end Mixpanel -->
    <!--[if lt IE 8]>
  <p class="browserupgrade">You are using an <strong>outdated</strong> browser. Please <a href="http://browsehappy.com/">upgrade your browser</a> to improve your experience.</p>
<![endif]-->

<!--[if lte IE 9]>
  <script src="https://cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv.min.js"></script>
<![endif]-->

    <script>
  (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
  (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
  m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
  })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

  ga('create', 'UA-75467942-2', 'auto');
  ga('send', 'pageview');
</script>

  </head>

  <body>
    <div class="header">
  <div class="inner-wrapper">
    <a class="logo" href="/">
      <p class="logo-icon"></p><p>HEP Drug Interactions</p>
</a>    <div class="header-right-column">
      <a href="https://www.liverpool.ac.uk/" target="_blank" class="uol-header-logo"></a>
          <div class="header-button-stack">
            <a href="https://alumni.liv.ac.uk/give-back/donate/drug-interactions-donation-page" target="_blank" class="header-right-column-button">
              <p>Donate Now</p>
              <p class="header-button-icon"></p>
            </a>

            <div class="apps-dropdown-nav-wrapper">
              <a href="#" class="header-right-column-button apps-dropdown-button">
                <p>Apps</p>
                <p class="header-button-icon"></p>
              </a>
                <div class="apps-dropdown-nav">
                  <a href="https://itunes.apple.com/gb/app/liverpool-hep-ichart/id960012821?mt=8" target="_blank" class="appstore-link">
                    <p class="icon"></p>
                    <p>Download from the AppStore</p>
                  </a>
                  <a href="https://play.google.com/store/apps/details?id=com.liverpooluni.icharthep&hl=en" target="_blank" class="google-play-link">
                    <p class="icon"></p>
                    <p>Download from Google Play</p>
                  </a>
                </div>
            </div>
          </div>


    </div>


    <a href="javascript:;" class="mobile-nav-icon">
      <p></p>
      <p></p>
      <p></p>
    </a>
    <a href="https://www.liverpool.ac.uk/" target="_blank" class="uol-header-logo mobile-uol"></a>

  </div>
</div>
<a class="mobile-interaction-link" href="/checker">
  <p>Interaction Checker</p>
  <p class="header-button-icon"></p>
</a><a href="https://alumni.liv.ac.uk/give-back/donate/drug-interactions-donation-page" target="_blank" class="mobile-interaction-link donate-mobile-link">
  <p>Donate Now</p>
  <p class="header-button-icon"></p>
</a>

<div class="navigation">
  <div class="inner-wrapper">


    <div class="drop-down-nav-wrapper">
      <a href="javascript:;">Interaction Charts</a>

      <div class="drop-down-nav interaction-charts">
        <a href="/checker">Interaction Checker</a>
        <a href="/drug_queries/new">Interaction Checker Lite</a>
        <a href="/view_all_interactions/new">View All Checker</a>
        <a href="/printable_charts">Printable Charts</a>
        
      </div>
    </div>

    <a href="/site_updates">Site Updates</a>
    <!--
    <div class="drop-down-nav-wrapper">
      <a href="javascript:;">Site News/Updates</a>
      <div class="drop-down-nav site-news">
        <a href="/articles">Latest Articles</a>
        <a href="/site_updates">Site Updates</a>
      </div>
    </div>
    -->



      <a href="/query">Interaction Query Service</a>



    <div class="drop-down-nav-wrapper">
      <a href="javascript:;">About Us</a>
      <div class="drop-down-nav about-drop-down">
        <a href="/mission">Mission Statement</a>
        <a href="/board">Editorial Board</a>
      </div>
    </div>

    <div class="drop-down-nav-wrapper">
      <a href="javascript:;">Pharmacology Resources</a>
      <div class="drop-down-nav resources-drop-down">
        <a href="/fact_sheets">Fact Sheets</a>
      </div>
    </div>

    <a href="/feedback">Contact Us</a>

    <a href="/support-us">Support Us</a>

  </div>
</div>

    <div class="row">
  <div class="col-lg-12">


  </div>
</div>

    <div class="inner-body-wrapper">
  <div class="inner-wrapper">

    <div class="interaction-block-single-page-wrapper">


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Abacavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration of ombitasvir/paritaprevir/ritonavir + dasabuvir and abacavir/lamivudine (600/300 mg once daily) was studied in 12 HIV/HCV-negative subjects and had no clinically significant effect on the pharmacokinetics of ombitasvir, paritaprevir, ritonavir, dasabuvir, abacavir or lamivudine. No dose adjustment is required for ombitasvir/paritaprevir/ritonavir + dasabuvir or abacavir during coadministration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration of ombitasvir/paritaprevir/ritonavir + dasabuvir and abacavir/lamivudine (600/300 mg once daily) was studied in 12 HIV/HCV-negative subjects. During coadministration abacavir exposures were up to 13% lower; lamuvidine Cmax and AUC were up to 13% lower and Ctrough was 29% higher. Exposure of ombitasvir and dasabuvir were up to 18% lower, and paritaprevir and ritonavir Ctrough both decreased by 34%. No dose adjustment is recommended for ombitasvir/paritaprevir/ritonavir + dasabuvir or abacavir/lamuvudine during coadministration.<br /><em>Drug-drug interactions of ombitasvir/paritaprevir/r plus dasabuvir with dolutegravir or abacavir plus lamivudine.<br />Khatn A, Trinh R, Zhao W, et al. 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington DC, May 2015, Abstract 57.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Acamprosate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as acamprosate does not undergo significant metabolism.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Acarbose</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. After ingestion of acarbose the majority of active unchanged drug remains in the lumen of the gastrointestinal tract to exert its pharmacological effect and is metabolised by intestinal enzymes and by the gut microflora.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Acebutolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Acebutolol can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Acebutolol is mainly excreted in the urine as diacetolol and is substrate of P-gp in vitro. No significant interaction was observed with digoxin (a model P-gp substrate) and ombitasvir/paritaprevir/ritonavir + dasabuvir</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Acenocoumarol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Acenocoumarol is a substrate of CYP2C9 and CYP1A2. Ombitasvir/paritaprevir/ritonavir at steady-state did not affect the plasma exposures of the anticoagulant warfarin which is metabolised in a similar way. However, a case report describes a patient who required a significant increase in acenocoumarol weekly dose probably due to an interaction with ombitasvir/paritaprevir/ritonavir and/or dasabuvir. Ombitasvir/paritaprevir/ritonavir and acenocoumarol can be coadministered but with close monitoring of international normalized ratio (INR) as dose modifications may be necessary in some patients.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>A case was reported of a patient who required a significant increase in acenocoumarol weekly dose probably due to an interaction with ombitasvir/paritaprevir/ritonavir and/or dasabuvir. A causality assessment of the drug-drug interaction leading to a reduced INR was conducted according to the Naranjo algorithm. A score of 6 suggested that the adverse drug reaction was probable. Because of possible INR abnormalities during the concomitant use of acenocoumarol, ombitasvir/paritaprevir/ritonavir and dasabuvir, clinicians should closely monitor INR values.<br><em>Decreased INR after acenocoumarol, ombitasvir/paritaprevir/ritonavir and dasabuvir co-administration. de Lorenzo-Pinto A, Giménez-Manzorro Á, Rodríguez-González CG, et al. J Clin Pharm Ther. 2016 Aug;41(4):444-446.</em></p>

</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Acetazolamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but a clinically significant interaction is unlikely as acetazolamide is excreted unchanged in urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Aciclovir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but aciclovir can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Aciclovir is mainly excreted in urine</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Acitretin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as acitretin undergoes isomerization and conjugation by UGT1A9. Ombitasvir/paritaprevir/ritonavir + dasabuvir is not known to affect this enzyme.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Adefovir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as adefovir undergoes renal elimination.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Agomelatine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as agomelatine is metabolized predominantly by CYP1A2. Note,&nbsp;agomelatine is contraindicated in hepatic impairment as increases in exposure of 140-fold have been seen in cirrhotic patients.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Albendazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but may reduce the clinical effect of albendazole. Coadministration with ritonavir alone (200 mg twice daily) decreased the AUC of albendazole and the active metabolite albendazole sulfoxide by 73% and 59%, respectively, with Cmax decreasing by 74% and 48%, respectively.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Albiglutide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Albiglutide delays gastric emptying and therefore may affect absorption of concomitantly administered oral medicinal products. The clinical effect of this is unknown.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Alendronic acid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but alendronate can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Alendronate is not metabolised and is cleared from the plasma by uptake into bone and elimination via renal excretion. Although no pharmacokinetic interaction is expected, note that alendronate should be separated from food or other medicinal products and therefore should be separated from ombitasvir/paritaprevir/ritonavir + dasabuvir administration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Alfentanil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but alfentanil concentrations may be increased since it is a substrate of CYP3A4. Careful monitoring of therapeutic response and adverse effects (including respiratory depression) is recommended, especially at initiation of treatment. A dosage adjustment of alfentanil may be required.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Alfuzosin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration is contraindicated. Alfuzosin is a substrate and inhibitor of CYP3A4. Exposure may increase due to CYP3A4 inhibition by ritonavir causing potential hypotension.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Concomitant use is contraindicated. Coadministration has not been studied but is expected to increase alfuzosin concentrations due to inhibition of CYP3A by ritonavir. Medicinal products that are highly dependent on CYP3A for clearance and for which elevated plasma levels are associated with serious events, such as alfuzosin, must not be co-administered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div><div>&nbsp;</div></div><div>Coadministration is contraindicated due to the potential for hypotension.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Aliskiren</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration of aliskiren with P-gp inhibitors (such as ritonavir) is not recommended. Aliskiren is transported by P-gp and shows a 5-6 fold increase in exposure with itraconazole 100 mg twice daily (a CYP3A4 and P-gp inhibitor). A similar interaction is expected with ombitasvir/paritaprevir/ritonavir + dasabuvir. The aliskiren label recommends avoiding concomitant use with CYP3A4 and P-gp inhibitors.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Allopurinol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but allopurinol can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Allopurinol is a substrate of xanthine oxidase and no interaction is expected. Note,&nbsp;the European SPC and US Prescribing Information for allopurinol recommend a&nbsp;reduced dose in hepatic impairment.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Almotriptan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. In vitro studies indicate a minor role for CYP3A4 and CYP2D6 in the metabolism of almotriptan. It is possible that coadministration with ombitasvir/paritaprevir/ritonavir + dasabuvir may increase almotriptan concentrations through inhibition by ritonavir and clinical monitoring for an increase in side effects is suggested. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Aloe vera</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Aloe vera is only a weak inhibitor of CYPs in vitro and therefore is unlikely to cause clinically significant interactions. It does not inhibit P-gp and there is no evidence to suggest it impacts UGTs.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Alogliptin </p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Alogliptin does not undergo extensive metabolism and is excreted mainly unchanged in the urine and metabolism by CYPs is minimal. No transporter interactions have been described.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Alprazolam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration increased alprazolam AUC by 34% with no significant effect on exposures of ombitasvir, paritaprevir, ritonavir or dasabuvir. Clinical monitoring of patients is recommended. A decrease in dose may be considered based on clinical response.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Coadministration with alprazolam (0.5 mg single dose) increased alprazolam Cmax and AUC by 9% and 34% due to inhibition of CYP3A4 by ritonavir. Ombitasvir Cmax and Cmin both decreased by 2% and there was no change in AUC. Paritaprevir Cmax and AUC decreased by 9% and 4% with Cmin increasing by 12%. Dasabuvir Cmax and AUC decreased by 7% and 2% and there was no change in Cmin. Clinical monitoring of patients is recommended. A decrease in alprazolam dose can be considered based on clinical response.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em><br /><br /></div>Coadministration with alprazolam (0.5 mg single dose) was studied in 12 subjects. Ombitasvir Cmax and Cmin both decreased by 2% and there was no change in AUC. Paritaprevir Cmax and AUC decreased by 9% and 4% with Cmin increasing by 12%. Ritonavir Cmax and AUC decreased by 8% and 4%, with Cmin increasing by 1%. Dasabuvir Cmax and AUC decreased by 7% and 2% and there was no change in Cmin. Alprazolam Cmax and AUC increased by 9% and 34%. Clinical monitoring of patients is recommended. A decrease in alprazolam dose can be considered based on clinical response.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Aluminium hydroxide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but antacids can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. DAA exposures were not affected in the presence of an acid reducing agent such as omeprazole or metal chelators.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Alverine citrate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on limited understanding of metabolism and clearance a clinically significant interaction is unlikely. However as alverine citrate affects gastric motility, an effect on the absorption of ombitasvir/paritaprevir/ritonavir + dasabuvir cannot be ruled out. Doses of ombitasvir/paritaprevir/ritonavir + dasabuvir and alverine should be separated by 4 hours if possible.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Amantadine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as amantadine is only metabolized to a minor extent (principally N-acetylation) and is largely excreted unchanged in urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ambrisentan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but may increase ambrisentan concentrations due to inhibition of CYP3A4 and P-gp. The clinical significance of this is unknown and in the absence of further data, monitor for increased ambrisentan side effects.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Amikacin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as amikacin is largely excreted unchanged in urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Amiloride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but amiloride can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Amiloride is not metabolised by the liver with approximately 50% of an oral dose excreted in urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Amiodarone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Amiodarone is a substrate of CYP3A4 and exposure may increase due to CYP3A4 inhibition by ritonavir causing potential cardiac arrhythmias. Coadministration is contraindicated in the European product label, but the US product label advises caution and monitoring of the subjects. These interaction charts reflect the more cautious option.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Concomitant use is contraindicated. Coadministration has not been studied by is expected to increase amiodarone concentrations due to inhibition of CYP3A4 by ritonavir. Medicinal products that are highly dependent on CYP3A for clearance and for which elevated plasma levels are associated with serious events, such as amiodarone, must not be co-administered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div>&nbsp;</div><div>Coadministration may increase concentrations of this antiarrhythmic. Caution is warranted and therapeutic concentration monitoring (if available) is recommended for antiarrhythmics when co-administered.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Amisulpride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as amisulpride is largely excreted unchanged in urine and undergoes relatively little metabolism.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Amitriptyline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but amitriptyline can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Amitriptyline is a substrate of CYP2D6 and CYP2C19. Ritonavir inhibits CYP2D6 at higher doses but at the 100 mg dose it does not appear to markedly inhibit CYP2D6. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Amlodipine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Amlodipine is a substrate of CYP3A4 and coadministration increased amlodipine AUC by  2.6-fold. Caution is warranted. Consider a dose reduction for amlodipine (a dose reduction of 50% is recommended in the European SPC). Clinical monitoring of patients is recommended.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Coadministration with amlodipine (5 mg single dose) increased amlodipine Cmax by 26% and increased AUC by 2.57-fold. There was no change ombitasvir Cmax, AUC or Cmin. Paritaprevir Cmax, AUC and Cmin decreased by 23%, 22% and 12%, respectively. Dasabuvir Cmax and AUC increased by 5% and 1%, and Cmin decreased by 5%. Decrease amlodipine dose by 50% and monitor patients for clinical effects.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015</em>.</div></div><div>&nbsp;</div><div>Coadministration with amlodipine (5 mg single dose) was studied in 14 subjects. There was no change in Cmax, AUC or Cmin of ombitasvir. Paritaprevir Cmax, AUC and Cmin decreased by 23%, 22% and 12%, respectively. Ritonavir Cmax, AUC and Cmin decreased by 4%, 7% and 5%, respectively. Dasabuvir Cmax and AUC increased by 5% and 1% but Cmin decreased by 5%. Amlodipine Cmax and AUC increased by 26% and 2.57-fold. Consider dose reduction for amlodipine. &nbsp;Clinical monitoring is recommended.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Amodiaquine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Amodiaquine is a substrate of CYP2C8. No interaction with is expected with ombitasvir/paritaprevir/ritonavir + dasabuvir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Amoxicillin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but amoxicillin can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Amoxicillin is mainly excreted in the urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Amphetamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Ritonavir inhibits CYP2D6 at higher doses but at the 100 mg dose it does not appear to markedly inhibit CYP2D6. However, as dosing of recreational drugs can be variable, caution is advised.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Amphotericin B</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but amphotericin B can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Amphotericin B is mainly excreted in the urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ampicillin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but ampicillin can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Ampicillin is mainly excreted in the urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Anagrelide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Angarelide is metabolised by CYP1A2 and concentrations may decrease due to induction of CYP1A2 by ritonavir. Monitor for efficacy and consider a dose increase if clinically indicated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Anastrozole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Anastrozole is metabolized by multiple enzyme pathways and a clinically significant interaction is not expected.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Anidulafungin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as anidulafungin is not hepatically metabolized.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Antacids</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but antacids can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. DAA exposures were not affected in the presence of an acid reducing agent such as omeprazole or metal chelators.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Apixaban</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied and is not recommended. Concentrations of apixaban are expected to increase due to potent CYP3A4 and P-gp inhibition by ritonavir. Increased concentrations of apixiban increase the bleeding risk and the combination should be avoided if possible. No effect on ombitasvir/paritaprevir/ritonavir + dasbuvir is expected.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Aprepitant</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Aprepitant is a substrate, inhibitor and inducer of CYP3A4 and also inhibits CYP2C9. Aprepitant exposure may increase due to CYP3A4 inhibition by ritonavir and exposure of ombitasvir/paritaprevir/ritonavir + dasabuvir may decrease due to CYP3A4 induction by aprepitant. Monitor the subjects. A decrease in aprepitant dose may be needed.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Aripiprazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Aripiprazole is a substrate of CYP3A4 and CYP2D6. Aripiprazole exposure may increase due to CYP3A4 inhibition by ritonavir. Monitor the subjects. A decrease in aripiprazole dose may be needed. The aripiprazole label suggests decreasing the dose by one-half when administered with CYP3A4 inhibitors like ketoconazole.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Artemether</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Artemether is a substrate of CYP3A4 and exposure may increase due to CYP3A4 inhibition by ritonavir. Monitor for increased side effects.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Artemisinin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Artemisinin induces CYP3A4 and there is the possibility of a decrease in exposure of ombitasvir/paritaprevir/ritonavir + dasabuvir although it is difficult to judge the clinical relevance.  Monitor for therapeutic effect.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Artesunate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Dihydroartemisinin (the active metabolite of artesunate) induces CYP3A4 and there is the possibility of a decrease in exposure of ombitasvir/paritaprevir/ritonavir + dasabuvir although it is difficult to judge the clinical relevance. Monitor for therapeutic effect.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ascorbic acid (Vitamin C)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as ascorbic acid is largely hydrolysed to salicylic acid followed by conjugation with either glycine or glucuronic acid.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Aspirin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but aspirin can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Aspirin is metabolised by deacetylation and UGT2B7 conjugation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Astemizole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration is contraindicated in the European product label due to the potential for serious and/or life threatening reactions such as cardiac arrhythmias. Astemizole is a substrate of CYP3A4 and exposure may increase due to CYP3A4 inhibition by ritonavir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Concomitant use is contraindicated. Coadministration has not been studied but is expected to increase astemizole concentrations due to inhibition of CYP3A4 by ritonavir. Medicinal products that are highly dependent on CYP3A for clearance and for which elevated plasma levels are associated with serious events, such as astemizole, must not be co-administered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Atazanavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Atazanavir should be taken without ritonavir or cobicistat&nbsp;with ombitasvir/paritaprevir/ritonavir + dasabuvir since ritonavir is included in the regimen. Cobicistat or additional ritonavir is not recommended with atazanavir and&nbsp;ombitasvir/paritaprevir/ritonavir + dasabuvir.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Coadministration with atazanavir (300 mg once daily, given at the same time) decreased atazanavir Cmax and Cmin by 9% and 10%, but increased AUC by 1%. Ombitasvir Cmax, AUC and Cmin decreased by 23%, 17% and 11%. Paritaprevir Cmax and AUC increased by 46% and 94% and Cmin increased by 3.26-fold. Dasabuvir Cmax, AUC and Cmin decreased by 17%, 18% and 21%, respectively. The increase in paritaprevir exposures may be due to inhibition of OATP1B1/B3 and CYP3A by atazanavir. Coadministration with atazanavir/ritonavir (300/100 mg once daily administered 12 hour apart) increased atazanavir Cmax, AUC and Cmin by 2%, 19% and 68%, respectively. Ombitasvir Cmax and AUC decreased by 17% and 10% and there was no change in Cmin. Paritaprevir Cmax, AUC and Cmin increased by 2.19-, 3.16- and 11.95-fold, respectively. Dasabuvir Cmax, AUC and Cmin decreased by 19%, 19% and 20%, respectively. The increase in paritaprevir exposures may be due to inhibition of OATP1B1/B3 and CYP3A by atazanavir and CYP3A by the additional dose of ritonavir. The recommended dose of atazanavir is 300 mg, without ritonavir and must be administered at the same time as ombitasvir, paritaprevir, ritonavir and dasabuvir. Atazanavir should be taken without (additional) ritonavir, since ritonavir 100 mg once daily is provided as part of Viekirax. The combination carries an increased risk for hyperbilirubinemia (including ocular icterus), in particular when ribavirin is part of the hepatitis C regimen.<br><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br>Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div>&nbsp;</div>

<div>Coadministration with atazanavir/ritonavir (300/100 mg once daily in the evening) was studied in 11 subjects. Ombitasvir Cmax and AUC decreased by 17% and 10% and there was no change in Cmin. Paritaprevir Cmax, AUC and Cmin increased by 2.19-, 3.16- and 11.95-fold, respectively. Ritonavir Cmax increased by 60% and AUC and Cmin increased by 3.18- and 24.65-fold. Dasabuvir Cmax, AUC and Cmin decreased by 19%, 19% and 20%, respectively. Atazanavir Cmax, AUC and Cmin increased by 2%, 19% and 68%, respectively. When coadministered, atazanavir 300 mg (without ritonavir) should only be given in the morning.</div>

<div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Atenolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but atenolol can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Atenolol is mainly excreted in urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Atomoxetine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Atomoxetine is a substrate of CYP2D6 but at 100 mg dose, ritonavir does not markedly inhibit CYP2D6. Atomoxetine's active metabolite, 4-hydroxyatomoxetine, is a substrate of UGT and, theoretically, its exposure may increase due to UGT inhibition by ombitasvir/paritaprevir/ritonavir + dasabuvir. Monitor the subjects. A decrease in atomoxetine dose may be needed.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Atorvastatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration is contraindicated in the European product label. Coadministration has not been studied. Atorvastatin is a substrate of CYP3A4 and OATP1B1 and its exposure may increase due to CYP3A4 inhibition by ritonavir and OATP1B1 by paritaprevir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Concomitant use is contraindicated. Coadministration has not been studied but is expected to increase concentrations of atorvastatin due to inhibition of CYP3A4 and OATP1B. Medicinal products that are highly dependent on CYP3A for clearance and for which elevated plasma levels are associated with serious events, such as atorvastatin, must not be co-administered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Atovaquone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Atovaquone exposure may decrease when co-administered with ritonavir. The co-administration of lopinavir/ritonavir with atovaquone led to a decrease in atovaquone AUC of 74%. Monitor the subjects. An increase in atovaquone dose may be needed.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Atropine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Atropine metabolism has not been well described but is thought to be by oxidation and conjugation to inactive metabolites and up to 50% is excreted unchanged by the kidneys. A clinically significant interaction is unlikely; however, by possibly delaying gastric emptying, atropine may alter the absorption of ombitasvir/paritaprevir/ritonavir + dasabuvir but the clinical significance of this is unknown.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Azathioprine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but azathioprine can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. There is no overlap of metabolic pathways, so no interaction is expected. However note that azathioprine has an interaction with ribavirin such that if ribavirin is part of the regimen it is important to refer to the summary information given for ribavirin and azathioprine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Azilsartan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Azilsartan can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Azilsartan is a substrate of CYP2C9 but there was no interaction between ombitasvir/paritaprevir/ritonavir + dasabuvir and warfarin, a CYP2C9 substrate. Therefore, no interaction is expected with azilsartan.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Azithromycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Azithromycin may theoretically interact with the paritaprevir component of ombitasvir/paritaprevir/ritonavir + dasabuvir via MRP2 but no dose alteration is required.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Aztreonam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Aztreonam is only minimally metabolised and is eliminated mainly unchanged in the urine.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Baclofen</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but baclofen can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Baclofen is mainly excreted in the urine or deaminated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Basilixumab</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Basiliximab is an immunoglobulin and no metabolic drug-drug interactions are expected. Extensive studies have been carried out with concomitant medication showing no adverse effects.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Beclometasone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but beclometasone can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Beclometasone is metabolised by hydrolysis to beclometasone 17-monopropionate in vivo although it is a substrate of CYP3A4 in vitro. No evidence of adrenal suppression was observed with either darunavir/ritonavir or ritonavir and beclometasone.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Benazepril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Benazepril is a substrate of UGTs (the specific UGTs have not been well described) and its exposure may increase due to UGT inhibition by ombitasvir/paritaprevir/ritonavir + dasabuvir. The exposure of raltegravir (a UGT substrate) was increased by up to 2-fold with ombitasvir/paritaprevir/ritonavir + dasabuvir; a similar interaction is possible with other UGT substrates. In the absence of further data, monitor cardiac parameters and for increased side effects.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Bendroflumethiazide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Bendroflumethiazide is mainly eliminated by hepatic metabolism, although the exact pathway is not known. It is unlikely that CYP enzymes are involved in this process and no transporter interactions have been described.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Benztropine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Benztropine is primarily metabolised by CYP2D6, with minor involvement from CYP3A4. Ritonavir inhibits CYP2D6 at higher doses but at the 100 mg dose ritonavir does not markedly inhibit CYP2D6.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See&nbsp;Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Benzylpenicillin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but benzylpenicillin can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Benzylpenicillin is mainly excreted in the urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Bepridil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Do not coadminister unless unavoidable. Bepridil is a substrate of CYP3A4 and exposure may markedly increase due to CYP3A4 inhibition by ritonavir resulting in the potential for serious and/or life threatening reactions such as cardiac arrhythmias. If coadministration is warranted, use with caution and therapeutic concentration monitoring (if available) is recommended.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration may increase concentrations of this antiarrhythmic. Caution is warranted and therapeutic concentration monitoring (if available) is recommended for antiarrhythmics when co-administered.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Betamethasone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Betamethasone is a substrate of CYP3A4 and concentrations may increase due to inhibition of CYP3A4 by ritonavir, leading to an increased risk of corticosteroid side effects. A significant betamethasone dose reduction is recommended. Monitor the subject closely for corticosteroid side effects.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Bezafibrate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Bezafibrate is metabolised by hydroxylation, glucuronidation and renal elimination (~50%). Due to involvement of multiple metabolic pathways and renal elimination, a clinically significant interaction is not expected with ombitasvir/paritaprevir/ritonavir + dasabuvir Note,&nbsp;the European SPC for bezafibrate contraindicates its use in significant hepatic disease.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Bilastine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but bilastine can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Bilastine is not significantly metabolized and is mainly excreted in the urine. In-vitro studies show that bilastine is a substrate of P-gp, but as there is no significant interaction between ombitasvir/paritaprevir/ritonavir + dasabuvir and digoxin (a model P-gp substrate), no potential interaction due to P-gp involvement is expected with bilastine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Bisacodyl</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Bisacodyl increases colonic mass movements and may affect absorption of ombitasvir/paritaprevir/ritonavir + dasabuvir. The potential interaction can be resolved by giving bisacodyl at least 4 hours after ombitasvir/paritaprevir/ritonavir + dasabuvir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Bisoprolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Bisoprolol is a substrate of CYP3A4 and its exposure may increase due to CYP3A4 inhibition by ritonavir. Monitor the subjects. A decrease in bisoprolol dose may be needed.&nbsp;Note, the European product label for bisoprolol recommends a maximum of 10 mg in severe hepatic impairment;&nbsp;the US Prescribing Information recommends an initial 2.5 mg in hepatic impairment with caution in further dose titration.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Boceprevir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Ombitasvir/paritaprevir/ritonavir + dasabuvir is a complete regimen. There are no data to support the coadministration with other DAAs.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>The safety and efficacy of ombitasvir/paritaprevir/ritonavir have been established in combination with dasabuvir and/or ribavirin. Co-administration of ombitasvir/paritaprevir/ritonavir + dasabuvir with other directly acting antivirals has not been studied and therefore cannot be recommended.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em><br /></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Bortezomib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but may increase bortezomib concentrations due to inhibition of CYP34 by ritonavir. Coadministration with ketoconazole, a potent CYP3A4 inhibitor, increased bortezomib AUC by 35%. Therefore, patients should be closely monitored when given bortezomib with potent CYP3A4 inhibitors. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Bosentan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Avoid use of bosentan with ombitasvir/paritaprevir/ritonavir + dasabuvir. Bosentan is a substrate of CYP3A4 and CYP2C9, and OATPs 1B1 and 1B3. Bosentan exposure increased 30-fold when administered with cyclosporine, an OATP1B1 inhibitor. Paritaprevir is also an OATP1B1 inhibitor and a similar interaction is expected with ombitasvir/paritaprevir/ritonavir + dasabuvir. Bosentan exposure increased 5-fold and metabolite levels were undetectable due to CYP3A4 inhibition by ritonavir resulting in severe headache, nausea, vomiting, and liver problems. Thus, in addition to the OATP1B interaction potential, there is also CYP3A4 interaction potential. Use an alternative to bosentan.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Brivudine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as brivudine is an analog of thymidine and is incorporated into viral DNA. The metabolism of brivudine is poorly described but to date there is no evidence of CYP or P-gp involvement.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Bromazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but bromazepam can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Bromazepam is a substrate of CYP1A2 and CYP2D6. The pharmacokinetics and pharmacodynamics of bromazepam were not affected by itraconazole, suggesting that CYP3A4 is not involved in the metabolism of bromazepam to a major extent. Thus, no interaction is expected with ritonavir. There is also no interaction between ombitasvir/paritaprevir/ritonavir + dasabuvir and warfarin, a CYP2C9/CYP1A2 substrate. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Bromocriptine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Bromocritpine is a substrate of CYP3A4 and concentrations may increase due to inhibition of CYP3A4 by ritonavir. Monitor the subjects. A decrease in bromocriptine dose may be needed.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Bromperidol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Bromperidol is metabolised by CYP3A4 and concentrations may increase due to inhibition of CYP3A4 by ritonavir. Monitor for signs and symptoms of increased concentrations.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See&nbsp;Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Budesonide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Concomitant administration of ritonavir and glucocorticoids is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects. Cushing's syndrome and adrenal suppression have been reported when ritonavir has been co-administered with inhaled or intranasally administered budesonide. Use beclometasone as an alternative. Budesonide is a substrate and inhibitor of CYP3A4 and its exposure may increase due to CYP3A4 inhibition by ritonavir causing a decrease in plasma cortisol leading to Cushing's syndrome. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Bumetanide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as bumetanide is mainly excreted in the urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Bupivacaine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Bupivacaine is metabolised by UGT1A1, CYP1A2 and CYP3A4, and amide hydrolysis. Due to the involvement of UGT1A1 and CYP3A4 an increase in bupivacaine concentrations may occur. Monitor clinically and consider dose reduction.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Buprenorphine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration with buprenorphine (4-24 mg once daily) and naloxone (1-6 mg once daily) increased buprenorphine Cmax, AUC and Cmin by 2.18-, 2.07- and 3.12-fold, respectively; values for norbuprenorphine increased by 2.07-, 1.84- and 2.10-fold, respectively. There was no change in exposure of ombitasvir, paritaprevir or dasabuvir based on cross-study comparison. No a priori dose modification is required but patients should be closely monitored for sedation and cognitive effects.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Coadministration with buprenorphine (4-24 mg once daily) and naloxone (1-6 mg once daily) increased buprenorphine Cmax, AUC and Cmin by 2.18-, 2.07- and 3.12-fold, respectively; values for norbuprenorphine increased by 2.07-, 1.84- and 2.10-fold, respectively. Naloxone Cmax and AUC increased by 18% and 28%. (Dose normalised parameters reported for buprenorphine and naloxone.) The increases were due to CYP3A4 inhibition by ritonavir and UGT inhibition by paritaprevir, ombitasvir and dasabuvir. There was no change in exposure of ombitasvir, paritaprevir or dasabuvir based on cross-study comparison. No dose adjustment is necessary.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em><br /><br /></div>Coadministration with buprenorphine (4-24 mg once daily) and naloxone (1-6 mg once daily) was studied in 10 subjects. Cmax, AUC and Cmin of buprenorphine increased by 2.18-, 2.07- and 3.12-fold, respectively; values for norbuprenorphine increased by 2.07-, 1.84- and 2.10-fold, respectively. Naloxone Cmax and AUC increased by 18% and 28%. No dose adjustment of buprenorphine/naloxone is required upon co-administration. Patients should be closely monitored for sedation and cognitive effects.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Bupropion</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. No interaction was observed between ombitasvir/paritaprevir/ritonavir + dasabuvir and methadone (CYP2B6 substrate). Hence, it is not expected to interact with other CYP2B6 substrates. Short-term ritonavir (200 mg; 4 doses over 2 days) dosing has only minimal impact on the pharmacokinetics of bupropion while long term administration of low dose ritonavir (100 mg twice daily) doses has shown only ≤22% decrease in bupropion exposures. However, monitor the subjects and adjust bupropion dose if clinically indicated. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Buspirone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but may increase concentrations of buspirone due to inhibition of CYP3A4 by ritonavir. Using the lowest dose possible of buspirone is recommended, starting at 2.5mg. Monitor for increased side effects such as impaired psychomotor performance, nausea, vomiting, dizziness, drowsiness and miosis and decrease dose if symptomatic. Use with caution in cirrhosis.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Calcitonin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Calcitonin is metabolised primarily via proteolysis in the kidney.and to date no clinically significant interactions have been published that would be of concern.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Calcium resonium</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as calcium resonium is not absorbed.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Canagliflozin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Canagliflozin is a substrate of UGTs and P-gp and its exposure may increase due to inhibition of UGTs by ombitasvir/paritaprevir/ritonavir + dasabuvir. There was no interaction between ombitasvir/paritaprevir/ritonavir + dasabuvir and digoxin, a model P-gp substrate and any effect on canaglifoxin due to inhibition of P-gp is not considered likely. Monitor blood glucose.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Candesartan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Candesartan is mainly excreted in urine and is a substrate of OATP1B1. Candesartan exposure may increase due to OATP1B1 inhibition by the paritaprevir and ritonavir components of ombitasvir/paritaprevir/ritonavir + dasabuvir. Consider dose reduction and monitor blood pressure and heart rate.&nbsp;Note, use of candesartan in severe hepatic impairment is contraindicated in the European SPC;&nbsp;the US Prescribing Information recommends caution in moderate hepatic impairment.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Cannabis</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Tetrahydrocannabinol (THC, the psychoactive component of cannabis) is metabolised mainly by CYP2C9 and to a lesser extent by CYP3A4. Coadministration with ombitasvir/paritaprevir/ritonavir + dasabuvir may increase concentrations of THC by ritonavir inhibition of CYP3A4. The patient should be made aware of potential increased side effects. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Capecitabine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Capecitabine is a substrate of CYP2C9. There was no interaction between and warfarin, a CYP2C9 substrate, and ombitasvir/paritaprevir/ritonavir + dasabuvir, so no interaction is expected due to CYP2C9 involvement.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Capreomycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as capreomycin is mainly excreted in the urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Captopril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but captopril can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Captopril is metabolised by sulfation and approximately 40-50% is excreted in the urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Carbamazepine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration is contraindicated. Carbamazepine is a substrate and inducer of CYPs 3A4, 2C8 and 1A2. Ombitasvir/paritaprevir/ritonavir + dasabuvir exposures show significant decreases when administered with carbamazepine which may lead to virologic failure.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Co-administration with medicinal products that are strong or moderate enzyme inducers, such as carbamazepine, is expected to decrease ombitasvir, paritaprevir, and ritonavir plasma concentrations and reduce their therapeutic effect and must not be co-administered. Coadministration with carbamazepine (200 mg twice daily) increased carbamazepine Cmax, AUC and Cmin by 10%, 17% and 35%, respectively, with the Cmax, AUC and Cmin of the metabolite carbamazepine-10,11-epoxide decreasing by 16%, 25% and 43%, respectively. Ombitasvir Cmax and AUC both decreased by 31%. Paritaprevir Cmax and AUC decreased by 66% and 70%. Dasabuvir Cmax and AUC decreased by 55% and 70%.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015</em>.<br /><br /></div>Coadministration is contraindicated. Coadministration with carbamazepine (200 mg twice daily) was studied in 12 subjects. Ombitasvir Cmax and AUC both decreased by 31%. Paritaprevir Cmax and AUC decreased by 66% and 70%. Ritonavir Cmax and AUC decreased by 83% and 87%. Dasabuvir Cmax and AUC decreased by 55% and 70%. Carbamazepine Cmax, AUC and Cmin increased by 10%, 17% and 35%, respectively, with the Cmax, AUC and Cmin of the metabolite carbamazepine-10,11-epoxide decreasing by 16%, 25% and 43%, respectively. The decrease in ombitasvir, paritaprevir, ritonavir and dasabuvir exposures may lead to a potential loss of therapeutic activity of Viekira Pak&#174;.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Carbidopa</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Carbidopa is partly metabolized and partly eliminated unchanged (30% of the total urinary excretion).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Carbimazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Carbimazole is a pro-drug which undergoes rapid and virtually complete metabolism to the active metabolite, thiamazole (methimazole). There is little evidence of marked interactions with this drug.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Carboplatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Carboplatin is excreted primarily by renal glomerular filtration. In vitro studies have shown that carboplatin does not significantly inhibit cytochrome P450 metabolic enzymes.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Carisoprodol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Carisoprodol is a substrate of CYP2C19 and its exposure may decrease due to CYP2C19 induction by ritonavir. Exposure of omeprazole, a model CYP2C19 substrate, decreased by ~50% when administered with ombitasvir/paritaprevir/ritonavir + dasabuvir, but exposures of each component of the DAA regimen were not affected. An interaction of similar magnitude is expected with other CYP2C19 substrates. If coadministered, a higher dose of carisoprodol can be considered, if clinically indicated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Carvedilol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Carvedilol undergoes glucuronidation via UGTs 1A1, 2B4 and 2B7 and additionally metabolism via CYP2D6 and to a lesser extent CYPs 2C9 and 1A2. The net effect on carvedilol concentrations is difficult to predict. Ombitasvir/paritaprevir/ritonavir + dasabuvir could potentially increase carvedilol concentrations. Monitor clinical effect.&nbsp;Note, the US Prescribing Information contraindicates carvedilol in patients with severe liver impairment and the European SPC contraindicates it in patients with hepatic dysfunction.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Caspofungin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely as caspofungin undergoes spontaneous chemical degradation and non-CYP medicated metabolism. Note, no dose adjustment is required in patients with normal hepatic function but a dose reduction of caspofungin daily dose to 35 mg is recommended for adults with moderate hepatic impairment. There is no clinical experience in adults with severe hepatic impairment.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Cefaclor</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Cefaclor is predominantly eliminated unchanged by the kidneys.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Cefadroxil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Cefadroxil is not metabolised and is predominantly eliminated unchanged by the kidneys.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Cefalexin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but cefalexin can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Cefalexin is mainly excreted in urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Cefazolin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but cefazolin can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Cefazolin is mainly excreted in urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Cefixime</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but cefixime can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Cefixime is mainly excreted in urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Cefotaxime</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but cefotaxime can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Cefotaxime is mainly excreted in urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Cefradine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Cefradine is not metabolised and is predominantly eliminated unchanged by the kidneys.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ceftaroline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Ceftaroline is not metabolised by CYP enzymes and is primarily eliminated by the kidneys.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See&nbsp;Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ceftazidime</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but ceftazidime can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Ceftazidime is mainly excreted in urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ceftriaxone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but ceftriaxone can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Ceftriaxone is mainly excreted in urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Cefuroxime</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but cefuroxime can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Cefuroxime is mainly excreted in urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Celecoxib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but celecoxib can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Celecoxib is a substrate of CYP2C9. There was no interaction between ombitasvir/paritaprevir/ritonavir + dasabuvir and warfarin, a CYP2C9 substrate so no interaction is expected with celecoxib.&nbsp;Note, use in patients with severe liver impairment is contraindicated in the European SPC and not recommended in the US Prescribing Information. In patients with moderate liver impairment (serum albumin 25-35 g/L, Child-Pugh Class B), celecoxib&nbsp;treatment should be started at half the recommended dose.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Celiprolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but celiprolol can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Celiprolol is mainly excreted unchanged in urine and faeces.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Cetirizine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but cetirizine can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Cetirizine is metabolised only to a limited extent and is eliminated unchanged in the urine by glomerular filtration and tubular secretion. Cetirizine is also transported by P-gp but as there is no significant interaction between ombitasvir/paritaprevir/ritonavir + dasabuvir and digoxin (a model P-gp substrate), no potential interaction due to P-gp involvement is expected with cetirizine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Chlorambucil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but a clinically significant interaction is considered unlikely. Very little has been described about chlorambucil metabolism in humans but CYP450 enzymes are not involved.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Chloramphenicol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Chloramphenicol eye drops can be used for short term treatment. Chloramphenicol is an inhibitor of CYP2C19 and CYP3A4, and is mainly excreted in urine. Inhibition of CYP2C19 and CYP3A4 is the probable mechanism by which chloramphenicol decreases the clearance of some co-administered drugs and could theoretically interact with ombitasvir/paritaprevir/ritonavir + dasabuvir. Avoid unless benefit outweighs the risk.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Chloroquine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Following administration, chloroquine is rapidly metabolised by CYPs 2C8, 3A and 2D6 to desethylchloroquine and bisdesethylchloroquine which have activity similar to chloroquine. Chloroquine is also renally eliminated. Inhibition of CYP3A4 by ritonavir may decrease exposure to the active metabolites, but this may not affect overall activity. No a priori dosage adjustment is recommended for chloroquine.&nbsp;Note, the European SPC and US Prescribing Information for chloroquine both recommend caution in impaired hepatic function.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Chlorothiazide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Chlorothiazide is not metabolised and is eliminated rapidly by renal excretion.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Chlorphenamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Chlorphenamine is a substrate of CYP2D6 with possible involvement of CYP3A4. Ritonavir inhibits CYP2D6 at higher doses but at the 100 mg dose, ritonavir does not appear to markedly inhibit CYP2D6. While no a priori dose adjustment is required monitor for increased side-effects while co-administering chlorphenamine with ombitasvir/paritaprevir/ritonavir + dasabuvir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Chlorpromazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Chlorpromazine is a substrate of CYPs 2D6 (major), 1A2 and 3A4 in vitro. Chlorpromazine exposure may increase due to CYP3A4 and possibly CYP2D6 inhibition by ritonavir. No a priori dose modification is needed but monitor the subjects and dose decrease if required.&nbsp;Note, the European SPC for chlorpromazine advises that its use should be avoided in patients with hepatic dysfunction.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Chlortalidone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but chlortalidone can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Chlortalidone is mainly excreted in urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ciclesonide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Ciclesonide can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir without dose adjustment, but with close monitoring. There is a risk of steroid side effects occurring, particularly if a high dose is used or if used with another medicine containing corticosteroids. These side effects are also more likely during periods of physiological stress. Ciclesonide is substrate of CYP3A4. Coadministration of the strong CYP3A4 inhibitor ketoconazole (400 mg daily for 7 days) with orally inhaled ciclesonide (320 µg once daily) resulted in a 3.5-fold increase in the AUC and a 2-fold increase in the Cmax of des-ciclesonide, the active metabolite of ciclesonide. Concentrations of the parent ciclesonide were not significantly altered. Ciclesonide is mainly absorbed by lungs and hence interaction with ketoconazole would not require any dosage/therapy adjustments due to the low potential of ciclesonide to cause systemic effects.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ciclosporin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Ciclosporin is a substrate of CYP3A4. Ciclosporin AUC and Ctrough increases by 5.8-fold and 15.8-fold respectively when coadministered with ombitasvir/paritaprevir/ritonavir + dasabuvir. Give one-fifth of the total daily dose of ciclosporin once daily when coadministered. Monitor ciclosporin levels and adjust dose and/or dosing frequency as needed.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Coadministration increased ciclosporin Cmax by 1%, but increased AUC and Cmin by 5.82- and 15.8-fold (ciclosporin 100 mg dosed alone, 30 mg coadministered; dose normalized ciclosporin ratios are shown). Ombitasvir Cmax decreased by 1% but AUC and Cmin increased 8% and 15%. Paritaprevir Cmax, AUC and Cmin increased by 44%, 72% and 85%. Dasabuvir Cmax, AUC and Cmin decreased by 34%, 30% and 24%, respectively. The effect on ciclosporin is due to CYP3A4 inhibition by ritonavir and the increase in paritaprevir exposures may be due to OATP/BCRP/P-gp inhibition by ciclosporin. When starting co-administration, give one fifth of the total daily dose of ciclosporin once daily. Monitor ciclosporin levels and adjust dose and/or dosing frequency as needed. <br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div>&nbsp;</div><div>Coadministration with cyclosporine (30 mg single dose) was studied in 10 subjects and compared to values obtained with cyclosporine (100 mg) alone. Ombitasvir Cmax decreased by 1% but AUC and Cmin increased 8% and 15%. Paritaprevir Cmax, AUC and Cmin increased by 44%, 72% and 85%. Ritonavir Cmax decreased by 10%, but AUC and Cmin increased by 11% and 49%. Dasabuvir Cmax, AUC and Cmin decreased by 34%, 30% and 24%, respectively. When compared to 100 mg alone, cyclosporine Cmax increased by 1%, but AUC and Cmin increased by 5.82- and 15.80-fold. When initiating therapy with Viekira Pak&#174;, reduce cyclosporine dose to 1/5th of the patient&#8217;s current cyclosporine dose. Measure cyclosporine blood concentrations to determine subsequent dose modifications. &nbsp;Upon completion of Viekira Pak&#174; therapy, the appropriate time to resume pre-therapy dose of cyclosporine should be guided by assessment of cyclosporine blood concentrations. Frequent assessment of renal function and cyclosporine-related side effects is recommended.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Cidofovir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as cidofovir is mainly excreted in the urine via glomerular filtration and active secretion by OAT1/3.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Cilazapril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but cilazapril can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Cilazapril is metabolised by esterases to the active cilazaprilat which is excreted unchanged in urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Cilostazol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Cilostazol is extensively metabolised by CYP3A4 and CYP2C19 and to a lesser extent CYP1A2. Coadministration of ombitasvir/paritaprevir/ritonavir + dasabuvir may increase concentrations of cilostazol leading to increased side effects. The product label for cilostazol suggests a dose reduction to 50 mg twice daily when given with CYP3A4 and/or CYP2C19 inhibitors.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Cimetidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but a clinically significant interaction is unlikely. Cimetidine is an inhibitor of CYP isozymes but less potent than ritonavir. No effect of ombitasvir/paritaprevir/ritonavir + dasabuvir on cimetidine is expected since cimetidine is eliminated primarily by renal excretion.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ciprofloxacin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ciprofloxacin is primarily eliminated unchanged by the kidneys by glomerular filtration and tubular secretion via OAT3. It is also metabolized and partially cleared through the bile and intestine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration did not affect the exposures of the CYP2D6/CYP1A2 substrate, duloxetine. Other CYP1A2 substrates (e.g. ciprofloxacin) are not expected to require dose adjustments.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Cisapride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration is contraindicated in the European product label. Cisapride is a substrate of CYP3A4 and its exposure may increase due to CYP3A4 inhibition by ritonavir causing potential for serious and/or life-threatening reactions such as cardiac arrhythmias.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Concomitant use is contraindicated. Coadministration has not been studied but is expected to increase cisapride concentrations due to inhibition of CYP3A4 by ritonavir. Medicinal products that are highly dependent on CYP3A for clearance and for which elevated plasma levels are associated with serious events, such as cisapride, must not be co-administered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Cisatracurium</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cisatracurium undergoes mainly (80% of overall elimination) spontaneous degradation in plasma and tissues at physiological pH and temperature (Hofmann elimination).</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Cisplatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Cisplatin is eliminated renally via OCT2 and MATE1. Since paritaprevir/ritonavir can inhibit MATE-1, monitoring of the patient is recommended.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Citalopram</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but citalopram can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Citalopram is a substrate of CYP3A4 and CYP2C19. Escitalopram does not show any interaction with ombitasvir/paritaprevir/ritonavir + dasabuvir. Results from escitalopram can be extrapolated to citalopram. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Clarithromycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration is contraindicated in the European product label. Coadministration has not been studied but is expected to increase concentrations of clarithromycin, paritaprevir and dasabuvir due to inhibition of CYP3A4 and P-gp by clarithromycin and ritonavir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Concomitant use is contraindicated. Coadministration has not been studied but is expected to increase concentrations of clarithromycin, paritaprevir and dasabuvir due to inhibition of CYP3A4 and P-gp by clarithromycin and ritonavir. Co-administration with medicinal products that are strong inhibitors of CYP3A4, such as clarithromycin, is expected to increase paritaprevir plasma concentrations and must not be co-administered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Clavulanic acid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Clavulanic acid is extensively metabolized (likely by a non-CYP mediated pathway) and excreted in the urine by glomerular filtration. &nbsp;</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Clevidipine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Clevidipine is rapidly metabolised by hydrolysis of the ester linkage and does not undergo CYP metabolism.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Clindamycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Clindamycin is a substrate of CYP3A4 and its exposure may increase due to CYP3A4 inhibition by ritonavir. Monitor the subject and use caution. A decrease in clindamycin dose may be needed.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Clobazam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Clobazam is a substrate of CYP3A4 and to a lesser extent CYP2C19 but its exposure may increase due to CYP3A4 inhibition by ritonavir. Consider starting patient on current dose with close clinical monitoring for side effects associated with clobazam and decrease dose if necessary.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Clobetasol (topical)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but topical clobetasol can be used with caution. Clobetasol is a substrate of CYP3A4 and its exposure may increase due to CYP3A4 inhibition by ritonavir. Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Clobetasone (topical)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Following topical application to most areas of normal skin, only minimal amounts of the drug reach the dermis and subsequently the systemic circulation. Although clobetasone is a substrate of CYP3A4, a clinically significant effect is unlikely due to inhibition of CYP3A4 by ritonavir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Clomifene</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Studies suggest that clomifene is metabolised by CYP3A4, CYP2D6 and UGTs and concentrations may increase due to inhibition of CYP3A4 by ritonavir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Clomipramine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Clomipramine is a substrate of CYPs 2C19, 3A4 and 1A2. Clomipramine exposure may increase due to CYP3A4 inhibition by ritonavir. Monitor the subjects. Use the lowest possible dose of clomipramine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Clonazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Clonazepam is a substrate of CYP3A4 and its exposure may increase due to CYP3A4 inhibition by ritonavir, resulting in the possibility of prolonged and/or increased pharmacologic effects of the benzodiazepine, including sedation and respiratory depression. Therapeutic concentration monitoring is recommended, a decrease in dose of clonazepam may be needed.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Clonidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Clonidine is a substrate of CYP2D6 and CYP3A4. At 100 mg dose, ritonavir does not inhibit CYP2D6, but theoretically, clonidine exposure may increase due to CYP3A4 inhibition by ritonavir. Monitor the subjects. Use the lowest possible dose of clonidine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Clopidogrel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Clopidogrel is a prodrug and is converted to its active metabolite via CYPs 3A4, 2B6, 2C19 and 1A2. The effect on activation of clopidogrel to its active metabolite is difficult to predict due to induction of CYP2C19 and inhibition of CYP3A4 by ritonavir but is likely to decrease exposure of the active metabolite leading to non-responsiveness to clopidogrel. Coadministration with ketoconazole (an inhibitor of CYP3A4) decreased exposure of clopidogrel’s active metabolite by 22-29% and reduced inhibition of platelet aggregation by 22-33%. Non-responsiveness to clopidogrel has been reported in a HIV-positive patient with latent tuberculosis and treated with isoniazid and ritonavir-boosted darunavir. In addition, clinical studies have show a major metabolite of clopidogrel to be an inhibitor of CYP2C8 and therefore could increase dasabuvir concentrations. An alternative to clopidogrel should be considered.&nbsp;Note, the European SPC for clopidogrel contraindicates it use in severe hepatic impairment but the US Prescribing Information states no dose alteration.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>A 64-year-old man presented with increasing shortness of breath, fatigue and chest pain radiating to his left shoulder and neck. His home medications included darunavir, ritonavir, emtricitabine-tenofovir, isoniazid, pyridoxine, clopidogrel, aspirin, carvedilol, rosuvastatin, valsartan, sertraline, tamsulosin and esomeprazole. Potential drug-drug interactions between isoniazid and clopidogrel, and ritonavir and clopidogrel were identified that could interfere with clopidogrel activation. Based on this, platelet function testing was completed and impaired clopidogrel response was seen on two platelet function tests. There was no genetic cause (i.e., CYP2C19 genotype) for the impaired clopidogrel response.<br><em>A patient with HIV and tuberculosis with diminished clopidogrel response. Metzger NL, Momary KN. Int J STD AIDS, 2013, 25(7): 532-534.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Clorazepate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Clorazepate is a substrate of CYP3A4 and its exposure may increase due to CYP3A4 inhibition by ritonavir causing CNS depression, sedation. Monitor the subjects. A decrease in clorazepate dose may be needed.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Cloxacillin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but cloxacillin can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Cloxacillin is mainly excreted in the urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Clozapine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Clozapine is a substrate of CYPs 1A2, 2D6 and 3A4, and its exposure may increase due to CYP3A4 inhibition by ritonavir. Monitor the subject. A decrease in clozapine dose may be needed.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Cobicistat (with ATV or DRV)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration of ombitasvir/paritaprevir/ritonavir + dasabuvir with an additional pharmacokinetic booster, such as cobicistat, is contraindicated. Coadministration may increase concentrations of ombitasvir, paritaprevir and dasabuvir due to inhibition of CYP3A4 by cobicistat.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Concomitant use is contraindicated. Coadministration is expected to increase concentrations of ombitasvir, paritaprevir and dasabuvir due to inhibition of CYP3A4 by cobicistat.<br><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Cocaine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Cocaine is metabolised by several pathways with metabolism to norcocaine by CYP3A4 being less than 10% of the overall metabolic clearance. Although concentrations could increase due to inhibition of CYP3A4 it is difficult to judge the significance. Ensure the patient is aware of signs/symptoms of cocaine toxicity.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Codeine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Codeine is a substrate of CYP2D6 (major) and CYP3A4. Ritonavir inhibits CYP2D6 at higher doses but at the 100 mg dose, ritonavir does not appear to markedly inhibit CYP2D6. While no a priori dose adjustment is required for codeine, monitor for increased side-effects while co-administering codeine with ombitasvir/paritaprevir/ritonavir + dasabuvir. Decrease codeine dose, if clinically indicated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Colchicine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Colchicine is a substrate of CYP3A4 and P-gp. Colchicine exposure may increase due to CYP3A4 inhibition by ritonavir. Fatal colchicine toxicity has been reported with clarithromycin, a strong CYP3A4 inhibitor. Monitor the subjects. A decrease in colchicine dose may be needed. Patients with renal or hepatic impairment should not be given colchicine with ritonavir. Refer to the ritonavir product label.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration has not been studied but is expected to increase concentrations of colchicine due to inhibition of CYP3A4 by ritonavir. A reduction in colchicine dosage or an interruption of colchicine treatment is recommended in patients with normal renal or hepatic function. In patients with renal or hepatic impairment, use of colchicine is contraindicated.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Colestyramine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Colestyramine may delay or reduce the absorption of drugs. Administration of other drugs should be at least 1 hour before or 4-6 hours after colestyramine.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Conivaptan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but is expected to increase concentrations of conivaptan, paritaprevir + dasabuvir due to inhibition of CYP3A4 and P-gp by conivaptan and ombitasvir/paritaprevir/ritonavir. Coadministration of ombitasvir/paritavir/ritonavir + dasabuvir with conivaptan is contraindicated. Treatment with CYP3A substrates may be initiated no sooner than 1 week after the infusion of conivaptan has been completed.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration has not been studied but is expected to increase concentrations of conivaptan, paritaprevir and dasabuvir due to CYP3A4/P-gp inhibition by conivaptan and paritaprevir/ ritonavir/ ombitasvir. Coadministration of ombitasvir/paritavir/ritonavir with or without dasabuvir with medicinal products that are strong inhibitors of CYP3A4, such as conivaptan, is expected to increase paritaprevir plasma concentrations and must not be co-administered with Viekirax. <br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em><br /></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Cyclobenzaprine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Cyclobenzaprine undergoes a complex metabolic process involving glucuronidation and several CYP enzymes including CYPs 3A4 and 1A2. Coadministration may increase cyclobenzaprine concentrations due to inhibition of CYP3A4 by ritonavir, though the clinical significance of this is unknown. Monitor for signs and symptoms of toxicity.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Cytisine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied and the pharmacokinetics of cytisine are poorly described. There are no reports of drug interactions or CYP involvement.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Dabigatran</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Dabigatran exposure may theoretically increase due to P-gp inhibition by ombitasvir/paritaprevir/ritonavir + dasabuvir. Dabigatran is metabolised by hydrolysis and is a substrate of UGT and P-gp. Ombitasvir/paritaprevir/ritonavir + dasabuvir increased exposure of raltegravir (a UGT substrate) by up to 2-fold and a similar interaction is possible with other UGT substrates. Use with caution. Monitor the subjects; a reduction in dabigatran dose may be needed or start with the lowest possible dose. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration has not been studied but is expected to increase concentration of dabigatran due to inhibition of intestinal P-gp by paritaprevir and ritonavir. Use with caution.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Daclatasvir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Ombitasvir/paritaprevir/ritonavir + dasabuvir is a complete regimen. There are no data to support the coadministration with other DAAs.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>The safety and efficacy of ombitasvir/paritaprevir/ritonavir have been  established in combination with dasabuvir and/or ribavirin.  Co-administration of ombitasvir/paritaprevir/ritonavir + dasabuvir with  other directly acting antivirals has not been studied and therefore  cannot be recommended.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Dalteparin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as dalteparin is mainly excreted unchanged by the kidney.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Danaparoid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Danaparoid is renally excreted and no hepatic involvement was shown in animal studies. Note, caution is required if using in patients with renal impairment.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Dantron</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dantron is absorbed from the small intestine and acts at the large intestine.&nbsp;</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Dapagliflozin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Dapagliflozin is metabolised by UGT1A9 which is not known to be affected by ombitasvir/paritaprevir/ritonavir + dasabuvir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Dapsone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Metabolism is largely via N-acetylation and multiple CYP enzymes have been described. An interaction cannot be excluded but is unlikely. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Darbepoetin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Darbepoetin is not hepatically metabolized and to date no clinically significant interactions have been published that would be of concern.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Darunavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration with ombitasvir/paritaprevir/ritonavir + dasabuvir decreased darunavir Ctrough by ~50%, although Cmax and AUC did not show a clinically significant change. Although coadministration of darunavir with ombitasvir/paritaprevir/ritonavir + dasabuvir is not recommended in the US Prescribing Information, the European SPC states that coadministration is not recommended in patients with extensive HIV PI resistance. The European SPC advises that darunavir (dosed at 800 mg once daily and administered at the same time as ombitasvir/paritaprevir/ritonavir + dasabuvir) can be used in the absence of extensive HIV PI resistance and should be taken without additional ritonavir, since ritonavir 100 mg once daily is provided as part of the ombitasvir/paritaprevir/ritonavir fixed dose combination. Exercise caution with use dependent on knowledge of the patient. Darunavir/cobicistat should not be coadministered as ritonavir is part of the ombitasvir/paritaprevir/ritonavir fixed dose combination.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Coadministration with darunavir (800 mg once daily given at the same time) decreased darunavir Cmax, AUC and Cmin by 8%, 24% and 48%. Ombitasvir Cmax, AUC and Cmin decreased by 14%, 14% and 13%. Paritaprevir Cmax, AUC and Cmin increased by 54%, 29% and 30%, respectively. Dasabuvir Cmax increased by 10%, but AUC and Cmin decreased by 6% and 10%. Coadministration with darunavir/ritonavir (600/100 mg twice daily) decreased darunavir Cmax, AUC and Cmin by 13%, 20% and 43%, respectively. Ombitasvir Cmax, AUC and Cmin decreased by 24%, 27% and 27%. Paritaprevir Cmax, AUC and Cmin decreased by 30%, 41% and 17%, respectively. Dasabuvir Cmax, AUC and Cmin decreased by 16%, 27% and 46%, respectively. Coadministration with darunavir/ritonavir (800/100 mg once daily administered 12 hours apart) decreased darunavir Cmax and Cmin by 21% and 46%, but increased AUC by 34%. Ombitasvir Cmax, AUC and Cmin all decreased by 13%. Paritaprevir Cmax and AUC decreased by 30% and 19%, but Cmin increased by 59%. Dasabuvir Cmax, AUC and Cmin decreased by 25%, 28% and 35%. The recommended dose of darunavir is 800 mg once daily, without ritonavir, when administered at the same time as ombitasvir, paritaprevir, ritonavir and dasabuvir (ritonavir dose in Viekirax will provide darunavir pharmacokinetic enhancement). This regimen can be used in the absence of extensive PI resistance (i.e. lack of darunavir associated RAMs). Darunavir combined with ombitasvir, paritaprevir, ritonavir and dasabuvir is not recommended in patients with extensive PI resistance.<br><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, July 2015.<br>Exviera Summary of Product Characteristics, AbbVie Ltd, July 2015.</em></div>&nbsp;</div>

<div>Coadministration with darunavir (800 mg once daily) was studied in 9 subjects and compared to values obtained with darunavir/ritonavir (800/100 mg once daily) alone. Ombitasvir Cmax, AUC and Cmin decreased by 14%, 14% and 13%. Paritaprevir Cmax, AUC and Cmin increased by 54%, 29% and 30%, respectively. Ritonavir Cmax and AUC decreased by 16% and 15%, but Cmin increased by 7%. Dasabuvir Cmax increased by 10%, but AUC and Cmin decreased by 6% and 10%. Darunavir Cmax, AUC and Cmin decreased by 8%, 24% and 48%. Coadministration with darunavir (600 mg twice daily plus ritonavir 100 mg once daily in the evening) was studied in 7 subjects and compared to values obtained with darunavir/ritonavir (600/100 mg twice daily) alone. Ombitasvir Cmax, AUC and Cmin decreased by 24%, 27% and 27%. Paritaprevir Cmax, AUC and Cmin decreased by 30%, 41% and 17%, respectively. Ritonavir Cmax and AUC increased by 61% and 28%, but Cmin decreased by 12%. Dasabuvir Cmax, AUC and Cmin decreased by 16%, 27% and 46%, respectively. Darunavir Cmax, AUC and Cmin decreased by 13%, 20% and 43%, respectively. Coadministration with darunavir/ritonavir (800/100 mg once daily) was studied in 12 subjects and compared to values obtained with darunavir/ritonavir (800/100 mg once daily) alone. Ombitasvir Cmax, AUC and Cmin all decreased by 13%. Paritaprevir Cmax and AUC decreased by 30% and 19%, but Cmin increased by 59%. Ritonavir Cmax and AUC increased by 19% and 70%, with Cmin increasing by 14.15-fold. Dasabuvir Cmax, AUC and Cmin decreased by 25%, 28% and 35%. Darunavir Cmax and Cmin decreased by 21% and 46%, but AUC increased by 34%. Co-administration with darunavir/ritonavir is not recommended.</div>





<div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Dasatinib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but may increase concentrations of both dasatinib and ombitasvir/paritaprevir/ritonavir + dasabuvir. Dasatinib is a substrate and an inhibitor of CYP3A4. There could be a marked increase in dasatinib exposure and it is also possible that ombitasvir/paritaprevir/ritonavir + dasabuvir exposure may be increased. Coadministration is not recommended unless the benefit outweighs the risk. Use with caution.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Delavirdine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Delavirdine is a substrate and inhibitor of CYP3A4 and its exposure may increase due to CYP3A4 inhibition by ritonavir. Monitor the subjects. Appropriate doses of this combination, with respect to safety, efficacy and pharmacokinetics, have not been established.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Desipramine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but desipramine can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no a priori dose alteration is required. Desipramine is a substrate of CYP2D6, and did not show interaction with lopinavir/ritonavir (400/100 mg twice daily). Ritonavir inhibits CYP2D6 at higher doses but at the 100 mg dose ritonavir does not appear to markedly inhibit CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration did not affect the exposures of the CYP2D6/CYP1A2 substrate, duloxetine. Other CYP2D6 substrates (e.g. desipramine) are not expected to require dose adjustments.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Desloratidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of desloratidine is poorly characterised and no clinically relevant interaction have been observed with other inhibitors of CYP enzymes.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Desmopressin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as desmopressin undergoes no significant metabolism.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Desogestrel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Desogestrel is a prodrug that requires activation to etonogestrel. Activation to etonogestrel is by CYP2C9 (and possible CYP2C19); the metabolism of etonogestrel is mediated by CYP3A4. Coadministration may increase the conversion to the active metabolite etonogestrel due to inhibition of CYP3A4 by ritonavir. Although no dose adjustment is necessary for norethindrone (a progestogen) when coadministered with ombitasvir/paritaprevir/ritonavir + dasabuvir in the absence of an estrogen, it is unclear if this will apply to other orally administered progestogen only contraceptives.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Desvenlafaxine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Desvenlafaxine is a substrate of CYP2D6, CYP3A4 and P-gp. Ketoconazole, an inhibitor of CYP3A4/P-gp, increased exposure of venlafaxine and its metabolite by 20-141%. A similar magnitude of increase may be seen due to CYP3A4 inhibition by ritonavir when administered with ombitasvir/paritaprevir/ritonavir + dasabuvir. Monitor the subjects. A decrease in dose may be needed.&nbsp;Note, a maximum dose of 50 mg is recommended in moderate hepatic impairment.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Dexamethasone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Dexamethasone is a substrate of CYP3A4 and P-gp. Dexamethasone exposure (after IV and oral administration) increased by 3.3- to 3.7-fold when administered with itraconazole, a CYP3A4 inhibitor. A similar magnitude of increase may be seen with ombitasvir/paritaprevir/ritonavir + dasabuvir due to CYP3A4 inhibition by ritonavir. Monitor the subjects for side effects due to adrenal suppression. A decrease in dexamethasone dose is recommended. Dexamethasone is also known as a CYP3A4 inducer and it may potentially decrease concentrations and therefore efficacy of ombitasvir/paritaprevir/ritonavir + dasabuvir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Dextromethorphan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but dextromethorphan can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alternation is required. Dextromethorphan is a substrate of CYP2D6 but ritonavir at the 100 mg dose does not appear to markedly inhibit CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration did not affect the exposures of the CYP2D6/CYP1A2 substrate, duloxetine. Other CYP2D6 substrates (e.g. dextromethorphan) are not expected to require dose adjustments.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Dextropropoxyphene</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied and is not recommended. Dextropropoxyphene has been withdrawn from most European and North American countries due to the risk of arrhythmias and fatalities. As it is metabolised mainly by CYP3A4, coadministration with ombitasvir/paritaprevir/ritonavir + dasabuvir could markedly increase the exposure of dextropropoxyphene.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Diamorphine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Diamorphine is metabolised by hydrolysis to its metabolite morphine. Morphine is metabolized by UGT2B7, UGT1A3 with a minor contribution from CYP2D6 and CYP3A4. No a priori dose adjustment is required for diamorphine, however, monitor for side effects and decrease dose, if needed. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Diazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration of diazepam (2 mg single dose) and ombitasvir/paritaprevir/ritonavir plus dasabuvir increased diazepam Cmax by 18%, but decreased AUC by 22%. Nordiazepam Cmax increased by 10%, but AUC decreased by 40%. There was no clinically significant effect on exposures of ombitasvir, paritaprevir, ritonavir or dasabuvir. No a priori dose modification is recommended, but monitor the patient and adjust the dose if clinically indicated. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration of diazepam (2 mg single dose) and ombitasvir/paritaprevir/ritonavir plus dasabuvir was studied in 15 subjects. Diazepam Cmax increased by 18%, but AUC decreased by 22%; nordiazepam Cmax increased by 10%, but AUC decreased by 40%. There was no clinically significant effect on exposures of ombitasvir, paritaprevir, ritonavir or dasabuvir.<br /><em>Drug-drug interactions of commonly used medications with direct acting antiviral HCV combination therapy of paritaprevir/r, ombitasvir and dasabuvir. Polepally AR, et al. 16th International Workshop on Clinical Pharmacology of HIV &amp; Hepatitis Therapy, Washington, USA, May 2015, abstract 16.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Diclofenac</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Diclofenac is a substrate of CYP2C9, CYP3A4, UGT1A9 and UGT2B7. With multiple pathways diclofenac exposure is not expected to increase with ombitasvir/paritaprevir/ritonavir + dasabuvir. There was no interaction between and warfarin, a CYP2C9 substrate and ombitasvir/paritaprevir/ritonavir + dasabuvir, so no interaction is expected due to CYP2C9 involvement. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Didanosine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Didanosine is phosphorylated to its active triphosphate form and is not a substrate of any CYP isoenzyme. It is renally excreted.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Dienogest</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Dienogest is metabolised by CYP3A4 and coadministration may increase dienogest concentrations due to inhibition of CYP3A4 by ritonavir. The clinical significance of this is unknown. Note, coadministration is CONTRAINDICATED when given as a combined oral contraceptive with ethinylestradiol due to an increase in ALT.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Diflunisal</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as diflunisal is an aldoketoreductase inhibitor and ombitasvir/paritaprevir/ritonavir + dasabuvir is not known to affect this pathway.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Digoxin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration with digoxin (0.5 mg single dose) increased digoxin Cmax, AUC and Cmin by 15%, 16% and 1% due to inhibition of P-gp by paritaprevir. There were no clinically significant changes in exposures of ombitasvir, paritaprevir, ritonavir or dasabuvir. No a priori dose adjustment of digoxin is required, but appropriate monitoring of serum digoxin levels is recommended.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Coadministration with digoxin (0.5 mg single dose) increased digoxin Cmax, AUC and Cmin by 15%, 16% and 1% due to inhibition of P-gp by paritaprevir. Ombitasvir Cmax increased by 3%, there was no change in AUC and Cmin decreased by 1%. Paritaprevir Cmax, AUC and Cmin decreased by 8%, 6% and 8%, respectively. Dasabuvir Cmax, AUC and Cmin decreased by 1%, 3% and 1%, respectively. While no dose adjustment is necessary for digoxin, appropriate monitoring of serum digoxin levels is recommended.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em><br /><br /></div>No dose adjustments are recommended when ombitasvir, paritaprevir, ritonavir and dasabuvir are co-administered with digoxin.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Dihydroartemisinin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Dihydroartemisinin (the active metabolite of artesunate) induces CYP3A4 and there is the possibility of a decrease in exposure of ombitasvir/paritaprevir/ritonavir + dasabuvir although it is difficult to judge the clinical relevance. Monitor for therapeutic effect.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Dihydrocodeine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Dihydrocodeine is a substrate of CYP2D6, UGT2B7 and CYP3A4. Ritonavir inhibits CYP2D6 at higher doses but at the 100 mg dose it does not appear to markedly inhibit CYP2D6. While no a priori dose adjustment is required for dihydrocodeine, monitor for increased side-effects with ombitasvir/paritaprevir/ritonavir + dasabuvir. Decrease dihydrocodeine dose if clinically indicated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Dihydroergotamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration is contraindicated due to the potential for serious and/or life-threatening reactions such as acute ergot toxicity characterized by vasospasm and ischemia of the extremities and other tissues including the central nervous system.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Concomitant use is contraindicated. Coadministration has not been  studied but is expected to increase concentrations of ergot derivatives  due to inhibition of CYP3A4 by ritonavir. Medicinal products that are  highly dependent on CYP3A for clearance and for which elevated plasma  levels are associated with serious events, such as ergot derivatives,  must not be co-administered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></div><div>&nbsp;</div><div>Coadministration is contraindicated. Acute ergot toxicity characterized by vasospasm and tissue ischemia has been associated with co-administration of ritonavir and dihydroergotamine.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Diltiazem</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Diltiazem is a substrate of CYP3A4 and its exposure may increase due to CYP3A4 inhibition by ritonavir. Concentrations of paritaprevir may increase, but the efffect on dasabuvir is unclear (no change or concentrations may increase). Use with caution due to the expected increase in paritaprevir exposures. Monitor the subjects. Start with the lowest possible dose. Clinical monitoring of calcium channel blockers is recommended when co-administered.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration has not been studied but is expected to increase concentrations of diltiazem and paritaprevir due to inhibition of CYP3A4 and P-gp, and may increase (or have no effect on) concentrations of dasabuvir. Caution is advised due to the expected increase in paritaprevir exposures. Dose decrease and clinical monitoring of calcium channel blockers is recommended when co-administered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Diphenhydramine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely.&nbsp;Diphenhydramine is a substrate of CYP2D6. Ritonavir inhibits CYP2D6 at higher doses but at the 100 mg dose ritonavir does not appear to markedly inhibit CYP2D6. Note, diphenhydramine should be used with caution in patients with moderate to severe hepatic impairment.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Dipyridamole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Dipyridamole is glucuronidated but the UGTs involved have not been well described. Dipyridamole exposure may increase due to UGT inhibition by ombitasvir/paritaprevir/ritonavir + dasabuvir but the magnitude of the interaction is difficult to predict. Monitor for increased side effects and toxicities of dipyridamole but no dose change at onset should be required. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Disopyramide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Disopyramide is a substrate of CYP3A4 and CYP1A2. Its exposure may increase due to CYP3A4 inhibition by ritonavir causing cardiotoxicity. Therapeutic concentration monitoring should be done for disopyramide. A decrease in disopyramide dose may be needed.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration may increase concentrations of this antiarrhythmic. Caution is warranted and therapeutic concentration monitoring (if available) is recommended for antiarrhythmics when co-administered.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Disulfiram</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but disulfiram can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Disulfiram is an inhibitor of ALDH.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Dofetilide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied and is not recommended due to the increased risk of QT prolongation. Although dofetilide is only metabolised to a small extent by CYP3A4, use with concominant CYP3A4 inhibitors, such as ritonavir may increase dofetilide concentrations, increasing the risk of QT prolongation. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Dolutegravir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration of ombitasvir/paritaprevir/ritonavir + dasabuvir and dolutegravir (50 mg once daily) was studied in 12 HIV/HCV-negative subjects and had no clinically significant effect on the pharmacokinetics of ombitasvir, paritaprevir, ritonavir, dasabuvir or dolutegravir. No dose adjustment is required for ombitasvir/paritaprevir/ritonavir + dasabuvir or dolutegravir during coadministration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration of ombitasvir/paritaprevir/ritonavir + dasabuvir and dolutegravir (50 mg once daily) was studied in 12 HIV/HCV-negative subjects. During coadministration dolutegravir exposures were 22-38% higher, exposure of ombitasvir and dasabuvir were up to 18% lower, and paritaprevir and ritonavir Ctrough both decreased by 34%. No dose adjustment is recommended for ombitasvir/paritaprevir/ritonavir + dasabuvir or dolutegravir during coadministration.<br /><em>Drug-drug interactions of ombitasvir/paritaprevir/r plus dasabuvir with dolutegravir or abacavir plus lamivudine.<br />Khatn A, Trinh R, Zhao W, et al. 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington DC, May 2015, Abstract 57.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Domperidone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied and is contraindicated with potent CYP3A4 inhibitors, such as ritonavir. Domperidone is mainly metabolized by CYP3A4. Ombitasvir/paritaprevir/ritonavir + dasabuvir could potentially increase domperidone exposure and increase the risk of cardiac adverse effects (QT interval prolongation).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Dorzolamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as dorzolamide undergoes minimal metabolism and is mainly excreted unchanged by the kidney.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Doxazosin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Doxazosin is a substrate of CYP3A4 and its exposure may increase due to CYP3A4 inhibition by ritonavir. Monitor the subjects. Start with the lowest possible dose of doxazosin.&nbsp;Note, the European SPC does not recommend doxazosin in severe hepatic impairment;&nbsp;the US Prescribing Information has a caution for use in hepatic impairment.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Doxepin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but doxepin can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Doxepin is metabolised by CYP2D6 and CYP2C9. Ritonavir inhibits CYP2D6 at higher doses but at the 100 mg dose, ritonavir does not appear to markedly inhibit CYP2D6. Ombitasvir/paritaprevir/ritonavir at steady-state did not affect the plasma exposures of the anticoagulant warfarin which is metabolised by CYP2C9.&nbsp;Note, the European and US product labels for doxepin advise caution and monitoring in patients with hepatic impairment as a dosage reduction may be required.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Doxorubicin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Doxorubicin is a substrate of P-gp and MRP1 and may theoretically interact with the ombitasvir, paritaprevir, ritonavir components of ombitasvir/paritaprevir/ritonavir + dasabuvir causing cytotoxicity. Monitor subjects for an appropriate and expected response to doxorubicin or ombitasvir/paritaprevir/ritonavir + dasabuvir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Doxycycline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but doxycycline can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Doxycycline is mainly excreted in urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Dronedarone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Dronedarone is primarily metabolised by CYP3A4 and coadministration with potent inhibitors of CYP3A4, such as ritonavir, is contraindicated in its product labels due to increased risk of QT prolongation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Droperidol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but droperidol can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alternation is required. However, droperidol has a QT risk and concentrations may alter due to induction of CYP1A2 and inhibition of CYP3A4 by ritonavir. If coadministration is deemed necessary, caution is warranted and clinical monitoring for increased side effects should be performed including ECG monitoring.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Drospirenone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance an interaction is unlikely. Drospirenone is metabolised mainly without involvement of CYP enzymes with little known involvement of transporters. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Dulaglutide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Dulaglutide delays gastric emptying and has the potential to impact the rate of absorption of concomitantly administered oral medicinal products. It is advisable to separate administration if possible.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Duloxetine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Duloxetine can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Duloxetine is metabolized by CYP2D6 and CYP1A2. There was no interaction between duloxetine and ombitasvir/paritaprevir/ritonavir + dasabuvir. Coadministration with duloxetine (60 mg single dose) decreased duloxetine Cmax and AUC by 21% and 25%. Ombitasvir Cmax decreased by 2%, there was no change in AUC and Cmin increased by 1%. Paritaprevir Cmax, AUC and Cmin decreased by 21%, 17% and 23%, respectively. Dasabuvir Cmax, AUC and Cmin decreased by 6%, 8% and 12%, respectively.&nbsp;Note, duloxetine is contraindicated in patients with hepatic impairment as concentrations may increase due to decreased clearance of duloxetine.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Coadministration with duloxetine (60 mg single dose) decreased duloxetine Cmax and AUC by 21% and 25%. Ombitasvir Cmax decreased by 2%, there was no change in AUC and Cmin increased by 1%. Paritaprevir Cmax, AUC and Cmin decreased by 21%, 17% and 23%, respectively. Dasabuvir Cmax, AUC and Cmin decreased by 6%, 8% and 12%, respectively. No dose adjustments are required when coadministered.<br><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br>Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div>&nbsp;</div>

<div>No dose adjustments are recommended when ombitasvir, paritaprevir, ritonavir and dasabuvir are co-administered with duloxetine.</div>

<div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Dutasteride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Dutasteride is a substrate of CYP3A4 and its exposure may increase in the presence of ritonavir, a CYP3A4 inhibitor. Monitor the subjects. A decrease in dutasteride dose may be needed.&nbsp;Note, the European SPC (but not the US Prescribing Information) cautions against dutasteride use in mild to moderate hepatic impairment and contraindicates it in severe hepatic impairment.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Echinacea</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Studies using a cocktail of probe drugs showed Echinacea inhibited CYP1A2 and intestinal CYP3A activity, and induced hepatic CYP3A activity. However, coadministration of Echinacea and potent 3A4 inhibitor lopinavir/ritonavir showed no clinically significant effect of Echinacea on lopinavir or ritonavir concentrations (most likely due to the potent CYP3A inhibition by ritonavir). Based on these data, Echinacea is unlikely to alter exposure of ombitasvir/paritaprevir/ritonavir + dasabuvir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Eculizumab</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Eculizumab contains only naturally occurring amino acids and has no known active metabolites. Human antibodies are predominately catabolized by lysosomal enzymes to small peptides and amino acids. No drug interactions have been described to date.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Edoxaban</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but may increase edoxaban concentrations due to inhibition of P-gp by ritonavir. The European product label for edoxaban states to consider a dose reduction of edoxaban from 60 mg to 30 mg with strong P-gp inhibitors, however, the US product label recommends no dose modification.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Efavirenz</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration is contraindicated. Subjects had severe tolerability issues when efavirenz plus tenofovir, emtricitabine was administered with ombitasvir/paritaprevir/ritonavir and dasabuvir and the study was discontinued. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Concomitant use is contraindicated. Co-administration of efavirenz (enzyme inducer) based regimens with paritaprevir, ritonavir and dasabuvir resulted in ALT elevations and therefore, early discontinuation of the study. Co-administration with medicinal products that are strong or moderate enzyme inducers, such as efavirenz, is expected to decrease ombitasvir, paritaprevir, and ritonavir plasma concentrations and reduce their therapeutic effect and must not be co-administered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></div><div>&nbsp;</div><div>Coadministration is contraindicated. Co-administration of efavirenz based regimens with paritaprevir, ritonavir plus dasabuvir was poorly tolerated and resulted in liver enzyme elevations.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Elbasvir/Grazoprevir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>The safety and efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir have been established in combination with ribavirin. Coadministration with other directly acting antivirals has not been studied and therefore cannot be recommended.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Eletriptan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied and is not recommended. Concentrations of eletriptan are likely to increase due to inhibition of CYP3A4 by ritonavir. The US Prescribing Information for eletriptan contraindicates its use with potent CYP3A4 inhibitors and the European SPC advises that it should not be used with potent CYP3A4 inhibitors.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Eltrombopag</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance an interaction is unlikely. Eltrombopag is metabolised by cleavage, conjugation and to a minor extent by CYP1A2 and CYP2C8. No interaction with is expected with ombitasvir/paritaprevir/ritonavir + dasabuvir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Elvitegravir/cobi/FTC/TAF</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but is contraindicated as both fixed dose combinations contain a pharmacokinetic booster. Coadministration may increase concentrations of ombitasvir, paritaprevir and dasabuvir due to inhibition of CYP3A4 by cobicistat.&nbsp;</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Concomitant use is contraindicated. Coadministration is expected to increase concentrations of ombitasvir and paritaprevir due to inhibition of CYP3A4 by cobicistat.&nbsp;<br><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Elvitegravir/cobi/FTC/TDF</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Both regimens contain a pharmacokinetic booster and coadministration may increase concentrations of ombitasvir, paritaprevir and dasabuvir due to inhibition of CYP3A4 by cobicistat.&nbsp;</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Concomitant use is contraindicated. Coadministration is expected to increase concentrations of ombitasvir and paritaprevir due to inhibition of CYP3A4 by cobicistat.&nbsp;<br><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Empagliflozin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Empagliflozin is metabolised by UGTs and is a substrate of P-gp, BCRP, OAT3 and OATP1B1/1B3. Although ombitasvir/paritaprevir/ritonavir + dasabuvir inhibits&nbsp;UGT, P-gp and OATP, data with probenecid (a UGT inhibitor), verapamil (a P-gp inhibitor) and rifampicin (a OATP1B1/1B3 inhibitor) suggest a clinically relevant effect on empagliflozin is unlikely.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Emtricitabine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Emtricitabine can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Emtricitabine is mainly excreted in urine and there was no significant interaction with ombitasvir/paritaprevir/ritonavir + dasabuvir. Coadministration with emtricitabine/tenofovir (200/300 mg once daily) increased emtricitabine Cmax, AUC and Cmin by 5%, 7% and 9%. Ombitasvir Cmax, AUC and Cmin decreased by 11%, 1% and 3%, respectively. Paritaprevir Cmax and AUC decreased by 32% and 16%, but Cmin increased by 6%. Dasabuvir Cmax, AUC and Cmin all decreased by 15%.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Coadministration with emtricitabine/tenofovir (200/300 mg once daily) increased emtricitabine Cmax, AUC and Cmin by 5%, 7% and 9%; the Cmax, AUC and Cmin of tenofovir increased by 7%, 13% and 24%, respectively. Ombitasvir Cmax, AUC and Cmin decreased by 11%, 1% and 3%, respectively. Paritaprevir Cmax and AUC decreased by 32% and 16%, but Cmin increased by 6%. Dasabuvir Cmax, AUC and Cmin all decreased by 15%. No dose adjustment is necessary.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div>&nbsp;</div><div>No dose adjustments are recommended when ombitasvir, paritaprevir, ritonavir and dasabuvir are co-administered with emtricitabine.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Emtricitabine/TAF</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Tenofovir alafenamide (the prodrug of tenofovir) is a substrate of P-gp and inhibitors of P-gp such as ritonavir are expected to increase the absorption of tenofovir alafenamide, thereby increasing systemic concentrations. Descovy should be used at a dose of 200/10 mg once daily.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Enalapril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Enalapril is a substrate of OATP1B1 and its exposure may increase due to OATP1B1 inhibition by paritaprevir. Rosuvastatin (OATP1B1 substrate) shows 160% increase when administered with with ombitasvir/paritaprevir/ritonavir + dasabuvir and a similar increase in enalapril exposure may be expected. Monitor the subjects. A decrease in enalapril dose may be needed.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Enoxaparin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance an interaction is unlikely. Enoxaparin does not undergo CYP metabolism but is desulphated and depolymerised in the liver and is then excreted predominantly renally.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Entecavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Entecavir is mainly excreted unchanged by the kidney by both glomerular filtration and active transport.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Eplerenone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied and is not recommended. Concentrations of eplerenone may increase significantly due to inhibition of CYP3A4 by ritonavir increasing the risks of associated side effects and toxicities. The concomitant use of eplerenone with strong CYP3A4 inhibitors is contraindicated in its European and US product labels.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Epoetin alfa</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely.  There is no evidence that treatment with epoetin-alfa alters the metabolism of other medicinal products.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Eprosartan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Eprosartan can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Eprosartan is mainly excreted in urine and bile.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ergometrine (ergonovine)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration is contraindicated due to the potential for serious and/or life-threatening reactions such as acute ergot toxicity characterized by vasospasm and ischemia of the extremities and other tissues including the central nervous system.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Concomitant use is contraindicated. Coadministration has not been  studied but is expected to increase concentrations of ergot derivatives  due to inhibition of CYP3A4 by ritonavir. Medicinal products that are  highly dependent on CYP3A for clearance and for which elevated plasma  levels are associated with serious events, such as ergot derivatives,  must not be co-administered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></div><div>&nbsp;</div><div>Coadministration is contraindicated. Acute ergot toxicity characterized by vasospasm and tissue ischemia has been associated with co-administration of ritonavir and ergonovine.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ergotamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration is contraindicated due to the potential for serious and/or life-threatening reactions such as acute ergot toxicity characterized by vasospasm and ischemia of the extremities and other tissues including the central nervous system.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Concomitant use is contraindicated. Coadministration has not been studied but is expected to increase concentrations of ergot derivatives due to inhibition of CYP3A4 by ritonavir. Medicinal products that are highly dependent on CYP3A for clearance and for which elevated plasma levels are associated with serious events, such as ergot derivatives, must not be co-administered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></div><div>&nbsp;</div><div>Coadministration is contraindicated. Acute ergot toxicity characterized by vasospasm and tissue ischemia has been associated with co-administration of ritonavir and ergotamine.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Erlotinib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Erlotinib is a substrate for CYP3A4 and P-gp and coadministration could potentially increase erlotinib concentrations. Coadministration of a potent CYP3A4 inhibitor should be avoided, but if this is not possible, use with caution. Close monitoring for erlotinib mediated toxicity is necessary and a dose reduction may be required for erlotinib.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ertapenem</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as ertapenem undergoes minimal metabolism and is mainly excreted unchanged by the kidney by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Erythromycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Do not coadminister erythromycin with ombitasvir/paritaprevir/ritonavir + dasabuvir unless the benefit outweighs the risk. Erythromycin is a substrate and inhibitor of CYP3A4, P-gp and OATP. Exposure of erythromycin may increase due to possible OATP inhibition by paritaprevir and CYP3A4 inhibition by ritonavir. This may result in an increase of erythromycin-associated cardiac adverse reactions. Concentrations of paritaprevir and dasabuvir may also increase. If administered, monitor the subjects. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration has not been studied but is expected to increased concentrations of erythromycin, paritaprevir and dasabuvir due to inhibition of CYP3A4 and P-gp by erythromycin, paritaprevir, ritonavir and dasabuvir. Caution is advised.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Escitalopram</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Escitalopram can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Escitalopram is a CYP2C19, CYP2D6 and CYP3A4 substrate but there was no interaction with ombitasvir/paritaprevir/ritonavir + dasabuvir. Coadministration with escitalopram (10 mg single dose) had no effect on escitalopram Cmax and decreased AUC by 13%; Cmax and AUC of S-demethylcitalopram increased by 15% and 36%. Ombitasvir Cmax and AUC increased by 9% and 2%, but Cmin decreased by 3%. Paritaprevir Cmax increased by 12%, but AUC and Cmin decreased by 2% and 29%. Dasabuvir Cmax and AUC increased by 10% and 1%, but Cmin decreased by 11%.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Coadministration with escitalopram (10 mg single dose) had no effect on escitalopram Cmax and decreased AUC by 13%. The Cmax and AUC of S-demethylcitalopram increased by 15% and 36%. Ombitasvir Cmax and AUC increased by 9% and 2%, but Cmin decreased by 3%. Paritaprevir Cmax increased by 12%, but AUC and Cmin decreased by 2% and 29%. Dasabuvir Cmax and AUC increased by 10% and 1%, but Cmin decreased by 11%. No dose adjustment is necessary for escitalopram.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div>&nbsp;</div><div>No dose adjustments are recommended when ombitasvir, paritaprevir, ritonavir and dasabuvir are co-administered with escitalopram.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Eslicarbazepine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied and is not recommended as eslicarbazepine is an inducer of CYP3A4 and may give rise to reduced concentrations of ombitasvir/paritaprevir/ritonavir + dasabuvir. In addition eslicarbazepam is metabolised by CYP3A4 and concentrations may increase due to inhibition by ritonavir.  </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Esomeprazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Esomeprazole is a substrate of CYP2C19 and CYP2C9 and concentrations may decrease due to induction of CYP2C19 by ritonavir. .  Exposure of omeprazole, a model CYP2C19 substrate, decreased by 40-50% with ombitasvir/paritaprevir/ritonavir + dasabuvir. Use higher doses of esomeprazole if clinically indicated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration has not been studied but is expected to decrease concentrations of esomeprazole due to induction of CYP2C19 by ritonavir. If clinically indicated higher doses of esomeprazole may be needed.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em><br /><br /></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Estazolam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Estazolam is a substrate of CYP3A4. Exposure of estazolam may increase due to CYP3A4 inhibition by ritonavir causing CNS depression and sedation. Monitor the subjects. A decrease in estazolam dose maybe needed.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Estradiol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Estradiol is metabolized to estriol by CYPs 3A4 and 1A2, which is then glucuronidated by UGTs 1A1 and 2B7. Coadministration could increase estradiol concentrations due to inhibition of CYP3A4, but decrease concentrations due to induction of CYP1A2. Estriol concentrations could increase due to inhibition of UGT1A1. Monitoring is recommended as the overall effect and clinical significance is difficult to predict.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Estramustine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Estramustine is dephosphorylated and minimal data show it not to undergo any form of CYP metabolism.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Etanercept</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance an interaction is unlikely. However there have been reports of worsening of hepatitis C in patients receiving etanercept. Use with caution and monitor closely for worsening of HCV.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ethambutol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Ethambutol is partly metabolized by alcohol dehydrogenase (20%) and partly eliminated unchanged in the faeces (20%) and urine (50%)</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ethinylestradiol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>There is a potential for ALT elevations in female subjects using ethinylestradiol-containing medications such as combined oral contraceptives, contraceptive patches or contraceptive vaginal rings. Ethinylestradiol-containing medications must be discontinued prior to starting therapy with ombitasvir/paritaprevir/ritonavir + dasabuvir. Alternative methods of contraception (e.g, progestin only contraception or non-hormonal methods) are recommended. Ethinylestradiol-containing medications can be restarted approximately 2 weeks following completion of HCV treatment.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Use of ethinylestradiol-containing medicinal products such as those contained in most combined oral contraceptives or contraceptive vaginal rings is contraindicated. Patients who are taking ethinylestradiol-containing medicinal products (i.e. most combined oral contraceptives or contraceptive vaginal rings) must switch to an alternative method of contraception (e.g., progestin only contraception or non-hormonal methods) prior to initiating Viekirax and dasabuvir therapy. Coadministration with an oral contraceptive containing ethinylestradiol (0.035 mg) and norgestimate (0.25 mg) increased ethinylestradiol Cmax, AUC and Cmin by 16%, 6% and 12%, respectively. The Cmax, AUC and Cmin of the metabolites of norgestimate increased by 2.26-, 2.54- and 2.93-fold for norgestrel, and by 2.01-, 2.60- and 3.11-fold for norelgestromin. Ombitasvir Cmax increased by 5%, AUC decreased by 3% and there was no change in Cmin. Paritaprevir Cmax, AUC and Cmin decreased by 30%, 34% and13% respectively. Dasabuvir Cmax, AUC and Cmin decreased by 49%, 52% and 47%, respectively.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div>&nbsp;</div><div>Coadministration is contraindicated due to the potential for ALT elevations. Ethinyl estradiol-containing medications must be discontinued prior to starting therapy with Viekira Pak&#174;. Alternative methods of contraception (e.g, progestin only contraception or non-hormonal methods) are recommended during Viekira Pak&#174; therapy. Ethinyl estradiol-containing medications can be restarted approximately 2 weeks following completion of treatment with Viekira Pak&#174;. Coadministration with an oral contraceptive containing ethinylestradiol (0.035 mg) and norgestimate (0.25 mg) was studied in 7 subjects. Ombitasvir Cmax increased by 5%, AUC decreased by 3% and there was no change in Cmin. Paritaprevir Cmax, AUC and Cmin decreased by 30%, 34% and13% respectively. Ritonavir Cmax, AUC and Cmin decreased by 20%, 29% and 21%, respectively. Dasabuvir Cmax, AUC and Cmin decreased by 49%, 52% and 47%, respectively. Ethinylestradiol Cmax, AUC and Cmin increased by 16%, 6% and 12%, respectively (data from 8 subjects). Cmax, AUC and Cmin of the metabolites norelgestromin increased by 2.01-, 2.60- and 3.11-fold, respectively, whereas those of norgestrel increased by 2.26-, 2.54- and2.93-fold, respectively (data from 9 subjects).</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ethosuximide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but may increase concentrations of ethosuximide due to inhibition of CYP3A4 by ritonavir causing increased risk of CNS toxicity. Monitor the subjects. A decrease in ethosuximide dose may be needed.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Etoposide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Etoposide is partly metabolised by CYP3A4 to reactive catechol metabolites and partly metabolised by UGT1A1. Concentrations of etoposide may increase due to CYP3A4 inhibition by ritonavir, increasing risk and severity of mucositis, myelosuppression and transaminitis. Use with caution.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Etoricoxib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but etoricoxib can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Etoricoxib is a substrate of CYPs 3A4, 2D6, 2C9, 1A2 and 2C19. The involvement of multiple P450s, and the low first pass effect, effectively minimizes the potential for significant drug interactions with potent CYP450 inhibitors such as ritonavir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Etravirine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration is contraindicated in the European product label. Coadministration has not been studied but is expected to decrease plasma concentrations of ombitasvir/paritaprevir/ritonavir + dasabuvir due to CYP3A4 induction and reduce their therapeutic effect.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Concomitant use is contraindicated. Co-administration with medicinal products that are strong or moderate enzyme inducers, such as etravirine, is expected to decrease ombitasvir, paritaprevir, ritonavir and dasabuvir plasma concentrations and reduce their therapeutic effect and must not be co-administered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Everolimus</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Everolimus is a substrate of CYP3A4 and its exposure may increase due to CYP3A4 inhibition by ritonavir. Everolimus is not recommended with ombitasvir/paritaprevir/ritonavir + dasabuvir in the absence of study data. Use alternative immunosuppressants such as tacrolimus or ciclosporin.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Exemestane</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Exemestane is metabolised by CYP3A4 but coadministration with ketoconazole (a potent CYP3A4 inhibitor) showed no clinically significant effects and no effect is expected due to inhibition of CYP3A4 by ritonavir. No a priori dose adjustment is required.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Exenatide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration with exenatide has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as exenatide is eliminated via glomerular filtration. However, as exenatide slows gastric emptying it is advisable to take ombitasvir/paritaprevir/ritonavir + dasabuvir at least 1 hour before an exenatide injection.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ezetimibe</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Ezetimibe is a substrate of UGT. Ezetimibe glucuronide is a substrate of OATP1B1 and this metabolite may increase due to OATP1B1 inhibition by paritaprevir. Start with the lowest possible dose and monitor.&nbsp;Note,&nbsp;use of ezetemibe is not recommended in moderate to severe hepatic dysfunction.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Famotidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but famotidine can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Famotidine is mainly renally excreted. Exposures of ombitasvir/paritaprevir/ritonavir + dasabuvir were not affected in presence of omeprazole, an acid reducing agent. Hence, no interaction is expected with famotidine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Felodipine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Felodipine is a substrate of CYP3A4. Felodipine exposure may increase due to CYP3A4 inhibition by ritonavir resulting in the potential for hypotension and tachycardia (decreased blood pressure, increased heart rate, swelling of lower extremities, etc.). If possible, avoid concomitant use with ombitasvir/paritaprevir/ritonavir + dasabuvir.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Fenofibrate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as fenofibrate is metabolised by multiple enzyme pathways (esterases, UGT2B7 and UGT1A1).&nbsp;Note, fenofibrate is contraindicated in severe hepatic disease in its European SPC, and its US Prescribing Information contraindicates it in active liver disease.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Fentanyl</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Fentanyl is a substrate of CYP3A4 and its exposure may increase due to CYP3A4 inhibition by ritonavir. Monitor the subjects; a decrease in fentanyl dose should be considered.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Fexofenadine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Fexofenadine is a substrate of P-gp/OATP and is renally excreted. Although there was no interaction between ombitasvir/paritaprevir/ritonavir + dasabuvir and digoxin, a model P-gp substrate, fexofenadine concentrations may increase due to inhibition of OATP1B1 by paritaprevir. Use with caution. A dose decrease may be needed for fexofenadine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration has not been studied but is expected to increase fexofenadine concentrations due to inhibition of OATP1B1 by paritaprevir. Caution should be used when coadministered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Filgrastim</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. CYP involvement has not been displayed with filgrastim and it is mainly eliminated by neutrophil-mediated clearance, such that the serum concentration of pegfilgrastim declines rapidly with neutrophil recovery.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Finasteride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Finasteride is a substrate of CYP3A4 and its exposure may increase due to CYP3A4 inhibition by ritonavir. Monitor the subject.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Fingolimod</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fingolimod is metabolised mainly by CYP4F2 and is unlikely to interact with substrates of CYP enzymes or the main transporter proteins.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Fish oils</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but fish oils can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Although cytochrome P450 enzymes are involved in the hydroxylation of omega-3 there is no human data to indicate any clinical significance.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Flecainide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Flecainide is a substrate of CYP2D6. Ritonavir inhibits CYP2D6 at higher doses but at the 100 mg dose, ritonavir does not markedly inhibit CYP2D6. However flecainide is a narrow therapeutic index drug and caution is advised.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration may increase concentrations of this antiarrhythmic. Caution is warranted and therapeutic concentration monitoring (if available) is recommended for antiarrhythmics when co-administered.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Flibanserin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied and is contraindicated. Flibanserin is primarily metabolized by CYP3A4 and to a lesser extent by CYP2C19. Inhibition of CYP3A4 by ritonavir&nbsp;is expected to increase flibanserin concentrations which can cause severe hypotension and syncope.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Flucloxacillin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Flucloxacillin is mainly eliminated renally, partly by glomerular filtration and partly by active secretion via OAT1. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Fluconazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but fluconazole can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Fluconazole is mainly excreted in urine. Fluconazole exposure shows a clinically insignificant increase (12-15%) with ritonavir. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Flucytosine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Flucytosine is metabolised to 5-fluorouracil which undergoes further metabolism by dihydropyrimidine dehydrogenase.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Fludarabine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Fludarabine phosphate is rapidly hydrolyzed (non-CYP mediated) to 2F-ara-A, the principal metabolite, which is then eliminated renally.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Fludrocortisone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Concomitant administration of ritonavir and corticosteroids is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects. Fludrocortisone is a substrate of CYP3A4 and its exposure may increase due to CYP3A4 inhibition by ritonavir. Use alternative treatments.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Fluindione</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Fluinidone is metabolised by CYP2C9 (major) and CYP1A2 (minor). Clinical studies showed no interaction between and warfarin, a CYP2C9 substrate, and ombitasvir/paritaprevir/ritonavir + dasabuvir, so no interaction is expected due to CYP2C9 involvement. Any decrease in concentrations of fluindione due to induction of CYP1A2 by ombitasvir/paritaprevir/ritonavir + dasabuvir is unlikely to be of clinical significance as this is a minor route of metabolism. However, case reports have described alterations in INR for patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir with warfarin or acenocoumarol, so close monitoring of INR is recommended.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Flunisolide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but may increase flunisolide concentrations due to inhibition of CYP3A4 by ritonavir. An alternative to flunisolide should be used if available.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Fluoxetine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but fluoxetine can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Fluoxetine is an inhibitor of CYP2D6. Ritonavir exposures increased slightly (~19%) due to CYP2D6 inhibition by fluoxetine.&nbsp;Note,&nbsp;a lower or less frequent dose should be considered in cases of hepatic insufficiency.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Flupentixol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Flupentixol is metabolised by sulfoxidation and dealkylation and is a substrate of UGT. Flupenthixol exposure may increase with ombitasvir/paritaprevir/ritonavir + dasabuvir. A decrease in dose should be considered. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Fluphenazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Fluphenazine is metabolised by and is an inhibitor of CYP2D6. Ritonavir inhibits CYP2D6 at higher doses but at the 100 mg dose, ritonavir does not appear to markedly inhibit CYP2D6. However monitor for adverse events. The effect of fluphenazine on QT interval could also be potentiated by concurrent use of other drugs.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Flurazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Flurazepam is a substrate of CYP3A4. Exposure of flurazepam may increase due to CYP3A4 inhibition by ritonavir causing CNS depression and sedation. Monitor the subjects. A decrease in flurazepam dose may be needed.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Flurbiprofen</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but flurbiprofen can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alternation is required. Flurbiprofen is a substrate of CYP2C9 and multiple UGTs. There is no interaction between ombitasvir/paritaprevir/ritonavir + dasabuvir and warfarin, a CYP2C9 substrate, so no interaction is expected due to CYP2C9 involvement. The involvement of multiple UGTs means that no interaction is expected via this pathway.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Fluticasone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Concomitant administration of ritonavir and glucocorticoids is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects. Fluticasone is a substrate of CYP3A4. Exposure of fluticasone may markedly increase due to CYP3A4 inhibition by ritonavir causing a decrease in plasma cortisol leading to Cushing's syndrome and adrenal suppression. Cushing's syndrome and adrenal suppression have been reported when ritonavir has been co-administered with fluticasone. Use beclomethasone as an alternative.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Coadministration has not been studied but is expected to increase concentrations of fluticasone due to inhibition of CYP3A4 by ritonavir. Caution should be used with fluticasone or other glucocorticoids that are metabolised by CYP3A4. Concomitant use of inhaled glucocorticoids metabolised with CYP3A can increase systemic exposures of the glucocorticoids, and cases of Cushing&#8217;s syndrome and subsequent adrenal suppression have been reported with ritonavir-containing regimens. Concomitant use, particularly long-term use, should only be initiated if the potential benefit of treatment outweighs the risk of systemic corticosteroid effects.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></div><div>&nbsp;</div><div>Coadministration may increase concentrations of fluticasone. Concomitant use with inhaled or nasal fluticasone may reduce serum cortisol concentrations. &nbsp;Alternative corticosteroids should be considered, particularly for long term use.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Fluvastatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied and is not recommended. Fluvastatin is a substrate of CYPs 2C9, 3A4, 2C8, and OATPs 1B1, 1B3 and BCRP. Exposure of fluvastatin may increase due to possible inhibition of OATP1B1 and BCRP by paritaprevir and ritonavir. No effect on concentrations of dasabuvir, ombitasvir or paritaprevir is expected. A temporary suspension of fluvastatin is recommended for the duration of treatment with ombitasvir/paritaprevir/ritonavir + dasabuvir. If statin treatment is required, switch to dose reduced pravastatin or rosuvastatin.&nbsp;Note, use of fluvastatin in active liver disease is contraindicated.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration has not been studied but is expected to increase concentrations of fluvastatin due to inhibition of OATP1B1 and BCRP by paritaprevir. Coadministration is not recommended. A temporary suspension of fluvastatin is recommended for the duration of treatment with Viekirax. If statin treatment is required during the treatment period, a switch to dose reduced pravastatin or rosuvastatin is possible. No effect on concentrations of dasabuvir, ombitasvir or paritaprevir is expected. <br><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br>Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Fluvoxamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but fluvoxamine can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Fluvoxamine is a substrate of CYP2D6 and an inhibitor of CYPs 1A2, 2C9, 2C19 and 3A4. Ritonavir inhibits CYP2D6 at higher doses but at the 100 mg dose it does not appear to markedly inhibit CYP2D6. It is unlikely that fluvoxamine will affect ombitasvir/paritaprevir/ritonavir + dasabuvir exposure. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Folic acid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as folic acid undergoes deconjugation and reduction</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Fondaparinux</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but fondaparinux can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Fondaprinux is mainly excreted in urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Formoterol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Formoterol is a substrate of UGT and CYPs 2D6, 2C19, 2C9 and 2A6. Due to involvement of multiple enzymes, inhibition of a single pathway may not affect formoterol exposures. However, use with caution and decrease formoterol dose, if clinically indicated. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Fosamprenavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration of fosamprenavir with ombitasvir/paritaprevir/ritonavir + dasabuvir is not recommended. Fosamprenavir is hydrolysed to amprenavir and then metabolised by CYP3A4. However amprenavir also inhibits CYP3A4. Exposure of ombitasvir/paritaprevir/ritonavir + dasabuvir and fosamprenavir may be altered.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Foscarnet</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely as foscarnet is mainly renally eliminated.  </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Fosinopril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Fosinopril is a prodrug metabolised in the liver by a non-CYP mechanism to the active metabolite.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See&nbsp;Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Frovatriptan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Frovatriptan is metabolised by CYP1A2 and exposure may be reduced with ombitasvir/paritaprevir/ritonavir + dasabuvir due to induction of CYP1A2 by ritonavir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Furosemide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration increased furosemide Cmax by 42%, although AUC was not significantly affected. No significant effects on ombitasvir, paritaprevir, ritonavir or dasabuvir were observed. Caution is warranted. Clinical monitoring of patients is recommended. The European SPCs for ombitasvir/paritaprevir/ritonavir + dasabuvir suggest a decrease in furosemide dose of up to 50% may be required.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Coadministration with furosemide (20 mg single dose) increased furosemide Cmax and AUC by 42% and 8%. Ombitasvir Cmax, AUC and Cmin increased by 14%, 7% and 12%, respectively. Paritaprevir Cmax and AUC decreased by 7% and 8%, but Cmin increased by 26%. Dasabuvir Cmax, AUC and Cmin increased by 12%, 9% and 6%, respectively. This is possibly due to UGT1A1 inhibition by paritaprevir, ombitasvir and dasabuvir. Patients should be monitored for clinical effects; a decrease in furosemide dose of up to 50% may be required.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></div><div>&nbsp;</div><div>Coadministration with furosemide (20 mg single dose) was studied in 12 subjects. Ombitasvir Cmax, AUC and Cmin increased by 14%, 7% and 12%, respectively. Paritaprevir Cmax and AUC decreased by 7% and 8%, but Cmin increased by 26%. Ritonavir Cmax, AUC and Cmin increased by 10%, 45 and 7%, respectively. Dasabuvir Cmax, AUC and Cmin increased by 12%, 9% and 6%, respectively. Furosemide Cmax and AUC increased by 42% and 8%. Clinical monitoring of patients is recommended and therapy should be individualized based on patient&#8217;s response.&nbsp;</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Gabapentin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but gabapentin can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Gabapentin is mainly excreted in urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Gadopentetate (gadolinium)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely as gadopentetate is mainly renally eliminated.  </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Gamma-hydroxybutyrate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied and based on metabolism and clearance an interaction is possible. The metabolism of GHB is not well characterised but may involve CYP3A4. The exposure of GHB could increase due to inhibition of CYP3A4 by ritonavir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Garlic</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but, based on metabolism and clearance, a clinically significant interaction is unlikely as garlic extract had no clinically significant effect on CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Gefitinib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Gefitinib is metabolised by CYP3A4 and concentrations may increase significantly due to inhibition of CYP3A4 by ritonavir. A physiologically-based pharmacokinetic model recommended a gefitinib dose of 125 mg in the presence of ritonavir.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>In a developed physiologically based pharmacokinetic model, steady state gefitinib concentrations were simulated in a virtual population of 50 individuals receiving gefitinib 250 mg once daily with and without ritonavir 100 mg. Gefitinib AUC was estimated to increase 3.85-fold when coadministered with ritonavir and a dose reduction to gefitinib 125 mg once daily when coadministered with ritonavir 100 mg daily was suggested.&nbsp;<br><em>Physiologically based pharmacokinetic model to predict drug-drug interaction in patients receiving antiretroviral and antineoplastic therapies. Molto J, Rajoli R, Back D, et al. 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, May 2015, Washington DC, Abstract 4.</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Gemcitabine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as gemcitabine is metabolised by cytidine deaminase.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Gemfibrozil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration is contraindicated. Dasabuvir exposure increased by ~10-fold in the presence of gemfibrozil which may increase the risk of QT prolongation. The mean half-life of dasabuvir increased from 5 to 92 hours. Paritaprevir and ritonavir exposures were comparable with and without gemfibrozil.&nbsp;</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Concomitant use is contraindicated. Coadministration of gemfibrozil (600 mg twice daily) and paritaprevir, ritonavir and dasabuvir increased paritaprevir Cmax and AUC by 21% and 38%, but increased dasabuvir Cmax and AUC by 2.01- and 11.25-fold. The increase in dasabuvir exposure is possibly due to CYP2C8 inhibition and the increase in paritaprevir possibly due to OATP1B1 inhibition by gemfibrozil.<br><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br>Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em><br><br></div></div>

<div>Gemfibrozil is contraindicated with dasabuvir due to an increase in dasabuvir exposures by 10-fold which may increase the risk of QT prolongation. Coadministration with gemfibrozil (600 mg twice daily) was studied in 11 subjects in the absence of ombitasvir. Paritaprevir Cmax and AUC increased by 21% and 38%. Ritonavir Cmax and AUC decreased by 16% and 10%. Data for dasabuvir were available from 3 subjects and showed increased of 2.01- and 11.25-fold for Cmax and AUC.</div>

<div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Gentamicin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but gentamicin can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Gentamicin is mainly excreted in urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ginkgo biloba</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but standard doses (up to 240 mg) of Ginkgo biloba can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. It is possible that Ginkgo biloba could cause a small increase in ombitasvir/paritaprevir/ritonavir + dasabuvir but this is unlikely to have any clinical relevance.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ginseng</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but ginseng can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alternation is required. Ginseng had no effect on alprazolam (a CYP3A4 substrate) in an in vivo study and in vitro data show no effect on a number of CYP isoforms, including CYPs 3A4, 1A2, 2E1 and 2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Glibenclamide (Glyburide)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Glibenclamide is mainly metabolized by CYP3A4 and to a lesser extent by CYP2C9. Glibenclamide exposure could be increased due to inhibition of CYP3A4 by ritonavir. Monitor clinical effect and reduce glibenclamide dosage if needed.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Gliclazide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but gliclazide exposure may decrease when administered with ombitasvir/paritaprevir/ritonavir + dasabuvir. Gliclazide is a substrate of CYP2C9 and CYP2C19. There was no interaction between ombitasvir/paritaprevir/ritonavir + dasabuvir and warfarin (a CYP2C9 substrate) so no interaction is expected due to CYP2C9 involvement. However, exposure of omeprazole (a model CYP2C19 substrate) decreased by 40-50% with ombitasvir/paritaprevir/ritonavir + dasabuvir. An interaction of similar magnitude is expected with other CYP2C19 substrates. Monitor the subject for lack of response. Increase the dose of gliclazide if needed.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Glimepiride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but glimepiride can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Glimepiride is a substrate of CYP2C9. There was no interaction between ombitasvir/paritaprevir/ritonavir + dasabuvir and warfarin, a CYP2C9 substrate like warfarin, so no interaction is expected with glimepiride. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration did not affect the exposures of the CYP2C9 substrate,  warfarin. Other CYP2C9 substrates such as glimepiride are not expected to  require dose adjustments.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Glipizide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but glipizide can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Glipizide is a substrate of CYP2C9. There was no interaction between ombitasvir/paritaprevir/ritonavir + dasabuvir and warfarin, a CYP2C9 substrate like warfarin, so no interaction is expected with glipizide.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration did not affect the exposures of the CYP2C9 substrate,  warfarin. Other CYP2C9 substrates such as glipizide are not expected to  require dose adjustments.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Goserelin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. There is minimal metabolism of goserelin and no clinically relevant accumulation with higher doses of the implant. Goserelin is renally cleared with no dose alteration required&nbsp;in renal or hepatic impairment.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See&nbsp;Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Grapefruit juice</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but it could increase ombitasvir/paritaprevir/ritonavir + dasabuvir exposure through inhibition of intestinal CYP3A4. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Griseofulvin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied and should only be considered if no alternative is available. Griseofulvin may induce CYP3A4 and decrease concentrations of ombitasvir/paritaprevir/ritonavir + dasabuvir. Griseofulvin is also metabolised by CYP3A4 and concentrations may increase due to inhibition of CYP3A4 by ritonavir. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Halofantrine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but concentrations of halofantrine may be increased through inhibition of CYP3A4 by ritonavir.  Increased concentrations of halofantrine may be associated with serious and/or life threatening events.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Haloperidol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Haloperidol is a substrate of CYP3A4 and UGT. Haloperidol exposure may increase due to CYP3A4 inhibition by ritonavir. UGT inhibitors have been shown not to affect haloperidol exposure. It is recommended to start with the lowest possible dose. Monitor for any adverse events.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Heparin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely as heparin is cleared by the reticuloendothelial system and is renally excreted.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Hydralazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied based on metabolism and clearance a clinically significant interaction is unlikely. Hydralazine is metabolised by multiple pathways including hydroxylation, conjugation and by N-acetylation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Hydrochlorothiazide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but hydrochlorothiazide can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Hydrochlorothiazide is mainly excreted in urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Hydrocodone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Hydrocodone exposures may markedly increase due to inhibition of CYP3A4 and CYP2D6 mediated metabolism. Monitor the subjects. A 50% decrease in hydrocodone dose may be needed with titration to effect.&nbsp;Note, use with caution in patients with hepatic impairment.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Hydrocortisone (topical)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Hydrocortisone cream/lotion can be used if applied on small areas. Concomitant administration of ritonavir and corticosteroids is not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects. Hydrocortisone is a substrate of CYP3A4 and its exposure may increase due to CYP3A4 inhibition by ritonavir. Use beclometasone as an alternative. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Hydromorphone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Hydromorphone exposures may increase with ombitasvir/paritaprevir/ritonavir + dasabuvir. Hydromorphone is a substrate of CYP2D6, CYP3A4, UGT1A3 and UGT2B7. Monitor the subjects. A reduction in hydromorphone dose may be needed.&nbsp;Note, use with caution in patients with hepatic impairment.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Hydroxychloroquine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but hydroxychloroquine can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Hydroxychloroquine is a CYP2D6 substrate. Ritonavir inhibits CYP2D6 at higher doses but at the 100 mg dose, ritonavir does not markedly inhibit CYP2D6.&nbsp;Note, the European SPC for hydroxychloroquine recommends caution in impaired hepatic function.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Hydroxyzine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but hydroxyzine can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Hydroxyzine is converted to its active metabolite, cetirizine.&nbsp;Note, as hydroxyzine elimination is impaired in patients with hepatic dysfunction, daily dose or dose frequency should be reduced in patients with impaired liver function.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Hyoscine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Hyoscine acts predominantly locally and undergoes minimal absorption.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ibandronic acid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but ibandronate can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. The portion of ibandronate that is not removed from the circulation via bone absorption is eliminated unchanged by the kidney (approximately 50% of the absorbed dose). However, note that ibandronate should be separated from food or other medicinal products.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ibuprofen</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but ibuprofen can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Ibuprofen is a substrate of CYP2C9. There was no interaction between ombitasvir/paritaprevir/ritonavir + dasabuvir and warfarin, a CYP2C9 substrate, so no interaction is expected with ibuprofen. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration did not affect the exposures of the CYP2C9 substrate, warfarin. Other CYP2C9 substrates such as ibuprofen are not expected to require dose adjustments.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Idarubicin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Idarubicin is converted to idarubicinol by aldoketoreductase.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Iloperidone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Iloperidone is metabolised by CYP3A4 and coadministration with ombitasvir/paritaprevir/ritonavir + dasabuvir may lead to an increase in iloperidone exposure. The US Prescribing Information suggests a dose reduction of ~50% when coadministered with strong inhibitors of CYP3A4 such as ritonavir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Iloprost</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Iloprost is metabolised by beta-oxidation of the carboxyl side chain with only a minor role for CYP metabolism.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Imatinib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Imatinib is metabolised by CYP3A4 and is a substrate for BCRP. Concentrations of imatinib may increase due to inhibition by paritaprevir and ritonavir. Increased imatinib exposure can be associated with serious and life threatening events. Clinical monitoring and lower doses of imatinib are recommended.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Imipenem</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Imipenem is metabolised renally and is predominantly eliminated in the urine.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Imipramine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Imipramine is metabolised by CYP3A4, CYP2C19 and CYP1A2 to desimpramine. Imipramine and desipramine are both metabolised by CYP2D6. Ritonavir could increase imipramine exposure via CYP3A4 inhibition. Monitor side effects and consider a dose reduction if required.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Indapamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Indapamide is a substrate of CYPs 2C9, 2D6 and 3A4 in vitro. Exposure of indapamide may increase due to CYP3A4 inhibition by ritonavir. Monitor the subjects. A dose decrease may be needed. Start with a lowest possible dose.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Indinavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration is contraindicated in the European product label. Coadministration has not been studied but concentrations of paritaprevir are expected to increase due to inhibition of CYP3A4 by indinavir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Concomitant use is contraindicated. Coadministration has not been studied but is expected to increase paritaprevir concentrations due to inhibition of CYP3A4 by indinavir. <br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Indometacin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but indometacin can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alternation is required. Indometacin is a substrate of CYP2C9 and multiple UGTs. There was no interaction between ombitasvir/paritaprevir/ritonavir + dasabuvir and warfarin (a CYP2C9 substrate) so no interaction is expected due to CYP2C9 involvement. The involvement of multiple UGTs means that no interaction is expected via this pathway.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Insulin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but insulin can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Insulin is metabolised by hydrolysis.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ipilimumab</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Ipilimumab is not metabolised by cytochrome P450 and no drug interactions were involved in studies involving multiple CYP isozymes.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ipratropium bromide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but ipratropium bromide can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Ipratropium bromide is metabolised by esterases.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Irbesartan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Irbesartan is a substrate of UGT, CYP2C9 and OATP1B1. Ombitasvir/paritaprevir/ritonavir + dasabuvir increased exposure of raltegravir (a UGT substrate) by up to 2-fold and a similar interaction is possible with other UGT substrates. Paritaprevir is an inhibitor of OATP1B1 and may increase irbesartan exposure. Consider irbesartan dose reduction and monitor blood pressure and heart rate.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Irinotecan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Irinotecan is substrate of CYP3A4, P-gp and UGT1A1. Exposure of irinotecan may increase due to inhibition CYP3A4 by ritonavir. Use with caution and monitor closely for increased cytotoxic side effects. A decrease in irinotecan dose may be needed.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Iron supplements</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but iron supplements can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alternation is required.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Isoflurane</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Isoflurane is mainly metabolised by CYP2E1 which is not affected by ombitasvir/paritaprevir/ritonavir + dasabuvir.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Isoniazid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as isoniazid is metabolised by N-acetyl transferase and CYP2E1. Ombitasvir/paritaprevir/ritonavir + dasabuvir are not known to affect these enzymes.&nbsp;However, use of isoniazid should be carefully monitored with patients with current chronic liver disease. Severe and sometimes fatal hepatitis associated with isoniazid therapy may occur and may develop even after many months of treatment.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Isotretinoin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Isotretinoin is metabolized mainly by CYP2C8 and CYP3A4 with participation from CYP2B6 and CYP2C9; exposure may be increased due to inhibition of CYPs 3A4 and 2C8 by ritonavir. Monitoring of side effects is recommended.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ispaghula husk</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. The mode of action of ispaghula husk is physical and does not depend on absorption into the systemic circulation. However, ispaghula husk may delay or reduce gastrointestinal absorption of other drugs and it is advisable to separate administration if possible.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Isradipine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Concentrations of isradipine may increase due to inhibition of CYP3A4 and P-gp. Monitor heart rate and blood pressure, and for side effects such as oedema, postural hypotension and headache.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Itraconazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration is contraindicated in the European product label. Coadministration has not been studied. Itraconazole is a substrate and inhibitor of CYP3A4 and P-gp. Exposure of itraconazole may increase due to inhibition CYP3A4 by ritonavir. Exposure of ombitasvir/paritaprevir/ritonavir + dasabuvir could also increase.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Concomitant use is contraindicated. Coadministration has not been studied but is expected to increase concentrations of itraconazole, paritaprevir and dasabuvir due to inhibition of CYP3A4 and/or P-gp by itraconazole, paritaprevir, ritonavir and ombitasvir.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ivabradine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied however ivabradine is metabolised by CYP3A4 and coadministration with strong CYP3A4 inhibitors is contraindicated as it is likely to increase ivabradine concentrations to a level associated with a risk of excessive bradycardia.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ivermectin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Ivermectin is metabolised by CYP3A4 and there is the potential for marked inhibition by ritonavir. The clinical relevance of the increase is not clear.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ketamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Ketamine exposure may increase when administered with ombitasvir/paritaprevir/ritonavir + dasabuvir. Ketamine is a substrate of CYP3A4. If used outside of anaesthesia ensure that the patient is aware of signs of toxicity such as respiratory depression and hallucinations.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ketoconazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration increased ketoconazole AUC by ~2-fold  and increased paritaprevir AUC by 98%. The European product label states that the combination must not be coadministered whereas the US product label advises that high doses of ketoconazole (greater than 200 mg/day) are not recommended. These interaction charts reflect the more cautious option.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Co-administration with medicinal products that are strong inhibitors of CYP3A4, such as ketoconazole, is expected to increase paritaprevir plasma concentrations and must not be co-administered. Coadministration with ketoconazole (400 mg once daily) increased ketoconazole Cmax by 15% and increased AUC by 2.17-fold. Ombitasvir Cmax decreased by 2% and AUC increased by 17%. Paritaprevir Cmax and AUC increased by 37% and 98%. Dasabuvir Cmax and AUC increased by 16% and 42%.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div>&nbsp;</div><div>Coadministration with ketoconazole (400 mg once daily) was studied in 12 subjects. Ombitasvir Cmax decreased by 2% and AUC increased by 17%. Paritaprevir Cmax and AUC increased by 37% and 98%. Ritonavir Cmax and AUC increased by 27% and 57%. Dasabuvir Cmax and AUC increased by 16% and 42%. Ketoconazole Cmax increased by 15% and AUC increased by 2.17-fold. When co-administered, the maximum daily dose of ketoconazole should be limited to 200 mg per day.&nbsp;</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ketoprofen</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but ketoprofen can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alternation is required. Ketoprofen is a substrate of multiple UGTs. The involvement of multiple UGTs means that no interaction is expected via this pathway.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Labetalol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is possible. The metabolism of labetalol is thought to be via conjugation involving UGT1A1 and UGT2B7. As ombitasvir/paritaprevir/ritonavir + dasabuvir inhibit UGT1A1 an increase in labetalol concentrations may be seen. Monitor blood pressure and consider dose reduction if required. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Lacidipine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Lacidipine is a substrate of CYP3A4 and exposure of lacidipine may increase due to inhibition CYP3A4 by ritonavir. Caution is advised and a dose titration may be required.&nbsp;Note, caution is advised in patients with hepatic impairment.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Lacosamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Lacosamide is metabolised by CYP3A4 and caution is recommended with strong inhibitors of CYP3A4 such as ritonavir&nbsp;which may increase systemic exposure of lacosamide. Monitor for increased side effects.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Lactulose</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Lactulose may affect absorption of ombitasvir/paritaprevir/ritonavir + dasabuvir. The potential interaction can be resolved by giving lactulose 4 hours after ombitasvir/paritaprevir/ritonavir + dasabuvir administration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Lamivudine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration of ombitasvir/paritaprevir/ritonavir + dasabuvir and abacavir/lamivudine (600/300 mg once daily) was studied in 12 HIV/HCV-negative subjects and had no clinically significant effect on the pharmacokinetics of ombitasvir, paritaprevir, ritonavir, dasabuvir, abacavir or lamivudine. No dose adjustment is required for ombitasvir/paritaprevir/ritonavir or lamivudine during coadministration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration of ombitasvir/paritaprevir/ritonavir + dasabuvir and abacavir/lamivudine (600/300 mg once daily) was studied in 12 HIV/HCV-negative subjects. During coadministration abacavir exposures were up to 13% lower; lamuvidine Cmax and AUC were up to 13% lower and Ctrough was 29% higher. Exposure of ombitasvir and dasabuvir were up to 18% lower, and paritaprevir and ritonavir Ctrough both decreased by 34%. No dose adjustment is recommended for ombitasvir/paritaprevir/ritonavir + dasabuvir or abacavir/lamuvudine during coadministration.<br /><em>Drug-drug interactions of ombitasvir/paritaprevir/r plus dasabuvir with dolutegravir or abacavir plus lamivudine.<br />Khatn A, Trinh R, Zhao W, et al. 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy, Washington DC, May 2015, Abstract 57.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Lamivudine (HBV)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but lamivudine can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Given the findings from the interaction study conducted with emtricitabine and tenofovir, along with the known similar elimination pathway for lamivudine, a pharmacokinetic drug interaction is not expected.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Lamotrigine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Lamotrigine is a substrate of UGT1A4. Atazanavir (UGT1A1 inhibitor) does not affect lamotrigine glucuronidation, however, atazanavir + ritonavir decreases lamotrigine AUC by 32%. A similar interaction is possible with ombitasvir/paritaprevir/ritonavir + dasabuvir. Monitor the subjects with adjustment of lamotrigine dose as appropriate.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Lanreotide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. The limited information available indicate that somatostatin analogues, such as lanreotide, may increase concentrations of CYP450 substrates. Given that ritonavir is present in the current regimen the effect of lanreotide may be limited, however an interaction cannot be excluded. Monitor for side effects.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Lansoprazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Lansoprazole exposure may decrease when administered with ombitasvir/paritaprevir/ritonavir + dasabuvir. Lansoprazole is a substrate of CYP2C19 and CYP3A4. Exposure of omeprazole, a model CYP2C19 substrate, decreased by 40-50% when administered with ombitasvir/paritaprevir/ritonavir + dasabuvir, but exposures of the DAAs were not affected. An interaction of similar magnitude is expected with other CYP2C19 substrates. Monitor the subject for lack of response and increase the dose of lansoprazole if needed.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration has not been studied but is expected to decrease concentrations of lansoprazole due to induction of CYP2C19 by ritonavir. If clinically indicated higher doses of lansoprazole may be needed.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Lapatinib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but is not recommended. Concentrations of lapatinib may increase due to inhibition of CYP3A4 and P-gp inhibition by ritonavir. Lapatinib is an inhibitor of CYPs 3A4 and 2C8 but given the presence of ritonavir in this regimen it is unclear if there would be any additional increase in exposure of paritaprevir. Coadministration should be avoided if possible. If coadministration is unavoidable, a dose decrease of lapatinib will be required.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See&nbsp;Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ledipasvir/Sofosbuvir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Ombitasvir/paritaprevir/ritonavir + dasabuvir is a complete regimen. There are no data to support the coadministration with other DAAs.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>The safety and efficacy of ombitasvir/paritaprevir/ritonavir have been  established in combination with dasabuvir and/or ribavirin.  Co-administration of ombitasvir/paritaprevir/ritonavir + dasabuvir with  other directly acting antivirals has not been studied and therefore  cannot be recommended.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Lercanidipine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Avoid concomitant use with ombitasvir/paritaprevir/ritonavir + dasabuvir. Lercanidipine is a substrate of CYP3A4 and its exposure may increase with ritonavir, a CYP3A4 inhibitor. Ketoconazole, a strong CYP3A4 inhibitor, increased plasma levels of the eutomer S-lercanidipine (AUC by 15-fold, Cmax by 8-fold). Consequently, the lercanidipine product label says that coprescription of lercanidipine with inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, ritonavir, erythromycin, troleandomycin) should be avoided.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Letrozole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but letrozole is a substrate of CYP3A4. Exposure of letrozole may increase due to inhibition CYP3A4 by ritonavir. Caution is advised and a dose titration may be required.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Levetiracetam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but levetiracetam can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Levetiracetam is metabolised by hydrolysis and is renally excreted.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Levocetirizine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but levocetirizine can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Less than 14% of cetirizine is metabolised (CYP3A4 and multiple identified enzymes).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Levofloxacin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but levofloxacin can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Levofloxacin is mainly excreted in urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Levomepromazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but levomepromazine can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Levomepromazine is metabolised in part by CYP2D6. Ritonavir inhibits CYP2D6 at higher doses but at the 100 mg dose it does not appear to markedly inhibit CYP2D6. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Levothyroxine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Levothyroxine exposure may be increased due to UGT1A1 inhibition by ombitasvir/paritaprevir/ritonavir + dasabuvir. Levothyroxine is metabolised by sequential deiodination, glucuronidation and sulfation. Thyroid stimulating hormone (TSH) levels should be carefully monitored in patients receiving levothyroxine and ombitasvir/paritaprevir/ritonavir + dasabuvir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration has not been studied but is expected to increase concentrations of levothyroxine due to inhibition of UGT1A1 by paritaprevir, ombitasvir and dasabuvir. Clinical monitoring and dose adjustment may be required for levothyroxine.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em><br /></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Lidocaine (Lignocaine)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Lidocaine is a substrate of CYP3A4. Exposure of lidocaine may increase due to CYP3A4 inhibition by ritonavir causing adverse effects (common adverse reactions are those from the central and peripheral nervous system). Therapeutic concentration monitoring should be done for lidocaine and a decrease in lidocaine dose maybe needed. Topical lidocaine can be used since there is minimal systemic absorption and adverse effects are averted.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration may increase concentrations of this antiarrhythmic. Caution is warranted and therapeutic concentration monitoring (if available) is recommended for antiarrhythmics when co-administered.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Linaclotide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Linaclotide is metabolised locally within the gastrointestinal tract and extensive studies have shown no CYP or transporter interactions occur.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Linagliptin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Linagliptin is a substrate and a mild inhibitor of CYP3A4 and P-gp. However data with ritonavir (a potent 3A4/P-gp inhibitor) indicated that despite an increase in exposure of linagliptin, a clinically relevant interaction would not be expected due to the large safety window of linagliptin.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Linezolid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Linezolid is not metabolised by CYP450 and is not known to affect any of the key enzymes.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Liraglutide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Liraglutide is metabolised in a similar manner to large proteins with no specific organ having been identified as major route of elimination.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Lisinopril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but lisinopril can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Lisinopril does not undergo metabolism and is excreted entirely unchanged into the urine.&nbsp;Note, lisinopril exposure is increased in cirrhotic patients due to decreased clearance.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Lithium </p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but lithium can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Lithium is mainly excreted in urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Lixisenatide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Lixisenatide is a peptide and is not metabolised by cytochrome P450. However, delayed gastric emptying due to lixisenatide may reduce absorption of orally administered medicinal products. Ombitasvir/paritaprevir/ritonavir + dasabuvir should be taken at least 1 hour before or 4 hours after lixisenatide injection.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Loperamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but loperamide can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Loperamide is substrate of P-gp but no significant interaction was observed with digoxin (a model P-gp substrate) and ombitasvir/paritaprevir/ritonavir + dasabuvir.&nbsp;Note,&nbsp;use with caution&nbsp;in patients with hepatic impairment as&nbsp;no pharmacokinetic data are available and&nbsp;in such patients&nbsp;reduced first pass metabolism may result in a relative overdose leading to CNS toxicity.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Lopinavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration is contraindicated in the European product label and not recommended in the US product label. Lopinavir/ritonavir (800/200 mg once daily or 400/100 mg twice daily) in combination with ombitasvir/paritaprevir/ritonavir + dasabuvir increased paritaprevir AUC by up to 2.2-fold. This is due to the higher total dose of ritonavir (300 mg/day).</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Concomitant use is contraindicated. Coadministration with lopinavir/ritonavir (400/100 mg twice daily) decreased lopinavir Cmax and AUC by 13% and 6%, but increased Cmin by 15%. Ombitasvir Cmax, AUC and Cmin increased by 14%, 17% and 24 % respectively. Paritaprevir Cmax, AUC and Cmin increased by 2.04-, 2.17- and 2.36-fold, respectively. Dasabuvir Cmax, AUC and Cmin decreased by 1%, 7% and 32%, respectively. When lopinavir/ritonavir (800/200 mg once daily administered in the evening) was coadministered, the effect on Cmax and AUC of DAAs and lopinavir was similar to that observed when lopinavir/ritonavir 400/100 mg twice daily was administered. The increase in paritaprevir exposures may be due to inhibition of CYP3A/efflux transporters by lopinavir and higher dose of ritonavir. Co-administration with medicinal products that are strong inhibitors of CYP3A4, such as lopinavir/ritonavir, is expected to increase paritaprevir plasma concentrations and must not be co-administered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></div><div>&nbsp;</div><div>Coadministration with lopinavir/ritonavir (400/100 mg twice daily) was studied in 6 subjects. Ombitasvir Cmax, AUC and Cmin increased by 14%, 17% and 24 % respectively. Paritaprevir Cmax, AUC and Cmin increased by 2.04-, 2,.17- and 2.36-fold, respectively. Ritonavir Cmax increased by 55% and AUC and Cmin increased by 2.05- and 5.25-fold. Dasabuvir Cmax, AUC and Cmin decreased by 1%, 7% and 32%, respectively. Lopinavir Cmax and AUC decreased by 13% and 6%, but Cmin increased by 15%. Coadministration with lopinavir/ritonavir (800/200 mg once daily) was studied in 12 subjects. Ombitasvir Cmax and AUC decreased by 13% and 3%, but Cmin increased by 11%. Paritaprevir Cmax decreased by 1%, AUC increased by 87% and Cmin increased by 8.23-fold. Ritonavir Cmax increased by 57% and AUC and Cmin increased by 2.62- and 19.46-fold. Dasabuvir Cmax, AUC and Cmin decreased by 44%, 46% and 53%, respectively. &nbsp;Lopinavir Cmax and AUC decreased by 14% and 6% but Cmin increased by 3.18-fold. Co-administration with lopinavir/ritonavir is not recommended.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Loratadine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Loratadine is substrate of CYP3A4 and a substrate and inhibitor of P-gp and its exposure may increase with ombitasvir/paritaprevir/ritonavir + dasabuvir due to CYP3A4 inhibition. No a priori dose adjustment is required but monitor for increased drowsiness.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Lorazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Lorazepam is a substrate of multiple UGTs and its exposure may increase with ombitasvir/paritaprevir/ritonavir + dasabuvir due to UGT inhibition. Monitor the subjects and decrease lorazepam dose, if clinically indicated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Lormetazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Lormetazepam is a substrate of UGT and its exposure may increase with ombitasvir/paritaprevir/ritonavir + dasabuvir due to UGT inhibition. Ombitasvir/paritaprevir/ritonavir + dasabuvir increased exposure of raltegravir (a UGT substrate) by up to 2-fold and a similar interaction is possible with other UGT substrates. Monitor the subjects and a decrease in dose may be needed for lormetazepam.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Losartan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Losartan is converted to its active metabolite by CYP2C9 and to a minor extent by CYP3A4. Ombitasvir/paritaprevir/ritonavir at steady-state did not affect the plasma exposures of the CYP2C9 substrate warfarin. An interaction between ombitasvir/paritaprevir/ritonavir + dasabuvir and losartan is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Lovastatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration is contraindicated. Lovastatin is a substrate of CYP3A4 and OATP1B1. Exposure of lovastatin may increase due to CYP3A4 inhibition by ritonavir causing potential for serious reactions such as risk of myopathy including rhabdomyolysis.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Concomitant use is contraindicated. Coadministration has not been studied but is expected to increase concentrations of lovastatin due to inhibition of CYP3A4 and OATP1B. Medicinal products that are highly dependent on CYP3A for clearance and for which elevated plasma levels are associated with serious events, such as lovastatin, must not be co-administered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></div><div>&nbsp;</div><div>Coadministration is contraindicated due to the potential for myopathy including rhabdomyolysis.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Lubiprostone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Metabolism of lubiprostone rapidly occurs within the stomach and jejunum, most likely in the absence of any systemic absorption. In vitro studies show that no CYP mediated interactions occur.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Lumefantrine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration is not recommended unless there is no alternative. Lumefantrine is a substrate of CYP3A4 and its exposure may increase due to CYP3A4 inhibition by ritonavir. Lumefantrine and ombitasvir/paritaprevir/ritonavir + dasabuvir should not be coadministered unless there is no alternative. Monitor the subjects.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Lymecycline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely. Lymecycline is not metabolised and is excreted unchanged by renal and biliary routes.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Lysergic acid diethylamide (LSD)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. LSD (lysergic acid diethylamide) is metabolized to O-H-LSD and N-desmethyl-LSD partly by CYP (unknown isoenzyme). Coadministration could potentially increase LSD concentrations. Ensure the patient is aware of signs/symptoms of LSD toxicity (i.e. hallucinations, agitation, psychosis, flashbacks).</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Macitentan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Macitentan is metabolised by CYP3A4 and caution is recommended with a strong inhibitor of CYP3A4 such as ritonavir as it is expected to increase macitentan concentrations. Monitor closely for side effects.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Macrogol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but a clinically significant interaction with is unlikely as macrogol is not absorbed from the gastro-intestinal tract and is excreted in urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Maprotiline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but maprotiline can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Maprotiline is metabolised by CYP2D6; ritonavir inhibits CYP2D6 at higher doses but at the 100 mg dose it does not appear to markedly inhibit CYP2D6. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Maraviroc</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Maraviroc is a substrate of CYP3A4 and its exposure may increase due to CYP3A4 inhibition by ritonavir. Monitor the subjects. A decrease in maraviroc dose may be needed as with other boosted regimens. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>MDMA (Ecstasy)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. MDMA (Ecstasy) is metabolised by CYP2D6; ritonavir inhibits CYP2D6 at higher doses but at the 100 mg dose it does not appear to markedly inhibit CYP2D6. However there have been fatalities reported in subjects taking ritonavir-boosted HIV protease inhibitors and MDMA. Caution is strongly advised.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Mebeverine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but mebevirine can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Mebevinine is metabolised by hydrolysis. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Mefenamic acid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Mefenamic acid is metabolised by CYP2C9 and conjugated with UGT2B7 and UGT1A9. Ombitasvir/paritaprevir/ritonavir at steady-state did not affect the plasma exposures of warfarin (a CYP2C9 substrate) so it is unlikely that it will affect mefenamic acid. Ombitasvir/paritaprevir/ritonavir + dasabuvir does not affect UGT1A9 and UGT2B7.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Mefloquine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration of mefloquine with ombitasvir/paritaprevir/ritonavir + dasabuvir is not recommended unless the benefit outweighs the risk due to QTc prolongation. Mefloquine is a substrate of CYP3A4. Co-administration of mefloquine (500 mg single oral dose) with the CYP3A4 inhibitor ketoconazole (400 mg once daily for 10 days) in 8 healthy volunteers increased the mean Cmax and AUC of mefloquine by 64% and 79%, respectively. A similar interaction may occur with ombitasvir/paritaprevir/ritonavir + dasabuvir.&nbsp;Note, the European SPC for mefloquine (but not the US Prescribing Information) contraindicates&nbsp;the use of mefloquine in patients with severe hepatic impairment.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Melatonin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Melatonin is a substrate of CYP1A2&nbsp;and concentrations may decrease due to induction of CYP1A2 by ombitasvir/paritaprevir/ritonavir + dasabuvir. However, based on studies with ombitasvir/paritaprevir/ritonavir + dasabuvir and duloxetine (a sensitive CYP1A2/CYP2D6 substrate), no a priori dose alteration is recommended.&nbsp;</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Meloxicam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Meloxicam is a substrate of CYP2C9 (major) and CYP3A4 (minor) and concentrations may be increased due to inhibition of CYP3A4 by ritonavir. There was no interaction between ombitasvir/paritaprevir/ritonavir + dasabuvir and warfarin (a CYP2C9 substrate) so no interaction is expected due to CYP2C9 involvement.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Mephedrone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mephedrone is metabolized mainly by CYP2D6. Ritonavir inhibits CYP2D6 at higher doses but at the 100 mg dose it does not appear to markedly inhibit CYP2D6. However, as dosing of recreational drugs can be variable, caution is advised. Ensure the patient is aware of signs/symptoms of mephedrone toxicity (i.e., agitation, tachycardia, hypertension).</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Mercaptopurine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Mercaptopurine is converted into active thioguanine nucleotides by the enzyme xanthine oxidase and undergoes methylation by thiopurine methyltransferase to form S- methylated nucleotides, which are also cytotoxic. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Meropenem</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but meropenem can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Meropenem is mainly excreted in urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Mesalazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely as mesalazine largely acts locally in the gut and is acetylated there.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Metamizole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied and is not recommended. Ombitasvir/paritaprevir/ritonavir and dasabuvir&nbsp;exposures may decrease due to induction of CYP3A4 by metamizole.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Metformin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Metformin is mainly excreted in urine by active secretion via OCT-2 and MATE-1. Despite evidence that paritaprevir/ritonavir can inhibit MATE-1, preliminary unpublished data suggest there is no clinically significant interaction.&nbsp;Note, metformin is contraindicated with hepatic insufficiency, acute alcohol intoxication, and alcoholism.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Methadone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Methadone can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Methadone is a substrate of CYP3A4 and CYP2B6 and a substrate of P-gp, however, no interaction was observed between methadone and ombitasvir/paritaprevir/ritonavir + dasabuvir. Coadministration with methadone (20-120 mg once daily) increased R-methadone Cmax and AUC by 4% and 5%, but decreased Cmin by 6%. S-methadone Cmax, AUC and Cmin decreased by 1%, 1% and 14%, respectively. There was no change in exposure of ombitasvir, paritaprevir or dasabuvir based on cross-study comparison.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Coadministration with methadone (20-120 mg once daily) increased R-methadone Cmax and AUC by 4% and 5%, but decreased Cmin by 6%. S-methadone Cmax, AUC and Cmin decreased by 1%, 1% and 14%, respectively. (Dose normalised parameters reported for methadone.) There was no change in exposure of ombitasvir, paritaprevir or dasabuvir based on cross-study comparison. No dose adjustment is necessary.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em><br /><br /></div>No dose adjustments are recommended when ombitasvir, paritaprevir, ritonavir and dasabuvir are co-administered with methadone.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Methamphetamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Methamphetamine is metabolised by CYP2D6. Ritonavir inhibits CYP2D6 at higher doses but at the 100 mg dose it does not appear to markedly inhibit CYP2D6. However, as dosing of recreational drugs can be variable, caution is advised.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Methenamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically relevant drug interaction is unlikely. Methenamine is mainly excreted unchanged in the urine</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Methotrexate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but methotrexate can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Methotrexate undergoes intracellular metabolism.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Methylcellulose</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Methylcellulose is not absorbed and a pharmacokinetic interaction is unlikely. However, bulk laxatives such as oral methylcellulose lower the transit time through the gut and could affect the absorption of other drugs. It is advisable to separate administration if possible.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Methyldopa</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as methyldopa is mainly renally cleared. However methyldopa is contraindicated in active hepatitis and active cirrhosis in both the European and US product labels.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Methylergonovine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but methylergonovine is contraindicated due to the potential for serious and/or life-threatening reactions such as acute ergot toxicity characterized by vasospasm and ischemia of the extremities and other tissues including the central nervous system.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Concomitant use is contraindicated. Coadministration has not been  studied but is expected to increase concentrations of ergot derivatives  due to inhibition of CYP3A4 by ritonavir. Medicinal products that are  highly dependent on CYP3A for clearance and for which elevated plasma  levels are associated with serious events, such as ergot derivatives,  must not be co-administered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></div><div>&nbsp;</div><div>Coadministration is contraindicated. Acute ergot toxicity characterized by vasospasm and tissue ischemia has been associated with co-administration of ritonavir and methylergonovine.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Methylphenidate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but methylphenidate can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Methylphenidate is metabolised by de-esterification.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Methylprednisolone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Methylprednisolone is a substrate of CYP3A4 and P-gp. Methylprednisolone exposure (after oral/IV administration) increased by 2.6- to 3.9-fold with itraconazole, a CYP34 inhibitor. A similar interaction may be seen with ritonavir due to CYP3A4 inhibition by ritonavir. Monitor the subjects for side effects due to adrenal suppression. A decrease in methylprednisolone dose is recommended.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Metoclopramide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but metoclopramide can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Metoclopramide is mainly excreted in urine.&nbsp;Note, a reduced dosage is recommended in patients with hepatic insufficiency.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Metolazone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but metolazone can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Metolazone is mainly excreted in urine. There is little published data on transporter interactions.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Metoprolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but metoprolol can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Metoprolol is metabolised by CYP2D6. Ritonavir inhibits CYP2D6 at higher doses but at the 100 mg dose ritonavir does not markedly inhibit CYP2D6.&nbsp;Note, in patients with severe hepatic dysfunction a reduction in dosage may be necessary.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Metronidazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but no dose adjustment is needed with ombitasvir/paritaprevir/ritonavir + dasabuvir. The metabolism of metronidazole is not well described.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Mexiletine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but mexiletine can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Mexiletine is a substrate and inhibitor of CYP2D6 and a substrate of CYP1A2. Ritonavir inhibits CYP2D6 at higher doses but at the 100 mg dose ritonavir does not markedly inhibit CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration may increase concentrations of this antiarrhythmic. Caution is warranted and therapeutic concentration monitoring (if available) is recommended for antiarrhythmics when co-administered.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Miconazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. A clinically significant interaction is unlikely after topical administration due to the limited systemic availability. When administered systemically miconazole is an inhibitor of CYP3A4 and CYP2C9, but no additional inhibition of CYP3A4 is expected due to the presence of ritonavir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Midazolam (oral)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration is contraindicated. Midazolam is a substrate of CYP3A4 and its exposure may increase with ritonavir causing serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Concomitant use is contraindicated. Coadministration has not been studied but is expected to increase midazolam concentrations due to inhibition of CYP3A4 by ritonavir. Medicinal products that are highly dependent on CYP3A for clearance and for which elevated plasma levels are associated with serious events, such as midazolam, must not be co-administered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></div><div>&nbsp;</div><div>Coadministration is contraindicated. Orally administered midazolam is extensively metabolized by CYP3A4. Coadministration may cause large increases in the concentration of this benzodiazepine. The potential exists for serious and/or life threatening events such as prolonged or increased sedation or respiratory depression.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Midazolam (parenteral)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Midazolam is a substrate of CYP3A4 and concomitant use of parenteral midazolam with ritonavir may increase midazolam exposures. Co-administration should be done in a setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. Dosage reduction for midazolam should be considered, especially if more than a single dose of midazolam is administered.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration has not been studied but is expected to increase midazolam concentrations due to inhibition of CYP3A4 by ritonavir. If parenteral midazolam is co-administered, close clinical monitoring for respiratory depression and/or prolonged sedation should be exercised and dosage adjustment should be considered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Mifepristone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but may increase mifepristone concentrations due to CYP3A4 inhibition by ritonavir. Monitor for increased side effects and for subsequent increase in toxicities. A decrease in mifepristone dose may be needed.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Milk thistle</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Drug interaction studies suggest that milk thistle has limited clinical impact on substrates of CYP3A, UGT, P-gp and OATP.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Milnacipran</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as milnacipran undergoes minimal CYP450 related metabolism. Note, no dosage adjustment is necessary for patients with hepatic impairment, but caution should be exercised in patients with severe hepatic impairment. Milnacipran should ordinarily not be prescribed to patients with substantial alcohol use or evidence of chronic liver disease.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Minoxidil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Minoxidil is a substrate of UGTs (the specific UGTs have not been well described) and its exposure may increase due to UGT inhibition by ombitasvir/paritaprevir/ritonavir + dasabuvir. The exposure of raltegravir (a UGT substrate) was increased by up to 2-fold with ombitasvir/paritaprevir/ritonavir + dasabuvir; a similar interaction is possible with other UGT substrates. In the absence of further data, monitor cardiac parameters and for increased side effects.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Mirtazapine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Mirtazapine is a substrate of CYP3A4, CYP2D6 and CYP1A2 and its exposure may increase due to CYP3A4 inhibition by ritonavir. Monitor the subjects. A decrease in mirtazapine dose may be needed.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Misoprostol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Misoprostol is predominantly metabolised via fatty acid oxidising systems and has no effect on the CYP450 enzyme system.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Moclobemide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Moclobemide is metabolised by multiple pathways, including CYP2C19 and CYP2D6. Exposure of omeprazole, a model CYP2C19 substrate, decreased by 40-50% when administered with ombitasvir/paritaprevir/ritonavir + dasabuvir, but exposures of each component of the DAA regimen were not affected. Ritonavir inhibits CYP2D6 at higher doses but at the 100 mg dose ritonavir does not markedly inhibit CYP2D6. Due to multiple enzyme pathways involved in moclobemide metabolism, a clinically significant interaction is not expected. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Modafinil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration of modafinil is not recommended with ombitasvir/paritaprevir/ritonavir + dasabuvir. Modafinil is a substrate of CYP3A4, an inhibitor of CYP2C9 and CYP2C19, an inducer of CYPs 1A2, 2B6 and 3A4 and a substrate of P-gp. Exposures of ombitasvir/paritaprevir/ritonavir + dasabuvir may decrease due to CYP3A4 induction by modafinil which may potentially decrease efficacy. Use alternative drugs.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Mometasone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Mometasone is substrate of CYP3A4. Mometasone plasma concentrations increased in some subjects on co-administration of ketoconazole. Since mometasone plasma levels appear to increase and plasma cortisol levels decrease with ketoconazole, caution should be exercised on coadministration with ombitasvir/paritaprevir/ritonavir + dasabuvir. A decrease in dose of mometasone is recommended. Monitor the subject closely for any adrenal suppression effects. Beclometasone can be used as an alternative.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Montelukast</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Montelukast is a substrate of CYP2C8.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Morphine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Morphine is metabolised by UGT2B7, UGT1A3 with a minor contribution from CYP2D6 and CYP3A4. No a priori dose adjustment is required for morphine, however, monitor for side effects and decrease dose, if needed.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Moxifloxacin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Moxifloxacin is a substrate of UGT. Moxifloxacin shows a QT prolongation of 6 msec at its prescribed doses. Monitor the subjects. A reduction in moxifloxacin dose may be needed.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Moxonidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but a clinically significant interaction is unlikely as moxonidine is only minimally metabolized and undergoes renal excretion.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See&nbsp;Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Mycophenolate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Mycophenolic acid may interact with paritaprevir and ritonavir. Mycophenolic acid exposures may increase. A reduction in dose may be needed.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Naftidrofuryl</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The metabolism of naftidrofuryl is not well described. There is no a priori reason for dose modification.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Naloxegol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied and is contraindicated. Naloxegol is metabolised by CYP3A4 and concentrations are expected to increase due to inhibition of CYP3A4 by ritonavir. Coadministration with ketoconazole (a potent CYP3A4 inhibitor) increased naloxegol AUC by ~13-fold; a similar increase would be expected with ritonavir.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Naloxone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Naloxone can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Coadministration of ombitasvir/paritaprevir/ritonavir + dasabuvir with buprenorphine (4-24 mg once daily) and naloxone (1-6 mg once daily) increased naloxone Cmax and AUC by 18% and 28%. There was no change in exposure of ombitasvir, paritaprevir or dasabuvir based on cross-study comparison.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration with buprenorphine (4-24 mg once daily) and naloxone  (1-6 mg once daily) increased buprenorphine Cmax, AUC and Cmin by 2.18-,  2.07- and 3.12-fold, respectively; values for norbuprenorphine  increased by 2.07-, 1.84- and 2.10-fold, respectively. Naloxone Cmax and  AUC increased by 18% and 28%. (Dose normalised parameters reported for  buprenorphine and naloxone.) The increases were due to CYP3A4 inhibition  by ritonavir and UGT inhibition by paritaprevir, ombitasvir and  dasabuvir. There was no change in exposure of ombitasvir, paritaprevir  or dasabuvir based on cross-study comparison. No dose adjustment is  necessary.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em><br /><br />Coadministration  with buprenorphine (4-24 mg once daily) and naloxone (1-6 mg once  daily) was studied in 10 subjects. Cmax, AUC and Cmin of buprenorphine  increased by 2.18-, 2.07- and 3.12-fold, respectively; values for  norbuprenorphine increased by 2.07-, 1.84- and 2.10-fold, respectively.  Naloxone Cmax and AUC increased by 18% and 28%. No dose adjustment of  buprenorphine/naloxone is required upon co-administration. Patients  should be closely monitored for sedation and cognitive effects.<br /><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Naltrexone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but naltrexone can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Naltrexone is metabolised by dihydrodiol dehydrogenase.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Naproxen</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but naproxen can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Naproxen is a substrate of CYPs 1A2, CYP2C9, CYP2C8 and multiple UGTs. There was no interaction between ombitasvir/paritaprevir/ritonavir and warfarin, a CYP2C9/CYP1A2 substrate, so no interaction is expected with naproxen.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Naratriptan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Naratriptan is metabolised by a wide range of CYP enzymes and is mainly excreted in urine. Significant metabolic drug interactions with naratriptan are not anticipated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Nateglinide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but nateglinide can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required.  Nateglinide is a substrate of CYP2C9. There was no interaction between ombitasvir/paritaprevir/ritonavir + dasabuvir and warfarin, a CYP2C9 substrate, so no interaction is expected with nateglinide.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Nebivolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but nebivolol can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Nebivolol is a substrate of CYP2D6 and UGT. At a dose of 100 mg ritonavir does not markedly inhibit CYP2D6.&nbsp;Note, the European SPC contraindicates the use of nebivolol in patients with hepatic insufficiency, whereas the US Prescribing Information recommends an initial dose of 2.5 mg once daily in patients with moderate hepatic impairment.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Nefazodone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but may increase nefazodone concentrations due to CYP3A4 inhibition by ritonavir. Monitor for increased side effects and for subsequent increase in toxicities. A decrease in nefazodone dose may be needed.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Nelfinavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Nelfinavir is a substrate of CYP3A4 and CYP2C19. Exposure of nelfinavir may increase due to CYP3A4 inhibition by ritonavir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Neostigmine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Neostigmine metabolism has not been well described but limited data suggest metabolism occurs via hydrolysis by cholinesterase with up to 50% of a dose being excreted unchanged in urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Nevirapine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but is contraindicated in the European product label. The effect is difficult to predict since there could be a 2-way interaction. Nevirapine is expected to decrease ombitasvir, paritaprevir, ritonavir and dasabuvir plasma concentrations and reduce their therapeutic effect. In addition, nevirapine is metabolised by CYP3A4 and therefore exposure could increase due to inhibition by ritonavir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Concomitant use is contraindicated. Co-administration with medicinal products that are strong or moderate enzyme inducers, such as nevirapine, is expected to decrease ombitasvir, paritaprevir, ritonavir and dasabuvir plasma concentrations and reduce their therapeutic effect and must not be co-administered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Nicardipine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Nicardipine is a substrate of CYP3A4 and of P-gp. Exposure of nicardipine may increase due to CYP3A4 inhibition by ritonavir causing potential for hypotension and cardiac arrhythmias. Monitor the subjects. Start with the lowest possible dose.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Nicorandil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as nicorandil metabolism is mainly by denitrition or the molecule into the nicotinamide pathway.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Nifedipine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Nifedipine is a substrate of CYP3A4 and P-gp. Exposure of nifedipine may increase due to CYP3A4 inhibition by ritonavir causing potential for hypotension and cardiac arrhythmias. Monitor the subjects. Start with the lowest possible dose. Clinical monitoring of calcium channel blockers is recommended when co-administered.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration has not been studied but is expected to increase concentrations of nifedipine. Dose decrease and clinical monitoring of calcium channel blockers is recommended when co-administered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Nilotinib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Concentrations of nilotinib may increase due to inhibition of CYP3A4 by ritonavir. Avoid combination if possible or monitor both drugs closely, including for QT prolongation. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Nisoldipine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Nisoldipine is a substrate of CYP3A4 and a substrate of P-gp. Exposure of nisoldipine may increase due to CYP3A4 inhibition by ritonavir causing potential for hypotension and cardiac arrhythmias. If possible use an alternative.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Nitrendipine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Nitrendipine exposure may increase when administered with ombitasvir/paritaprevir/ritonavir + dasabuvir. Nitrendipine is a substrate of CYP3A4 and UGT. Monitor the subjects. Start with a lowest possible dose.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Nitrofurantoin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but nitrofurantoin can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. 50-70% of a nitrofurantoin dose is metabolised (unknown mechanism) and 30% is excreted in urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Norethisterone (Norethindrone)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Norethindrone as a PROGESTIN ONLY can be administered with ombitasvir/paritaprevir/ritonavir and dasabuvir and no dose alteration is required. Norethindrone is metabolised by glucuronidation and sulfation. Ombitasvir/paritaprevir/ritonavir and dasabuvir did not cause a clinically significant change in norethindrone AUC. However it is CONTRAINDICATED when given as a combined oral contraceptive with ethinylestradiol due to an increase in ALT.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Coadministration of a progestin only contraceptive containing norethindrone (0.35 mg) decreased norethindrone Cmax, AUC and Cmin by 17%, 9% and 15%, respectively. Ombitasvir Cmax was unchanged and AUC and Cmin decreased by 1% and 3%. Paritaprevir Cmax, AUC and Cmin increased by 24%, 23% and 43%, respectively. Dasabuvir Cmax increased by 1%, but AUC and Cmin decreased by 4% and 5%. No dose adjustment is necessary.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></div><div>&nbsp;</div><div>No dose adjustments are recommended when ombitasvir, paritaprevir, ritonavir and dasabuvir are co-administered with progestin only contraceptives.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Norfloxacin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Norfloxacin is is excreted by the kidney and in the bile following partial metabolism by CYP1A2.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Nortriptyline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but nortriptyline can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Nortriptyline is a substrate and inhibitor of CYP2D6, but at 100 mg dose ritonavir does not markedly inhibit CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Nystatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Systemic absorption of nystatin from oral or topical dosing is minimal and nystatin is mainly excreted in the faeces.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ofloxacin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but ofloxacin can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Olfloxacin is mainly excreted in urine by glomerular filtration and active transport.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Olanzapine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Olanzapine is a substrate of UGT1A4 and CYP1A2. Olanzapine exposure may decrease due to both UGT1A4 and CYP1A2 induction by ombitasvir/paritaprevir/ritonavir + dasabuvir. Although based on studies with ombitasvir/paritaprevir/ritonavir + dasabuvir and duloxetine (a sensitive CYP1A2/CYP2D6 substrate) no a priori dose alteration is required, it is suggested to monitor the subjects.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Olmesartan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Olmesartan is substrate of OATP1B1 and its exposure may increase due to inhibition of OATP1B1/3 by paritaprevir. Consider dose reduction and monitor blood pressure and heart rate.&nbsp;Note, the European SPC for olmesartan recommends an initial 10 mg dose of olmesartan (with a maximum 20 mg daily dose) in moderate hepatic impairment. It does not recommend olmersartan in severe hepatic impairment. No dosage restrictions are given in the US Prescribing Information.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Omalizumab</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Cytochrome P450 enzymes, efflux pumps and protein-binding mechanisms are not involved in the metabolism and clearance of omalizumab.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Omeprazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration decreased omeprazole exposure by ~40% with no significant effect on ombitasvir, paritaprevir, ritonavir or dasabuvir. Monitor patients for decreased efficacy of omeprazole. Use higher doses of omeprazole if clinically indicated but avoid use of more than 40 mg per day of omeprazole.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Coadministration with omeprazole (40 mg once daily) decreased omeprazole Cmax and AUC both by 38% due to induction of CYP2C19 by ritonavir. Ombitasvir Cmax, AUC and Cmin increased by 2%, 5% and 4%, respectively. Paritaprevir Cmax and AUC increased by 19% and 18%, but Cmin decreased by 8%. Dasabuvir Cmax, AUC and Cmin increased by 13%, 8% and 5%. If clinically indicated higher doses of omeprazole should be used.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em><br /><br /></div>Coadministration with omeprazole (40 mg once daily) was studied in 11 subjects. Ombitasvir Cmax, AUC and Cmin increased by 2%, 5% and 4%, respectively. Paritaprevir Cmax and AUC increased by 19% and 18%, but Cmin decreased by 8%. Ritonavir Cmax and AUC increased by 4% and 2%, but Cmin decreased by 3%. Dasabuvir Cmax, AUC and Cmin increased by 13%, 8% and 5%. Omeprazole Cmax and AUC both decreased by 38%. Monitor patients for decreased efficacy of omeprazole. Consider increasing the omeprazole dose in patients whose symptoms are not well controlled; avoid use of more than 40 mg per day of omeprazole.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ondansetron</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but ondansetron can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Ondansetron is a substrate of CYP3A4, CYP2D6 and CYP1A2. Exposure of ondansetron was not affected by aprepitant, a moderate CYP3A4 inhibitor. As multiple enzymes are involved in the metabolism of ondansetron, it is likely that inhibition or loss of one enzyme will be compensated by others and may result in little change in overall rates of ondansetron elimination.&nbsp;Note, ondansetron clearance is significantly reduced and half-life significantly increased in subjects with moderate or severe hepatic impairment; in such patients a total daily dose of 8&nbsp;mg should not be exceeded and parenteral or oral administration is recommended.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Orlistat</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Orlistat should only be used with ombitasvir/paritaprevir/ritonavir + dasabuvir if separated by 4-5 hours. Orlistat reduces lipid digestion and may affect absorption of the paritaprevir, ritonavir and ombitasvir components of the DAA.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Orphenadrine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Orphenadrine is an inhibitor of CYP2B6 but this enzyme is not involved in the metabolism of ombitasvir/paritaprevir/ritonavir + dasabuvir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Oseltamivir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Oseltamivir is converted to oseltamivir carboxylate by esterases and ombitasvir/paritaprevir/ritonavir + dasabuvir is unlikely to play a role in this process.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Oxaliplatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Oxaliplatin undergoes non enzymatic biotransformation and is eliminated renally, via OCT2 and MATE2-K and, to a lesser extent, MATE-1. Since paritaprevir/ritonavir can inhibit MATE-1, monitoring of the patient is recommended.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Oxamniquine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but oxamniquine can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Limited data suggest that oxamniquine is likely to be a substrate of CYP2D6 but ritonavir at the 100 mg dose does not markedly inhibit CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Oxazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Oxazepam is a substrate of UGT and its exposure may increase due to UGT inhibition by ombitasvir/paritaprevir/ritonavir + dasabuvir.  Monitor the subjects. A reduction in oxazepam dose may be needed.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Oxcarbazepine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied and alternative drugs should be used. Ombitasvir/paritaprevir/ritonavir + dasabuvir exposures may decrease due to induction of CYP3A4 by oxcarbazepine. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Oxprenolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Oxprenolol is a substrate of UGTs and its exposure may increase due to UGT inhibition by ombitasvir/paritaprevir/ritonavir + dasabuvir. Monitor the subjects and either start with lower dose or consider a dose reduction.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Oxycodone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Oxycodone is a substrate of CYP3A4. Ketoconazole, a CYP3A4 inhibitor, increased oxymorphone AUC by 3-fold and reduced noroxycodone and noroxymorphone AUCs by 80%. Inhibition of CYP3A4 resulted in metabolism by the CYP2D6 pathway. A similar effect could be anticipated with ritonavir. Monitor the subjects. A decrease in oxycodone dose may be needed.&nbsp;Note, use of oxycodone in patients with moderate to severe hepatic failure is contraindicated in the European SPC but not in the US Prescribing Information.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Paliperidone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Paliperidone is a substrate of P-gp and concentrations may increase due to P-gp inhibition by ombitasvir/paritaprevir/ritonavir + dasabuvir. However, there was no interaction between ombitasvir/paritaprevir/ritonavir + dasabuvir and digoxin, a model P-gp substrate and hence an interaction with paliperidone is not considered likely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Pamidronate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration with pamidronate has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pamidronate is not hepatically metabolised and is almost exclusively renally excreted.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Pantoprazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Pantoprazole exposure may decrease when administered with by ombitasvir/paritaprevir/ritonavir + dasabuvir. Pantoprazole is a substrate of CYP2C19, CYP3A4 and CYP2C9, and is also metabolised by sulfotranseferases. Exposure of omeprazole, a model CYP2C19 substrate, decreased by 40-50% when administered with ombitasvir/paritaprevir/ritonavir + dasabuvir, but exposure of the DAA was not affected. An interaction of similar magnitude is expected with other CYP2C19 substrates. Use higher doses of pantoprazole, if clinically indicated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Paracetamol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but paracetamol can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Due to the involvement of multiple metabolic pathways (UGT1A1, GSH conjugation, CYP2E1, CYP1A2), an interaction is unlikely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Paroxetine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but paroxetine can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Paroxetine is a substrate and inhibitor of CYP2D6, but at 100 mg dose ritonavir does not markedly inhibit CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Peg-IFN alfa</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied as ombitasvir/paritaprevir/ritonavir + dasabuvir is a complete interferon free regimen.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Penicillamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as multiple mechanisms are thought to be involved in the metabolism of penicillamine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Penicillin V</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but penicillin V can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Penicillin V is mainly excreted in urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Pentamidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but pentamidine can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Pentamidine is a substrate of CYP2D6 and CYP1A2 but at 100 mg dose ritonavir does not markedly inhibit CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Pentoxifylline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but pentoxifylline can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. The metabolism of pentoxifylline is not well characterised.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Perampanel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Perampanel is metabolised by CYP3A4 and concentrations may increase due to inhibition of CYP3A4 by ritonavir. In the absence of further data, monitor for increased side effects. Although perampanel is an inducer of CYP3A4, a clinically significant effect on the components of the DAA regimen is unlikely in the presence of ritonavir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Perazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but is not recommended unless there is clear benefit due to the potential increase in perazine due to ritonavir CYP3A4 inhibition. Cardiac conduction abnormalities have been associated with perazine and ECG monitoring is recommended in combination with ombitasvir/paritaprevir/ritonavir + dasabuvir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Pericyazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. The metabolism of percyazine has not been well characterised but it is likely to involve CYP2D6. At 100 mg dose ritonavir does not markedly inhibit CYP2D6 but in the absence of data with ombitasvir/paritaprevir/ritonavir + dasabuvir, monitor for increased side effects of pericyazine. Monitoring is recommended as cardiac conduction abnormalities, including QT prolongation may be seen with pericyazine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Perindopril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but perindopril can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Perindopril is metabolised by hydrolysis, glucuronidation and cyclization.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Perphenazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but perphenazine can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Perphenazine is a substrate of CYP2D6; ritonavir inhibits CYP2D6 at higher doses but at the 100 mg dose it does not appear to markedly inhibit CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Pethidine (Meperidine)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pethidine is metabolised mainly by CYP2B6 but no interaction was observed between ombitasvir/paritaprevir/ritonavir + dasabuvir and methadone (CYP2B6 substrate). Hence, it is not expected to interact with other CYP2B6 substrates</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Phencyclidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Phencyclidine is a substrate of CYP3A4. Exposure of phencyclidine may increase due to CYP3A4 inhibition by ritonavir causing potential for side effects/toxicity. Monitor the subjects. Start with the lowest possible dose.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Phenobarbital</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration is contraindicated. Ombitasvir/paritaprevir/ritonavir + dasabuvir exposures may decrease due to induction of CYP3A4 by phenobarbital. A clinically significant decrease in phenobarbital plasma exposure is likely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Concomitant use is contraindicated. Coadministration has not been studied but is expected to decrease concentrations of ombitasvir, paritaprevir and dasabuvir due to induction of CYP3A4 by phenobarbital. Co-administration with medicinal products that are strong or moderate enzyme inducers, such as phenobarbital, is expected to decrease ombitasvir, paritaprevir, and ritonavir plasma concentrations and reduce their therapeutic effect and must not be co-administered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em><br /><br /></div>Coadministration is contraindicated. Ombitasvir, paritaprevir, ritonavir and dasabuvir exposures may decrease leading to a potential loss of therapeutic activity of Viekira Pak&#174;.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Phenprocoumon</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Phenprocoumon is metabolized by CYP2C9 and CYP3A4. Ritonavir may increase phenprocoumon exposure by inhibition of CYP3A4 but the magnitude of the interaction is difficult to predict given that phenprocoumon is also metabolized by CYP2C9 and partly excreted unchanged. Monitor INR closely.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Phenylephrine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but phenylephrine can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Phenylephrine is metabolised by MAO.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Phenytoin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration is contraindicated. Ombitasvir/paritaprevir/ritonavir + dasabuvir exposures may decrease due to CYP3A4 induction by phenytoin. Phenytoin is a substrate of CYP2C9 and CYP2C19 and its exposure may decrease due to CYP2C19 induction by ritonavir. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Concomitant use is contraindicated. Coadministration has not been studied but is expected to decrease concentrations of ombitasvir, paritaprevir and dasabuvir due to induction of CYP3A4 by phenytoin. Co-administration with medicinal products that are strong or moderate enzyme inducers, such as phenytoin, is expected to decrease ombitasvir, paritaprevir, and ritonavir plasma concentrations and reduce their therapeutic effect and must not be co-administered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em><br /><br /></div>Coadministration is contraindicated. Ombitasvir, paritaprevir, ritonavir and dasabuvir exposures may decrease leading to a potential loss of therapeutic activity of Viekira Pak&#174;.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Pilocarpine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but pilocarpin can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Pilocarpine is metabolised by CYP2A6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Pimozide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration is contraindicated. Pimozide is a substrate of CYP3A4 and its exposure may increase due to CYP3A4 inhibition by ritonavir causing potential for serious and/or life-threatening reactions such as cardiac arrhythmias.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Concomitant use is contraindicated. Coadministration has not been studied but is expected to increase concentrations of pimozide due to inhibition of CYP3A4 by ritonavir. Medicinal products that are highly dependent on CYP3A for clearance and for which elevated plasma levels are associated with serious events, such as pimozide, must not be co-administered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></div><div>&nbsp;</div><div>Coadministration is contraindicated due to the potential for cardiac arrhythmias.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Pindolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pindolol is only partially metabolised and is renally excreted both unchanged and as metabolites. No CYP involvement described to date.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Pioglitazone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Pioglitazone is a substrate of CYP2C8 and CYP1A2. There could potentially be an increase in exposure of pioglitazone when given with ombitasvir/paritaprevir/ritonavir + dasabuvir. Closely monitor the clinical effect and reduce dose if needed.&nbsp;Note, pioglitazone is contraindicated in hepatic impairment in the European SPC, but caution is advised in the US Prescribing Information.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Piperacillin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Piperacillin is only minimally metabolised and is excreted largely unchanged in the urine.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Pipotiazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but pipotiazine can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. The metabolism of pipotiazine has not been well described but may involve CYP2D6. Ritonavir inhibits CYP2D6 at higher doses but at the 100 mg dose it does not appear to markedly inhibit CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Piracetam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but piracetam can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Piracetam is mainly excreted in urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Pirfenadone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pirfenidone is metabolised by CYP1A2 (70-80%) with minor contributions from CYPs 2C9, 2C19, 2D6, and 2E1. Although ritonavir induces CYP1A2, due to the involvement of multiple metabolic pathways a clinically significant&nbsp;interaction is unlikely.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Piroxicam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but piroxicam can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Piroxicam is a substrate of CYP2C9 and is also metabolised by hydrolysis. There was no interaction between Ombitasvir/paritaprevir/ritonavir and warfarin, a CYP2C9 substrate, so no interaction is expected with piroxicam.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Pitavastatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied and is not recommended. Pitavastatin is a substrate for several transporters which may be inhibited by ombitasvir/paritaprevir/ritonavir + dasabuvir. No effect on concentrations of dasabuvir, ombitasvir or paritaprevir is expected. A temporary suspension of pitavastatin is recommended for the duration of treatment. If a statin is required, switch to dose reduced pravastatin or rosuvastatin.&nbsp;Note,&nbsp;use of pitavastatin in active liver disease is contraindicated in its US Prescribing Information.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration has not been studied but is expected to increase concentrations of pitavastatin due to inhibition of OATP1B1 by paritaprevir. Coadministration is not recommended. A temporary suspension of pitavastatin is recommended for the duration of treatment with Viekirax. If statin treatment is required during the treatment period, a switch to dose reduced pravastatin or rosuvastatin is possible. No effect on concentrations of dasabuvir, ombitasvir or paritaprevir is expected.<br><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br>Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Pivmecillinam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Pivmecillinam is hydrolysed to mecillinam which is excreted primarily in the urine with some biliary excretion.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Pizotifen</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but pizotifen can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Pizotifen is conjugated by UGT2B10 and ombitasvir/paritaprevir/ritonavir + dasabuvir is not known to affect this enzyme.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Posaconazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration is contraindicated in the European product label. Coadministration has not been studied. Posaconazole is an inhibitor of CYP3A4 and P-gp and may increase the exposure of ombitasvir/paritaprevir/ritonavir + dasabuvir. Concentrations of posaconazole may increase due to inhibition of CYP3A4 and/or P-gp by paritaprevir, ritonavir and ombitasvir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Concomitant use is contraindicated. Coadministration has not been studied but is expected to increase concentrations of posaconazole, paritaprevir and dasabuvir due to inhibition of CYP3A4 and/or P-gp by posaconazole, paritaprevir, ritonavir and ombitasvir.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Potassium</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but potassium asparaginate can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Pramipexole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as pramipexole is not hepatically metabolised and is mainly excreted in urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Prasugrel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Prasugrel is a substrate of CYPs 3A4, 2B6, 2C9 and 2C19, and is also metabolised by hydrolysis. Ritonavir (100 mg) decreased the Cmax and AUC of the active metabolite of prasugrel by 45% and 38%, respectively. This effect is attributed to inhibition of CYP3A4 by ritonavir. However, concomitant administration of ketoconazole with prasugrel did not impact inhibition of platelet aggregation despite a 34-46% decrease in the Cmax of the active metabolite. Monitor subjects and adjust prasugrel dose if required.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Pravastatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration increased pravastatin Cmax and AUC 40% and 80%, respectively.  Exposures of ombitasvir, paritaprevir, ritonavir and dasabuvir were comparable with and without pravastatin. The European product label advises to reduce thepravastatin dose by 50% and the US product lable advises that it should not exceed 40 mg per day.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Coadministration with pravastatin (10 mg once daily) increased pravastatin Cmax and AUC by 37% and 82% due to inhibition of OATP1B1 by paritaprevir. Ombitasvir Cmax, AUC and Cmin decreased by 5%, 11% and 6%, respectively. Paritaprevir Cmax decreased by 4%, but AUC and Cmin increased by 13% and 39%. There was no change in dasabuvir Cmax, AUC decreased by 4% and Cmin increased by 3%. Reduce pravastatin dose by 50%.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></div><div>&nbsp;</div><div>Coadministration with pravastatin (10 mg once daily) was studied in 12 subjects. Ombitasvir Cmax, AUC and Cmin decreased by 5%, 6% and 6%, respectively. Paritaprevir Cmax decreased by 4%, but AUC and Cmin increased by 13% and 39%. Ritonavir Cmax and AUC decreased by 11% and 5%, but Cmin increased by 8%. There was no change in dasabuvir Cmax, AUC decreased by 4% and Cmin increased by 3%. Pravastatin Cmax and AUC increased by 37% and 82%. When co-administered, the dose of pravastatin should not exceed 40 mg per day.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Praziquantel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Praziquantel is a substrate of CYP3A4 and its exposure may increase due to CYP3A4 inhibition by ritonavir. No a priori dose reduction is required but monitoring of side effects is recommended.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Prazosin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Studies indicate that prazosin is extensively metabolised, primarily by demethylation and conjugation but no CYP450 involvement has been described to date.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Prednicarbate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prednicarbate is metabolised to prednisolone-17-ethylcarbonate and then further metabolised to prednisolone. Following topical application, neither prednicarbate not its metabolites are detected in the systemic circulation. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Prednisone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Prednisone is a substrate of CYP3A4 and its exposure may increase due to CYP3A4 inhibition by ritonavir. Use with caution and monitor subjects for an appropriate and expected response to prednisone.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Pregabalin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but pregabalin can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Pregabalin is mainly excreted in urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Primaquine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Primaquine is metabolised mainly by a non-CYP mediated mechanism with a small fraction of the drug metabolised by multiple CYPs.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Primidone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied and is not recommended. Primidone and its major metabolite, phenobarbital, are inducers of CYP3A4 and may decrease concentrations of ombitasvir/paritaprevir/ritonavir + dasabuvir, leading to loss of virologic response. Primidone exposure may increase due to inhibition of CYP3A4 by ritonavir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Prochlorperazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Prochlorperazine is a substrate of CYP2D6, CYP2C19 and CYP3A4 in vitro. Its exposure may increase due to CYP3A4 inhibition by ritonavir. Monitor the subjects. Start with the lowest dose of prochlorperazine.&nbsp;Note, prochlorperazine should be avoided in patients with hepatic&nbsp;or renal dysfunction.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Proguanil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Induction of CYP2C19 by ritonavir may decrease proguanil concentration but increase concentrations of cycloguanil, the active metabolite. The clinical significance of this is uncertain.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Promethazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but promethazine can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Promethazine is a substrate of CYP2D6, but at 100 mg dose ritonavir does not markedly inhibit CYP2D6.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Propafenone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Propafenone is a substrate of CYP2D6, CYP3A4 and CYP1A2 and its exposure may increase due to CYP3A4 inhibition by ritonavir. Monitor the subjects. A dose decrease in propafenone should be considered.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration may increase concentrations of this antiarrhythmic. Caution is warranted and therapeutic concentration monitoring (if available) is recommended for antiarrhythmics when co-administered.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Propofol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Propofol is conjugated by UGTs 1A9 and 1A8 and is also metabolised to a limited extent by CYP2B6. These enzymes are not known to be affected by ombitasvir/paritaprevir/ritonavir + dasabuvir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Propranolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but propranolol can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Propranolol is a substrate of CYP2D6, but at 100 mg dose, ritonavir does not markedly inhibit CYP2D6.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Protamine sulphate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied, but based on very limited data concerning the metabolism, elimination and toxicity profiles of protamine an interaction would appear unlikely. Protamine complexed with heparin is thought to be metabolised by fibrinolysin and no CYP metabolism has been described.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Prucalopride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Prucalopride undergoes mainly renal elimination and is a weak substrate for P-gp. Ketoconazole (200 mg twice daily) increased the systemic exposure of prucalopride by 40% but this magnitude of effect is considered not to be clinically relevant.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Pyrantel</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but pyrantel can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Only a very small proportion of pyrantel is absorbed from the gastrointestinal tract and therefore there is limited potential for interactions. Pyrantel is metabolised by CYP2D6 in vitro, but at 100 mg dose ritonavir does not markedly inhibit CYP2D6.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Pyrazinamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as pyrazinamide is metabolised by xanthine oxidase which is not known to be affected by ombitasvir/paritaprevir/ritonavir + dasabuvir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Pyrimethamine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Data on the exact pathways of metabolism of pyrimethamine are limited but few interactions have been described with this drug.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Quazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Quazepam is a substrate of CYP3A4, CYP2C9 and CYP2C19, and FMO. Quazepam exposure may theoretically increase due to CYP3A4 inhibition by ritonavir. Monitor the subjects. A decrease in quazepam dose maybe needed.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Quetiapine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but is contraindicated in the European product label. Quetiapine exposure may increase due to CYP3A4 inhibition by ritonavir. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Concomitant use is contraindicated. Coadministration has not been studied but is expected to increase concentrations of quetiapine due to inhibition of CYP3A4 by ritonavir. Medicinal products that are highly dependent on CYP3A for clearance and for which elevated plasma levels are associated with serious events, such as quetiapine, must not be co-administered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Quinapril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but quinapril can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Quinapril is metabolised by esterases and is mainly excreted in urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Quinidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Quinidine is a substrate of CYP3A4 and its exposure may markedly increase due to CYP3A4 inhibition by ritonavir. Coadministration is contraindicated in the European product label, but the US product label suggests caution and therapeutic concentration monitoring. These charts reflect the more cautious option.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Concomitant use is contraindicated. Coadministration has not been studied by is expected to increase quinidine concentrations due to inhibition of CYP3A4 by ritonavir. Medicinal products that are highly dependent on CYP3A for clearance and for which elevated plasma levels are associated with serious events, such as quinidine, must not be co-administered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div>&nbsp;</div><div>Coadministration may increase concentrations of this antiarrhythmic. Caution is warranted and therapeutic concentration monitoring (if available) is recommended for antiarrhythmics when co-administered.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Quinine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Quinine is a substrate of CYP3A4 and its exposure may increase due to CYP3A4 inhibition by ritonavir. Monitor the subjects. A decrease in quinine dose maybe needed.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Rabeprazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Rabeprazole is a substrate of CYP2C19 and CYP3A4. Since omeprazole exposure decreased by 40-50% with ombitasvir/paritaprevir/ritonavir + dasabuvir a similar interaction may be expected with rabeprazole. Use higher doses of rabeprazole if clinically indicated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Raltegravir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Raltegravir can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Raltegravir is a substrate of UGT1A1. Coadministration increased raltegravir Cmax and AUC by 133% and 134%, respectively. Exposures of ombitasvir, paritaprevir, ritonavir and dasabuvir were comparable to the historic data. Increases of up to 2 fold in raltegravir exposures are not clinically relevant for safety. Hence, no dose adjustment is necessary.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Coadministration with raltegravir (400 mg twice daily) increased raltegravir Cmax, AUC and Cmin by 2.33-, 2.34- and 2.00-fold respectively. The increase in raltegravir exposures may be due to UGT1A1 inhibition by paritaprevir, ombitasvir and dasabuvir. The combination was not linked to any particular safety issues in a limited set of patients treated for 12-24 weeks. No clinically relevant changes in dasabuvir, paritaprevir and ombitasvir exposures (based on comparison with historical data) were observed during co-administration. No dose adjustment is necessary.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div>&nbsp;</div><div>No dose adjustments are recommended when ombitasvir, paritaprevir, ritonavir and dasabuvir are co-administered with raltegravir.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ramipril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but ramipril can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Ramipril is metabolised by esterases and glucuronidation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ranitidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but ranitidine can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Exposures of ombitasvir/paritaprevir/ritonavir + dasabuvir were not affected by omeprazole, an acid reducing agent and so no interaction is expected with ranitidine. Ranitidine is mainly excreted in urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ranolazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration of ranolazine with potent CYP3A4 inhibitors is contraindicated due to the increase in exposure and potential for serious adverse effects. A marked interaction can be anticipated with ritonavir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Rasagiline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Rasagiline is a substrate of CYP1A2 (major) and UGT (minor) and its exposure may decrease due to CYP1A2 induction by ombitasvir/paritaprevir/ritonavir + dasabuvir. Monitor the subjects and consider a dose modification if necessary.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Repaglinide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Repaglinide is metabolised mainly by CYP2C8 with CYP3A4 playing a minor role and is a substrate of OATP1B1. Repaglinide exposure increased by 1.2-fold and 2.4-fold with atorvastatin and ciclosporin (both inhibitors of OATP1B1) and a similar interaction is expected with ombitasvir/paritaprevir/ritonavir + dasabuvir due to OATP1B1 inhibition by paritaprevir. A dose reduction is recommended.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration has not been studied but is expected to increase  repaglinide concentrations due to inhibition of OATP1B1 by paritaprevir.  Caution should be used and dose decrease may be needed for repaglinide  when administered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Retigabine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. However, there is the risk of QT prolongation with both drugs and ECG monitoring is recommended if coadministered.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Retinol (Vitamin A)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Retinol is substrate of UGTs and its exposure may increase due to UGT inhibition by ombitasvir/paritaprevir/ritonavir + dasabuvir. This is unlikely to be of clinical importance, unless high doses of retinol supplementation are given long term. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ribavirin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Ribavirin can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir based on a specific patient population. Refer to the product label for full prescribing details.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Riboflavin (Vitamin B2)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as riboflavin does not undergo CYP metabolism and is primarily eliminated in urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Rifabutin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. An increase in the exposure of rifabutin and its metabolite are expected due to CYP3A4 inhibition by ritonavir. Monitor the subjects. A dosage reduction of rifabutin by at least three-quarters of the usual dose of 300 mg/day is recommended (e.g., 150 mg every other day or three times a week). Further dosage reduction may be necessary.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Rifampicin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration is contraindicated. Rifampicin is an inducer of CYP3A4 and may decrease exposures of ombitasvir/paritaprevir/ritonavir + dasabuvir leading to loss of virologic response. Rifampicin exposure may increase resulting in increased likelihood of toxicity.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Concomitant use is contraindicated. Coadministration has not been studied but is expected to decrease concentrations of ombitasvir, paritaprevir and dasabuvir due to induction of CYP3A4 by rifampicin. Co-administration with medicinal products that are strong or moderate enzyme inducers, such as rifampicin, is expected to decrease ombitasvir, paritaprevir, and ritonavir plasma concentrations and reduce their therapeutic effect and must not be co-administered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></div><div>&nbsp;</div><div>Coadministration is contraindicated. Ombitasvir, paritaprevir, ritonavir and dasabuvir exposures may decrease leading to a potential loss of therapeutic activity of Viekira Pak&#174;.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Rifapentine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Rifapentine is an inducer of CYP3A4 and P-gp and may decrease the exposure of ombitasvir/paritaprevir/ritonavir + dasabuvir. Monitor subjects for anticipated response.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Rifaximin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Rifaximin is an inducer of CYP3A4 and a substrate and inhibitor of P-gp. Rifamixin did not show a clinically significant interaction with midazolam, a model CYP3A4 substrate, but exposure was about 10-, 13-and 20-fold higher in patients with mild (Child-Pugh A), moderate (Child-Pugh B) and severe (Child-Pugh C) hepatic impairment, respectively, compared to healthy volunteers. Monitor subjects for an appropriate and expected response to rifamixin and ombitasvir/paritaprevir/ritonavir + dasabuvir. Note, caution should be exercised when rifamixin is administered to patients with severe hepatic impairment.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Rilmenidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as rilmenidine is not metabolised to any great extent.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Rilpivirine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration of rilpivirine and ombitasvir/paritaprevir/ritonavir + dasabuvir is not recommended unless the benefit outweighs the risk due to potential for QT interval prolongation with higher concentrations of rilpivirine. Rilpivirine is a substrate of CYP3A4 and its exposure increased significantly (~3-fold increase in AUC) when administered with ombitasvir/paritaprevir/ritonavir + dasabuvir. Coadministration should only be considered in patients without known QT-prolongation, and without other QT-prolongation co-medications. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Rilpivirine exposure is substantially increased (3-fold) when rilpivirine is given in combination, with a consequent potential for QT-prolongation. If an HIV protease inhibitor is added (atazanavir, darunavir), rilpivirine exposure may increase even further and is therefore not recommended. Co-administration with rilpivirine once daily should only be considered in patients without known QT-prolongation, and without other QT-prolongation co-medications. Rilpivirine should be used cautiously, in the setting of repeated ECG monitoring. Coadministration with rilpivirine (25 mg once daily administered in the morning, with food) increased rilpivirine Cmax, AUC and Cmin by 2.55-, 3.25- and 3.62-fold, respectively. Ombitasvir Cmax, AUC and Cmin increased by 11%, 9% and 5%, respectively. Paritaprevir Cmax and AUC increased by 30% and 23%, but Cmin decreased by 5%. Dasabuvir Cmax, AUC and Cmin increased by 18%, 17% and 10%, respectively. Rilpivirine was also administered in the evening with food and at night 4 hours after dinner in other two arms in the study. The effect on rilpivirine exposures was similar to that observed when rilpivirine was administered in the morning with food.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></div><div>&nbsp;</div><div>Coadministration with rilpivirine (25 mg once daily) was studied in 10 subjects. Ombitasvir Cmax, AUC and Cmin increased by 11%, 9% and 5%, respectively. Paritaprevir Cmax and AUC increased by 30% and 23%, but Cmin decreased by 5%. Ritonavir Cmax and AUC increased by 10% and 8%, but Cmin decreased by 3%. Dasabuvir Cmax, AUC and Cmin increased by 18%, 17% and 10%. Rilpivirine Cmax, AUC and Cmin increased by 2.55-, 3.25- and 3.62-fold, respectively. Similar increases were observed when rilpivirine was dosed in the evening with food or 4 hours after food. Co-administration with rilpivirine once daily is not recommended due to potential for QT interval prolongation with higher concentrations of rilpivirine.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Rimantadine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Rimantadine undergoes complex liver metabolism being both hydroxylated and glucuronidated. Although ombitasvir/paritaprevir/ritonavir + dasabuvir can affect some CYP and UGT pathways, due to multiple enzyme pathways involved in the metabolism of rimantadine, a clinically significant interaction is not expected.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Risedronate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. There is no evidence of systemic metabolism of risedronate; 60% of the dose is distributed to bone and the remainder is excreted in urine. However the absorption of risedronate may be affected by food, drinks (other than plain water) or other medicinal products. Risendronate should be taken at least 2 hours before and at least 2 hours after any food, medicinal product or drink.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Risperidone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Risperidone is a substrate and inhibitor of CYPs 2D6, 1A1, 1A2, 2C9, 2C19 and 3 A4. At 100 mg dose, ritonavir does not markedly inhibit CYP2D6. Ketoconazole, an inhibitor of CYP3A4, increased the AUC of risperidone and its metabolite by 66% and 48%, respectively. An interaction of similar magnitude is expected with ritonavir. Monitor the subjects. A decrease in risperidone dose may be needed.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ritonavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Ombitasvir/paritaprevir/ritonavir + dasabuvir is a complete regimen containing ritonavir. Coadministration with additional ritonavir is not recommended.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Rituximab</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is not expected as rituximab is removed by opsonization via the reticularendothelial system. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Rivaroxaban</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Rivaroxaban is a substrate of CYP3A4, P-gp and BCRP. Ritonavir increased rivaroxaban AUC and Cmax by 150% and 60%, respectively. Similar increases in pharmacodynamic effects (i.e., factor Xa inhibition and PT prolongation) were also observed. Significant increases in rivaroxaban exposure may increase bleeding risk. Rivoroxaban label recommends avoiding use with ritonavir. Use alternative if possible.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Rizatriptan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but rizatriptan can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Rizatriptan is metabolised by MAO.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ropinirole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Ropinirole is a substrate of CYP1A2. Exposure of ropinirole may be decreased with ombitasvir/paritaprevir/ritonavir + dasabuvir due to induction of CYP1A2 by ritonavir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Rosiglitazone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Rosiglitazone is metabolized by CYP2C8 and concentrations may be increased due to inhibition of CYP2C8 by ritonavir and ombitasvir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Rosuvastatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Rosuvastatin is a substrate of CYP2C9 and CYP3A4, and OATPs 1B1, 1B3 and 1A2. Coadministration increased rosuvastatin Cmax and AUC by 7.1- fold and 2.6-fold, respectively. The European product label recommends that the maximum daily dose of rosuvastatin should be 5 mg whereas the US product label advises that the dose of rosuvastatin should not exceed 10 mg per day.&nbsp;Note, rosuvastatin is contraindicated in patients with active liver disease and should be used with caution in patients who consume excessive quantities of alcohol and/or have a history of liver disease.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Coadministration with rosuvastatin (5 mg once daily) increased rosuvastatin Cmax and AUC by 7.13- and 2.59-fold, but Cmin decreased by 41% due to OATP1B inhibition by paritaprevir and BCRP inhibition by paritaprevir, ritonavir or dasabuvir. Ombitasvir Cmax, AUC and Cmin decreased by 8%, 11% and 12%, respectively. Paritaprevir Cmax, AUC and Cmin increased by 59%, 52% and 43%, respectively. Dasabuvir Cmax, AUC and Cmin increased by 7%, 8% and 15%, respectively. If rosuvastatin treatment is required during the treatment period, the maximum daily dose of rosuvastatin should be 5 mg.<br><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br>Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015</em>.</div>&nbsp;</div>

<div>Coadministration with rosuvastatin (5 mg once daily) was studied in 11 subjects. Ombitasvir Cmax, AUC and Cmin decreased by 8%, 11% and 12%, respectively. Paritaprevir Cmax, AUC and Cmin increased by 59%, 52% and 43%, respectively. Ritonavir Cmax decreased by 2%, AUC increased by 2% and there was no change in Cmin. Dasabuvir Cmax, AUC and Cmin increased by 7%, 8% and 15%, respectively. Rosuvastatin Cmax and AUC increased by 7.13- and 2.59-fold, but Cmin decreased by 41%. When VIEKIRA PAK is co-administered with rosuvastatin, the dose of rosuvastatin should not exceed 10 mg per day.</div>

<div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Rufinamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but would not be recommended unless the benefit outweighs the risk. Rufinamide is a moderate inducer of CYP3A4 and P-glycoprotein and may decrease exposures of components of the DAA regimen which may lead to loss of virologic response. It is difficult to predict the overall effect of CYP3A4 induction on DAA exposure in the presence of ritonavir, a CYP3A4 inhibitor.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Salbutamol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but salbutamol can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Salbutamol is metabolised by sulfotransferases.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Salmeterol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration is contraindicated in the European product label and not recommended in the US product label.  Salmeterol is a substrate of CYP3A4 and its exposure may increase due to CYP3A4 inhibition by ritonavir. This may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations and sinus tachycardia.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Concomitant use is contraindicated. Coadministration has not been studied but is expected to increase salmeterol concentrations due to inhibition of CYP3A4 by ritonavir. Medicinal products that are highly dependent on CYP3A for clearance and for which elevated plasma levels are associated with serious events, such as salmeterol, must not be co-administered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div>&nbsp;</div><div>Coadministration may increase concentrations of salmeterol. Concurrent administration is not recommended. The combination may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations and sinus tachycardia.&nbsp;</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Saquinavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration is contraindicated in the European product label. Coadministration has not been studied but concentrations of paritaprevir are expected to increase due to inhibition of CYP3A4 by saquinavir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Concomitant use is contraindicated. Coadministration has not been studied but is expected to increase paritaprevir concentrations due to inhibition of CYP3A4 by saquinavir. <br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Saxagliptin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Saxagliptin is a substrate of CYP3A4 and its exposure may increase due to CYP3A4 inhibition by ritonavir. The recommended dose of saxagliptin is 2.5 mg once daily when coadministered with strong CYP3A4 inhibitors such as ritonavir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Senna</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but senna can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Serenoa repens</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Co-administration has not been studied.  Serenoa repens has been shown to be a potent inhibitor of CYP3A4 in vitro but given the presence of ritonavir in this regimen it is unclear if there would be any additional increase in exposure of paritaprevir.  Coadministration should be avoided if possible.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Sertraline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Sertraline is a substrate of CYPs 2B6 (major), 2C9, 2C19, 3A4 and 2D6, and a possible substrate of UGT2B7. Ombitasvir/paritaprevir/ritonavir + dasabuvir has not shown an interaction with a CYP2B6 substrate (methadone). However sertraline exposure may increase due to CYP3A4 inhibition by ritonavir. Use with caution. Monitor the subjects. A dose reduction of sertraline may be required.&nbsp;Note, use with caution in patients with hepatic impairment when a lower or less frequent dose may be required. Sertraline should not be used in patients with severe hepatic impairment.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Sevelamer</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Sevelamer is not absorbed from the GI tract and may potentially affect the bioavailability of other medicinal products. In the absence of data, when administering any medicinal product where a reduction in the bioavailability could have a clinically significant effect on safety or efficacy, the medicinal product should be administered at least one hour before or three hours after sevelamer.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Sildenafil (erectile dysfunction)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Sildenafil is a substrate of CYP3A4 and its exposure may increase due to CYP3A4 inhibition by ritonavir resulting in increased potential for sildenafil-associated adverse events, including visual abnormalities, hypotension, prolonged erection, and syncope. Use sildenafil for the treatment of erectile dysfunction with caution at reduced doses of 25 mg every 48 hours with increased monitoring for adverse events. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Sildenafil (pulmonary arterial hypertension)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Concomitant use of sildenafil with ritonavir is contraindicated in pulmonary arterial hypertension (PAH) patients as a safe and effective dose has not been established. Sildenafil is a substrate of CYP3A4 and its exposure may increase due to CYP3A4 inhibition by ritonavir resulting in increased potential for sildenafil-associated adverse events, including visual abnormalities, hypotension, prolonged erection, and syncope. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Concomitant use is contraindicated. Coadministration has not been studied but is expected to increase sildenafil concentrations due to inhibition of CYP3A4 by ritonavir. Medicinal products that are highly dependent on CYP3A for clearance and for which elevated plasma levels are associated with serious events, such as sildenafil, must not be co-administered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></div><div>&nbsp;</div><div>Coadministration is contraindicated. There is increased potential for sildenafil-associated adverse events such as visual disturbances, hypotension, priapism, and syncope.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Simeprevir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Ombitasvir/paritaprevir/ritonavir + dasabuvir is a complete DAA regimen. There are no data to support the coadministration with other DAAs.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>The safety and efficacy of ombitasvir/paritaprevir/ritonavir have been  established in combination with dasabuvir and/or ribavirin.  Co-administration of ombitasvir/paritaprevir/ritonavir + dasabuvir with  other directly acting antivirals has not been studied and therefore  cannot be recommended.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Simeticone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but a clinically significant interaction with is unlikely as simeticone is not absorbed from the gastro-intestinal tract.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Simvastatin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration is contraindicated. Simvastatin exposure may increase due to OATP/CYP3A4 inhibition by paritaprevir and ritonavir causing potential for serious reactions such as risk of myopathy including rhabdomyolysis.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Concomitant use is contraindicated. Coadministration has not been studied but is expected to increase concentrations of simvastatin due to inhibition of CYP3A4 and OATP1B. Medicinal products that are highly dependent on CYP3A for clearance and for which elevated plasma levels are associated with serious events, such as simvastatin, must not be co-administered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div>&nbsp;</div><div>Coadministration is contraindicated due to the potential for myopathy including rhabdomyolysis.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Sirolimus</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Sirolimus is a substrate of CYP3A4 and its exposure may increase due to CYP3A4 inhibition by ritonavir. Therapeutic monitoring required. A dose decrease may be needed for sirolimus.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Sitagliptin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Sitagliptan can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir to subjects with normal renal function and no dose alteration is required since metabolism (including via CYP3A4), plays only a minor role in sitagliptin clearance. In severe renal impairment or end-stage renal disease (ESRD) metabolism is more important and it is possible that ritonavir could alter the pharmacokinetics of sitagliptin in such patients.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Sodium stibogluconate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as elimination of sodium stibogluconate is predominantly by renal glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Sofosbuvir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Ombitasvir/paritaprevir/ritonavir + dasabuvir is a complete DAA regimen. However, studies are ongoing with this regimen plus sofosbuvir in certain patient groups.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>(See Summary)</div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Sorafenib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Caution is advised as sorafenib is a substrate of CYP3A4 and although no interaction was observed with ketoconazole, coadministration with ombitasvir/paritaprevir/ritonavir + dasabuvir has not been studied. Sorafenib has been shown to prolong the QT/QTc interval which may lead to an increased risk of ventricular arrhythmias.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Sotalol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Sotalol is mainly excreted in urine and a pharmacokinetic interaction is not expected. If coadministered, no dose alteration of ombitasvir/paritaprevir/ritonavir + dasabuvir is needed.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Spectinomycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as spectinomycin is predominantly eliminated unchanged via the kidneys.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Spironolactone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but spironolactone can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Spironolactone is metabolised by hydrolysis and sulfoxidation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Stavudine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as stavudine is predominantly eliminated unchanged via the kidneys.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>St John&#39;s wort</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration is contraindicated. St John’s wort is an inducer of CYP3A4 and may decrease ombitasvir/paritaprevir/ritonavir + dasabuvir exposures leading to loss of virologic response and possible resistance to paritaprevir or to the class of protease inhibitors.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Concomitant use is contraindicated. Coadministration has not been studied but is expected to decrease concentrations of dasabuvir, ombitasvir and paritaprevir due to induction of CYP3A4 by St John&#8217;s wort. Co-administration with medicinal products that are strong or moderate enzyme inducers, such as St John&#8217;s wort, is expected to decrease ombitasvir, paritaprevir, and ritonavir plasma concentrations and reduce their therapeutic effect and must not be co-administered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015</em>.<br /><br /></div>Coadministration is contraindicated. Ombitasvir, paritaprevir, ritonavir and dasabuvir exposures may decrease leading to a potential loss of therapeutic activity of Viekira Pak&#174;.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Streptokinase</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied however based on the metabolism, elimination and toxicity profiles of both drugs there is little potential for interaction as streptokinase does not undergo CYP metabolism in the liver and is eliminated renally.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Streptomycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as streptomcyin is predominantly eliminated unchanged via the kidneys.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Strontium ranelate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as strontium is predominantly eliminated unchanged via the kidneys. However, food and milk can affect strontium absorption and administration should be separated by at least 2 hours.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Sulfadiazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Sulfadiazine is thought to be metabolised via CYP2C9. Ombitasvir/paritaprevir/ritonavir at steady-state did not affect the plasma exposures of warfarin so it is unlikely to affect sulfadiazine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Sulfadoxine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Sulfadoxine is thought to be metabolised via CYP2C9. Ombitasvir/paritaprevir/ritonavir at steady-state did not affect the plasma exposures of warfarin so it is unlikely to affect sulfadoxine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Sulfasalazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but is expected to increase sulfasalazine concentrations due to inhibition of BCRP by paritaprevir, ritonavir and dasabuvir. Caution should be used when sulfasalazine is co-administered. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration has not been studied but is expected to increase sulfasalazine concentrations due to inhibition of BCRP by paritaprevir, ritonavir and dasabuvir. Caution should be used when sulfasalazine is co-administered.<br /><em>Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Sulpiride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but sulpiride can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. In vitro studies show that there is no CYP involvement in metabolism of sulpiride and 15-12% of the dose is excreted in urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Sultiame</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Limited data suggest that sultiame is a substrate and inhibitor of CYP3A4. Concentrations of sultiame could be increased when coadministered with ritonavir but the clinical significance of this is uncertain. Monitor for signs and symptoms of increased sultiame concentrations. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Sumatriptan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but sumatriptan can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Sumatriptan is metabolised by MAO.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Sunitinib</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but may increase concentrations of sunitinib due to inhibition of CYP3A4 by paritaprevir and ritonavir, causing potential for serious and or life threatening events. Coadministration is not recommended unless the benefit outweighs the risk. Use with caution.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Tacrolimus</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Tacrolimus is a substrate of CYP3A4. Ombitasvir/paritaprevir/ritonavir + dasabuvir increased tacrolimus Cmax, AUC and Cmin by 4-fold, 57-fold and 16-fold, respectively. Therapeutic monitoring is required. To maintain Ctrough in the therapeutic range, administer 0.5 mg/week when coadministered with ombitasvir/paritaprevir/ritonavir + dasabuvir. Monitor tacrolimus levels and adjust dose and/or dosing frequency as needed. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Coadministration increased tacrolimus Cmax, AUC and Cmin by 3.99-, 57.1- and 16.6-fold (tacrolimus 2 mg dosed alone, 2 mg coadministered; dose normalized tacrolimus ratios are shown). Ombitasvir Cmax, AUC and Cmin decreased by 7%, 6% and 6%, respectively. Paritaprevir Cmax, AUC and Cmin decreased by 43%, 34% and 27%, respectively. Dasabuvir Cmax and AUC decreased by 15% and 10%, but Cmin increased by 1%. The effect on tacrolimus is due to CYP3A4 inhibition by ritonavir. When starting co-administration, administer 0.5 mg tacrolimus once every week. Monitor tacrolimus levels and adjust dose and/or dosing frequency as needed.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em><br /></div><div>&nbsp;</div><div>Coadministration with tacrolimus (2 mg single dose) was studied in 12 subjects. Ombitasvir Cmax, AUC and Cmin decreased by 7%, 6% and 6%, respectively. Paritaprevir Cmax, AUC and Cmin decreased by 43%, 34% and 27%, respectively. Ritonavir Cmax and AUC decreased by 24% and 13%, but Cmin increased by 3%. Dasabuvir Cmax and AUC decreased by 15% and 10%, but Cmin increased by 1%. Tacrolimus Cmax, AUC and Cmin increased by 3.99-, 57.1- and 16.56-fold, respectively. When initiating therapy with Viekira Pak&#174;, the dose of tacrolimus needs to be reduced. &nbsp;Do not administer tacrolimus on the day Viekira Pak&#174; is initiated. Beginning the day after Viekira Pak&#174; is initiated; reinitiate tacrolimus at a reduced dose based on tacrolimus blood concentrations. &nbsp;Typical tacrolimus dosing is 0.5 mg every 7 days. Measure tacrolimus blood concentrations and adjust dose or dosing frequency to determine subsequent dose modifications. &nbsp;Upon completion of Viekira Pak&#174; therapy, the appropriate time to resume pre-therapy dose of tacrolimus should be guided by assessment of tacrolimus blood concentrations. Frequent assessment of renal function and tacrolimus related side effects is recommended.</div></div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Tadalafil (erectile dysfunction)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Tadalafil is a substrate of CYP3A4 and its exposure may increase due to CYP3A4 inhibition by ritonavir. Use tadalafil for erectile dysfunction with caution at reduced doses of no more than 10 mg every 72 hours with increased monitoring for adverse events. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Tadalafil (pulmonary arterial hypertension)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Tadalafil is a substrate of CYP3A4 and its exposure may increase due to CYP3A4 inhibition by ritonavir. When tadalafil is administered to patients with pulmonary arterial hypertension who are receiving ritonavir, refer to the tadalafil label for dosing information.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Tamoxifen</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but may potentially reduce the efficacy of tamoxifen as inhibition of CYP3A4 by ritonavir may reduce the amount of drug converted to endoxifen (a pharmacologically active metabolite). Tamoxifen metabolism occurs mostly via two pathways: the formation of N-desmethyltamoxifen (via mainly CYP3A4 and CYP3A5) is the main route (92%) and the formation of 4-hydroxytamoxifen (via CYP2D6 > 2C9/19, CYP3A4 and CYP2B6) is a minor route (7%). Further metabolism of both metabolites results in the formation of endoxifen which is thought to be the most important metabolite contributing to the pharmacologic activity of tamoxifen. Endoxifen is formed from N-desmethyltamoxifen via CYP2D6 and from 4-hydroxytamoxifen via CYP3A4.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Tamsulosin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Tamsulosin is a substrate of CYP3A4. Exposure of tamsulosin increases (2.2- to 2.8-fold) with ketoconazole, a CYP3A4 inhibitor. An interaction of similar magnitude is expected with ritonavir. Avoid use if possible. Use alternative.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Tazobactam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Tazobactam is only minimally metabolised and is eliminated primarily by renal excretion.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Telaprevir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Ombitasvir/paritaprevir/ritonavir + dasabuvir is a complete DAA regimen. There are no data to support the coadministration with other DAAs.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>The safety and efficacy of ombitasvir/paritaprevir/ritonavir have been  established in combination with dasabuvir and/or ribavirin.  Co-administration of ombitasvir/paritaprevir/ritonavir + dasabuvir with  other directly acting antivirals has not been studied and therefore  cannot be recommended.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Telbivudine </p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as telbivudine is predominantly eliminated unchanged via the kidneys.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Telithromycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration is contraindicated in the European product label. Coadministration has not been studied. Telithromycin is an inhibitor of CYP3A4, OAT1B1 and OAT1B3. Exposure of telithromycin and ombitasvir/paritaprevir/ritonavir + dasabuvir may increase due to CYP3A4 involvement. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Concomitant use is contraindicated. Coadministration has not been studied but is expected to increase concentrations of telithromycin, paritaprevir and dasabuvir due to inhibition of CYP3A4 and P-gp by ritonavir. Co-administration with medicinal products that are strong inhibitors of CYP3A4, such as telithromycin, is expected to increase paritaprevir plasma concentrations and must not be co-administered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Telmisartan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Telmisartan is a substrate of OATP1B1/3. Telmisartan exposure may increase due to inhibition of OATP1B3 by paritaprevir. Consider dose reduction and monitor blood pressure and heart rate.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Temazepam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Temazepam is metabolised by glucuronidation and sulfation. However UGT1A1 is not considered a major enzyme involved and an interaction is not considered likely.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Temocillin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as temocillin is excreted unchanged in the urine.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Tenofovir-DF</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Tenofovir can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. There was no significant interaction seen in clinical studies. Coadministration with emtricitabine/tenofovir (200/300 mg once daily) increased tenofovir Cmax, AUC and Cmin by 7%, 13% and 24%, respectively. Ombitasvir Cmax, AUC and Cmin decreased by 11%, 1% and 3%, respectively. Paritaprevir Cmax and AUC decreased by 32% and 16%, but Cmin increased by 6%. Dasabuvir Cmax, AUC and Cmin all decreased by 15%.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Coadministration with emtricitabine/tenofovir (200/300 mg once daily) increased emtricitabine Cmax, AUC and Cmin by 5%, 7% and 9%; the Cmax, AUC and Cmin of tenofovir increased by 7%, 13% and 24%, respectively. Ombitasvir Cmax, AUC and Cmin decreased by 11%, 1% and 3%, respectively. Paritaprevir Cmax and AUC decreased by 32% and 16%, but Cmin increased by 6%. Dasabuvir Cmax, AUC and Cmin all decreased by 15%. No dose adjustment is necessary.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div>&nbsp;</div><div>No dose adjustments are recommended when ombitasvir, paritaprevir, ritonavir and dasabuvir are co-administered with tenofovir.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Tenofovir-DF (HBV)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Tenofovir can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. There was no significant interaction seen in clinical studies. Coadministration with emtricitabine/tenofovir (200/300 mg once daily) increased tenofovir Cmax, AUC and Cmin by 7%, 13% and 24%, respectively. Ombitasvir Cmax, AUC and Cmin decreased by 11%, 1% and 3%, respectively. Paritaprevir Cmax and AUC decreased by 32% and 16%, but Cmin increased by 6%. Dasabuvir Cmax, AUC and Cmin all decreased by 15%.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration with emtricitabine/tenofovir (200/300 mg once daily) increased emtricitabine Cmax, AUC and Cmin by 5%, 7% and 9%; the Cmax, AUC and Cmin of tenofovir increased by 7%, 13% and 24%, respectively. Ombitasvir Cmax, AUC and Cmin decreased by 11%, 1% and 3%, respectively. Paritaprevir Cmax and AUC decreased by 32% and 16%, but Cmin increased by 6%. Dasabuvir Cmax, AUC and Cmin all decreased by 15%. No dose adjustment is necessary.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div><div>&nbsp;</div><div><div><div>No dose adjustments are recommended when ombitasvir, paritaprevir, ritonavir and dasabuvir are co-administered with tenofovir.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em>&nbsp;</div></div></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Terbinafine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but terbinafine can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Terbinafine is metabolized by at least seven CYPs and the potential for interaction with other drugs is predicted to be insignificant.&nbsp;Note, terbinafine in patients with chronic or active liver disease has not been studied in prospective clinical trials&nbsp;and therefore can not be recommended for such patients.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Terfenadine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration is contraindicated in the European product label. Terfenadine exposure may increase due to CYP3A4 inhibition by ritonavir causing increased risk of serious or life-threatening effects such as cardiotoxicity (cardiac arrhythmias), breathing difficulties, or excessive sleepiness.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Concomitant use is contraindicated. Coadministration has not been studied but is expected to increase terfenadine concentrations due to inhibition of CYP3A4 by ritonavir. Medicinal products that are highly dependent on CYP3A for clearance and for which elevated plasma levels are associated with serious events, such as terfenadine, must not be co-administered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Tetracyclines</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tetracyclines are predominantly eliminated unchanged via the kidneys</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Thalidomide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as thalidomide is cleared by non-enzymatic pathways of hydrolysis.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Theophylline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Theophylline is a substrate of CYP1A2 and exposure may be reduced with ombitasvir/paritaprevir/ritonavir + dasabuvir due to induction of CYP1A2 by ritonavir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Thiamine (Vitamin B1)</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as thiamine is predominantly eliminated unchanged via the kidneys.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Thiopental</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. The isoenzymes involved in thiopental metabolism have not been identified but data from animal studies suggest that enzyme inducers or inhibitors do not modify the duration of surgical anaesthesia or sleep time.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Thioridazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but thioridazine can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Thioridazine is substrate of CYP2D6 and P-gp. At 100 mg dose, ritonavir does not markedly inhibit CYP2D6 and there was no interaction with digoxin, a model P-gp substrate. It is unlikely that ombitasvir/paritaprevir/ritonavir + dasabuvir will interact with thioridazine although as it causes significant QT prolongation use lowest dose possible.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Tiagabine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but may increase tiagabine concentrations due to inhibition of CYP3A4 by ritonavir. Monitor for increased side effects and toxicities. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Tianeptine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tianeptine is predominantly metabolised by beta-oxidation and N-demethylation.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Tiapride</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tiapride is predominantly eliminated unchanged via the kidneys. However tiapride prolongs the QT interval and should be used with caution in combination with other drugs that could alter its exposure.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ticagrelor</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration is contraindicated. Ritonavir is a potent CYP3A4 inhibitor and data with ketoconazole (a CYP3A4 inhibitor) indicate a clinically significant increase in Cmax and AUC of ticagrelor and its active metabolite leading to potentially dangerous increases in exposure and bleeding risk.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ticarcillin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant drug interaction is unlikely. Ticarcillin is eliminated by the kidney and excreted largely unchanged in the urine.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ticlopidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Ticlopidine is a prodrug and is converted to its active metabolite by CYPs 3A4, 2B6 and 2C19. The effect on activation of ticlopidine to its active metabolite is difficult to predict due to induction of CYP2C19 and CYP2B6 and inhibition of CYP3A4 by ritonavir but may decrease exposure of the active metabolite leading to non-responsiveness to ticlopidine. Monitor the subject. An adjustment in ticlopidine dose may be needed.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Timolol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but timolol can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Timolol is a substrate of CYP2D6, and a 100 mg dose ritonavir does not markedly inhibit CYP2D6. Note,&nbsp;the European SPC and the US Prescribing Information mention that timolol should be used at a reduced dose in hepatic impairment.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Tinzaparin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Tinzaparin is partially metabolized by desulphation and depolymerization, and then renally excreted.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Tiotropium</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but tiotropium can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Tiotropium is metabolized by multiple pathways (including CYP2D6 and CYP3A4) and ~74% is excreted unchanged in the urine. Ritonavir at a 100 mg dose does not markedly inhibit CYP2D6 and any effect due to inhibition of CYP3A4 is unlikely to be of clinically significance.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Tipranavir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration is contraindicated in the European product label. Coadministration has not been studied but tipranavir could cause a marked change in the exposure of ombitasvir/paritaprevir/ritonavir + dasabuvir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Concomitant use is contraindicated. Coadministration has not been studied but is expected to increase paritaprevir concentrations due to inhibition of CYP3A4 by tipranavir. <br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Tizanidine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Tizanidine is metabolised via CYP1A2 and exposure may be reduced with ombitasvir/paritaprevir/ritonavir + dasabuvir due to induction of CYP1A2 by ritonavir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Tolbutamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but tolbutamide can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. There was no interaction between ombitasvir/paritaprevir/ritonavir + dasabuvir and warfarin, a CYP2C9 substrate, so no interaction is expected with tolbutamide.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Tolterodine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Tolterodine is metabolised by CYP2D6 or by CYP3A4 in individuals who are CYP2D6 poor metabolisers.  In such subjects, coadministration may increase tolterodine concentrations due to inhibition of CYP3A4 by ritonavir. The European SPC for tolterodine advises that coadministration with potent CYP3A4 inhibitors should be avoided whereas the US Prescribing Information recommends a maximum tolterodine dose of 1 mg twice daily.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Topiramate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Topiramate is mainly eliminated by renal elimination in unchanged form (up to 60% of the dose) and partly by oxidation. Weak induction of CYP isozymes has been observed with higher doses of topiramate but this is not considered to be of clinical relevance with ritonavir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Torasemide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but torasemide can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alternation is required. Torasemide is metabolized by CYP2C8 and CYP2C9. There is no interaction between ombitasvir/paritaprevir/ritonavir + dasabuvir and warfarin, a CYP2C9 substrate, so no interaction is expected due to CYP2C9 involvement.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Tramadol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Tramadol is a substrate of CYP3A4 and CYP2D6 and its exposure may increase due to CYP3A4 inhibition by ritonavir. If tramadol is used with ombitasvir/paritaprevir/ritonavir + dasabuvir, the combination should be used with caution and a lower dose of tramadol should be considered.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Trandolapril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but trandolapril can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Trandolapril is metabolised by esterases to trandolaprilat and then by glucuronidation.&nbsp;Note, dose modification may be required in patients with hepatic impairment.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Tranexamic Acid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as tranexamic acid is mainly cleared by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Trazodone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Trazodone is a substrate of CYP3A4 and its exposure may increase due to CYP3A4 inhibition by ritonavir. The effect of short-term administration of ritonavir (200 mg twice daily, 4 doses) on the pharmacokinetics of a single dose of trazodone (50 mg) increased trazodone Cmax, AUC and half-life by 34%, 2.4-fold, and 2.2-fold, respectively; clearance decreased by 52%. Use with caution and monitor the subject. A significant decrease in trazodone dose may be needed.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration has not been studied but is expected to increase trazodone concentrations due to inhibition of CYP3A4 by ritonavir. Trazodone should be used with caution and a lower dose of trazodone may be considered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Triamcinolone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Concomitant administration of ritonavir and corticosteroids not recommended unless the potential benefit of treatment outweighs the risk of systemic corticosteroid effects. Cushing's syndrome and adrenal suppression have been reported when ritonavir has been co-administered with triamcinolone. Triamcinolone is a substrate of CYP3A4 and its exposure may increase due to CYP3A4 inhibition by ritonavir causing a decrease in plasma cortisol leading to Cushing's syndrome and adrenal suppression. Use beclometasone as an alternative.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Triazolam</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration is contraindicated. Triazolam exposure may increase due to CYP3A4 inhibition by ritonavir causing the potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Concomitant use is contraindicated. Coadministration has not been studied but is expected to increase triazolam concentrations due to inhibition of CYP3A4 by ritonavir. Medicinal products that are highly dependent on CYP3A for clearance and for which elevated plasma levels are associated with serious events, such as triazolam, must not be co-administered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></div><div>&nbsp;</div><div>Coadministration is contraindicated. Triazolam is extensively metabolized by CYP3A4. Coadministration may cause large increases in the concentration of this benzodiazepine. The potential exists for serious and/or life threatening events such as prolonged or increased sedation or respiratory depression.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Trifluoperazine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied and there are limited data on the metabolism of trifluoperazine, though animal studies have shown little affinity for CYP enzymes. In the absence of further data, monitor for increased side effects of all drugs. In addition, there is the risk of QT prolongation with the combination and ECG monitoring is recommended if coadministered. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Trimebutine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Trimbutine does not appear to be metabolised by CYP enzymes and there are no data on involvement of transporters.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Trimethoprim/ Sulfamethoxazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Trimethoprim is mainly excreted in urine (40-60%) with some evidence that it may be a substrate and inhibitor of CYP2C8. There is a theoretical risk of an interaction with dasabuvir due to CYP2C8 involvement. Although this is unlikely to be clinically relevant, monitoring the subjects is recommended. No interaction is expected with sulphamethoxazole since it is mainly excreted in urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Trimipramine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but trimipramine can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Trimipramine is a substrate of CYP2D6, and at a 100 mg dose ritonavir does not markedly inhibit CYP2D6. Note, the European SPC for trimipramine contraindicates&nbsp;its use&nbsp;in severe liver disease;&nbsp;the US Prescribing Information recommends caution in impaired liver function.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Troglitazone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Troglitazone is a substrate of CYPs 2C8 and 2C9.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Troleandomycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Troleandomycin is an inhibitor of CYP3A4 and OATP1B1 and OATP1B3. Exposure of troleandomycin and ombitasvir/paritaprevir/ritonavir + dasabuvir may increase due to CYP3A4 involvement. Monitor the subjects. A dose decrease in troleandomycin should be considered.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ursodeoxycholic acid</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>A clinically significant interaction was not seen between ursodeoxycholic acid and ombitasvir/paritaprevir/ritonavir + dasabuvir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Valaciclovir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but valaciclovir can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Valaciclovir is eliminated renally (as aciclovir) by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Valerian</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as valerian has no significant effect on CYP enzymes. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Valproate</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Valproate is metabolised by multiple UGTs with minor involvement of CYP enzymes. No a priori dose adjustment is required with ombitasvir/paritaprevir/ritonavir + dasabuvir. Perform therapeutic drug monitoring and adjust if required.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Valsartan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Valsartan is a substrate of OATP1B1. Valsartan exposure may increase when administered with ombitasvir/paritaprevir/ritonavir + dasabuvir due to OATP1B1 inhibition by paritaprevir. Consider dose reduction and monitor blood pressure and heart rate.&nbsp;Note, the European SPC for valsartan states a maximum dose of 80 mg in mild to moderate hepatic impairment, but the US Prescribing Information states no dosage requirement in this level of impairment.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration has not been studied but is expected to increase valsartan concentrations due to inhibition of OATP1B by paritaprevir. Clinical monitoring and dose reduction is recommended when coadministered.<br><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Vancomycin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but vancomycin can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Vancomycin is mainly excreted in urine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Vardenafil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Vardenafil is a substrate of CYP3A4 and its exposures may increase with ombitasvir/paritaprevir/ritonavir + dasabuvir due to CYP3A4 inhibition by ritonavir. This may result in an increase in PDE5 inhibitor associated adverse events, including hypotension, syncope, visual changes, and prolonged erection. Use vardenafil with caution at reduced doses of no more than 2.5 mg every 72 hours with increased monitoring for adverse events.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Varenicline</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as varenicline is predominantly eliminated unchanged via the kidneys.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Velpatasvir/Sofosbuvir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>The safety and efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir have been established in combination with ribavirin. Coadministration with other directly acting antivirals has not been studied and therefore cannot be recommended.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Venlafaxine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Venlafaxine is a substrate of CYP2D6, CYP3A4 and P-gp. Ketoconazole, an inhibitor of CYP3A4/P-gp, increased exposure of venlafaxine and its metabolite by 20-141%. A similar magnitude of increase may be seen due to CYP3A4 inhibition by ritonavir when administered with ombitasvir/paritaprevir/ritonavir + dasabuvir. Monitor the subjects. A decrease in venlafaxine dose may be needed.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Verapamil</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Verapamil is a substrate of CYP3A4 and its exposure may increase due to CYP3A4 inhibition by ritonavir. Concentrations of paritaprevir may increase, but the efffect on dasabuvir is unclear (no change or concentrations may increase). Use with caution due to the expected increase in paritaprevir exposures. Monitor the subjects. Start with the lowest possible dose. Clinical monitoring of calcium channel blockers is recommended when co-administered.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div>Coadministration has not been studied but is expected to increase concentrations of verapamil and paritaprevir due to inhibition of CYP3A4 and P-gp, and may increase (or have no effect on) concentrations of dasabuvir. Caution is advised due to the expected increase in paritaprevir exposures. Dose decrease and clinical monitoring of calcium channel blockers is recommended when co-administered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Vernakalant</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Vernakalant is metabolised by CYP2D6 and UGTs. Although at a 100 mg dose ritonavir does not markedly inhibit CYP2D6 caution is recommended since glucuronidation can also be inhibited by ombitasvir/paritaprevir/ritonavir + dasabuvir and currently it is not clear which isozymes are involved. Given the potential risk of QT prolongation with vernakalant, caution is advised.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Vigabatrin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but a clinically significant interaction is unlikely as vigabatrin is not metabolised and is cleared mainly by glomerular filtration.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Vildagliptin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but vildagliptin can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. Vildagliptin is metabolised by hydrolysis and is a substrate of P-gp. There are no in vivo interactions between vildagliptin and CYP3A4, CYP2C9 and CYP2C8 substrates. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Vinblastine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Vinblastine is a substrate of CYP3A4 and its exposure may increase when administered with ombitasvir/paritaprevir/ritonavir + dasabuvir due to CYP3A4 inhibition by ritonavir resulting in the potential for increased adverse events usually associated with vinblastine. Carefully monitor the subjects. Consideration should be given to temporarily withholding the ritonavir containing regimen in patients who develop significant haematologic or gastrointestinal side effects when ritonavir is administered concurrently with vinblastine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Vincristine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Vincristine is a substrate of CYP3A4 and its exposure may increase when administered with ombitasvir/paritaprevir/ritonavir + dasabuvir due to CYP3A4 inhibition by ritonavir resulting in the potential for increased adverse events usually associated with vincristine. Carefully monitor the subjects. Consideration should be given to temporarily withholding the ritonavir containing regimen in patients who develop significant hematologic or gastrointestinal side effects when ritonavir is administered concurrently with vincristine.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Vinorelbine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Vinorelbine is metabolised by CYP3A4 and concentrations may increase due to inhibition of CYP3A4 by ritonavir. Use with extreme caution and monitor closely for toxicity as increased concentrations may increase the risk and severity of autonomic and peripheral neuropathy, and myelosuppression.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Vitamin E</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as vitamin E is minimally metabolised by the liver.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header red">
               Do Not Coadminister
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Voriconazole</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Voriconazole is a substrate and inhibitor of CYP2C19 and CYP3A4. Ritonavir alone decreased voriconazole Cmax and AUC by 24% and 39%, respectively which may lead to loss of antifungal response. Concentrations of dasabuvir and paritaprevir are expected to increase. Coadministration is contraindicated in the European product label but the US product label advises that coadministration is not recommended unless the benefit-to-risk ratio justifies the use of voriconazole. These interaction charts reflect the more cautious option.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Concomitant use is contraindicated. Coadministration has not been studied but in CYP2C19 extensive metabolisers it is expected to decrease voriconazole concentrations and increase concentrations of paritaprevir and dasabuvir. In CYP2C19 poor metabolisers, coadministration is expected to increase concentrations of voriconazole, dasabuvir and paritaprevir. This is due to induction of CYP2C19 and inhibition of CYP3A4 by ritonavir. Co-administration with medicinal products that are strong inhibitors of CYP3A4, such as voriconazole, is expected to increase paritaprevir plasma concentrations and must not be co-administered.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div>&nbsp;</div><div>Coadministration may decrease concentrations of voriconazole. Co-administration with voriconazole is not recommended unless an assessment of the benefit-to-risk ratio justifies the use of voriconazole.&nbsp;</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Vortioxetine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance, a clinically significant interaction is unlikely. Vortioexetine is primarily metabolised by CYP2D6, with minor involvement from CYP3A4. Ritonavir inhibits CYP2D6 at higher doses but at the 100 mg dose it does not appear to markedly inhibit CYP2D6.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Warfarin</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Ombitasvir/paritaprevir/ritonavir + dasabuvir and warfarin can be coadministered with close monitoring of international normalized ratio (INR). Warfarin is a substrate of CYP2C9 and CYP1A2. Ombitasvir/paritaprevir/ritonavir had no significant effect on the plasma exposures of S-warfarin or R-warfarin. Coadministration with warfarin (5 mg single dose) increased R-warfarin Cmax by 5%, but decreased AUC and Cmin by 12% and 6%; the Cmax, AUC and Cmin of S-warfarin decreased by 4%, 12% and 5%, respectively. Ombitasvir Cmax, AUC and Cmin decreased by 6%, 4% and 2%. Paritaprevir Cmax and Cmin decreased by 2% and 4%, but AUC increased by 7%. Dasabuvir Cmax and AUC decreased by 3% and 2%, but Cmin increased by 3%.&nbsp;However, a case report describes a patient's international normalized ratio (INR) becoming subtherapeutic two weeks after starting ombitasvir/paritaprevir/ritonavir + dasabuvir with ribavirin. Close monitoring is recommended as dose modifications may be necessary in some patients.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>Coadministration with warfarin (5 mg single dose) increased R-warfarin Cmax by 5%, but decreased AUC and Cmin by 12% and 6%; the Cmax, AUC and Cmin of S-warfarin decreased by 4%, 12% and 5%, respectively. Ombitasvir Cmax, AUC and Cmin decreased by 6%, 4% and 2%. Paritaprevir Cmax and Cmin decreased by 2% and 4%, but AUC increased by 7%. Dasabuvir Cmax and AUC decreased by 3% and 2%, but Cmin increased by 3%. While no dose adjustment is necessary for warfarin, appropriate monitoring of international normalised ratio (INR) is recommended.<br><em class="redactor-inline-converted">Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br>Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></p>

<p><br></p>





<p>No dose adjustments are recommended when ombitasvir, paritaprevir, ritonavir and dasabuvir are co-administered with warfarin.<br><em class="redactor-inline-converted">Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></p>







<p><br></p>





<p>A case report describes a patient's international normalized ratio (INR) becoming subtherapeutic two weeks after starting ombitasvir/paritaprevir/ritonavir + dasabuvir with ribavirin, Eleven weeks into therapy and following a 125% total increase in the weekly warfarin dose, therapeutic INR was achieved. Thirteen days after DAA therapy was completed and discontinued, the patient's INR became critically supratherapeutic. The INR should be monitored closely upon initiation and discontinuation of therapy.<br><em>Paritaprevir/ritonavir/ombitasvir+dasabuvir plus ribavirin therapy and inhibition of the anticoagulant effect of warfarin: a case report. Puglisi GM, Smith SM, Jankovich RD et al. J Clin Pharm Ther. 2016, [Epub ahead of print].</em></p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Xipamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Xipamide is 50% excreted unchanged but is a substrate of UGT and its exposure may increase due to UGT inhibition by ombitasvir/paritaprevir/ritonavir + dasabuvir. Monitor the subjects and adjust dose if required.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Zaleplon</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but may increase zaleplon concentrations due to inhibition of CYP3A4 by ritonavir. Monitor for increased sedation and consider a dose reduction if clinically indicated.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Zanamivir</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on the metabolism and clearance a clinically significant drug interaction is unlikely. Zanamivir is not extensively metabolised and only a small amount of the orally inhaled drug is systematically absorbed. Absorbed zanamivir is excreted unchanged in the urine whereas unabsorbed zanamivir is excreted in the faeces.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Zidovudine</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as zidovudine is metabolised by UGT 2B7 and 1A9 which are not known to be affected by ombitasvir/paritaprevir/ritonavir + dasabuvir.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Ziprasidone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Ziprasidone is a substrate of CYP3A4 and CYP1A2 and its exposure may increase when administered with ombitasvir/paritaprevir/ritonavir + dasabuvir due to CYP3A4 inhibition by ritonavir. Ketoconazole, a CYP3A4 inhibitor, increased ziprasidone exposure by 35-40%. Monitor the subjects. A decrease in ziprasidone dose may be needed.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Zofenopril</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied but based on metabolism and clearance a clinically significant pharmacokinetic interaction is unlikely. Zofenopril is a prodrug metabolised in the liver by a non-CYP mechanism to zofenoprilat, the active metabolite.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Zolmitriptan</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Zolmitripan is a substrate of CYP1A2. Zolmitriptan exposure may be reduced with ombitasvir/paritaprevir/ritonavir + dasabuvir due to induction of CYP1A2 by ritonavir. Monitor the patient and dose modify if required.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Zolpidem</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration with zolpidem (5 mg single dose) had no significant effect on exposures of zolpidem (Cmax and AUC decreased by 6% and 5%) nor on ombitasvir, paritaprevir or dasabuvir. Zolpidem can be administered with ombitasvir/paritaprevir/ritonavir + dasabuvir and no dose alteration is required. </span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><div><div>Coadministration with zolpidem (5 mg single dose) decreased zolpidem Cmax and AUC by 6% and 5%. Ombitasvir Cmax, AUC and Cmin increased by 7%, 3% and 4%, respectively. Paritaprevir Cmax and AUC decreased by 37% and 32%, but Cmin increased by 23%. Dasabuvir Cmax, AUC and Cmin decreased by 7%, 5% and 8%, respectively. No dose adjustments are necessary.<br /><em>Viekirax Summary of Product Characteristics, AbbVie Ltd, January 2015.<br />Exviera Summary of Product Characteristics, AbbVie Ltd, January 2015.</em></div>&nbsp;</div><div>No dose adjustments are recommended when ombitasvir, paritaprevir, ritonavir and dasabuvir are co-administered with zolpidem.</div><div><em>Viekira Pak US Prescribing Information, AbbVie, December 2014.</em></div></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header green">
               No Interaction Expected
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Zonisamide</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely as zonisamide is a weak P-gp inhibitor and any clinical significance is unclear.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Zopiclone</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span><p>Coadministration has not been studied. Zopiclone is a substrate of CYP3A4 and its exposure increased by 80% with erythromycin, a moderate CYP3A4 inhibitor. A greater magnitude of interaction is expected with ritonavir, a strong CYP3A4 inhibitor. Coadministration of eszopiclone (its structural analogue) with ketoconazole (a CYP3A4 inhibitor) increased eszopiclone exposure by 2.2-fold. Monitor the subjects. Start with a lowest possible dose of zopiclone.&nbsp;Note,&nbsp;elimination of zopiclone may be reduced in patients with hepatic dysfunction and&nbsp;a lower dose of zopiclone nightly is recommended for these patients.&nbsp;Zopiclone is contraindicated in patients with severe hepatic insufficiency.</p></span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span><p>(See Summary)</p></span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


        <div class="interaction-table-modal">

          <div class="interaction-block interaction-list">
            <p class="interaction-block-header orange">
               Potential Interaction
             </p>
                  

            <div class="interaction-block-inner">
              <p>OBV/PTV/r + DSV</p>
              <p>Zuclopentixol</p>
            </div>

            <div class="interaction-block-footer">
              <div class="interaction-info-block">
                <p>
                </p>
                <div class="interaction-info-divide">
                  <p>
                    <strong>Summary:</strong>
                    <div class="interaction-info-divide">
                      <span>Coadministration has not been studied. Zuclopenthixol exposure may increase due to CYP3A4 inhibition by ritonavir and UGT inhibition by ombitasvir/paritaprevir/ritonavir + dasabuvir. Zuclopenthixol is a substrate of CYP2D6, CYP3A4 and UGT, but the relative contribution of each metabolic pathway is unknown. Monitor the subjects. Start with a lowest possible dose of zuclopenthixol.</span>
                    </div>
                  </p>
                </div>
                <p>
                  <strong>Description:</strong>
                  <div class="interaction-info-divide">
                    <span>(See Summary)</span>
                  </div>
                </p>
              </div>
            </div>

          </div>

        </div>


    </div>

  </div>

</div>

    <div class='commercial sponsors' id='sponsors'>
<div class='inner-wrapper'>
<div class='sponsors-title'>
SPONSORS
</div>
<a target="_blank" href="http://www.janssen-emea.com/"><img src="https://liverpool-web-production.s3.amazonaws.com/sponsors/images/000/000/011/tiny/sponsor-logo-janssen.png?1456406819" alt="Sponsor logo janssen" />
</a><a target="_blank" href="http://www.gilead.com/"><img src="https://liverpool-web-production.s3.amazonaws.com/sponsors/images/000/000/012/tiny/sponsor-logo-gilead.png?1456406901" alt="Sponsor logo gilead" />
</a><a target="_blank" href="http://www.merck.com/"><img src="https://liverpool-web-production.s3.amazonaws.com/sponsors/images/000/000/013/tiny/sponsor-logo-msd.png?1456406928" alt="Sponsor logo msd" />
</a><a target="_blank" href="http://www.bms.com/"><img src="https://liverpool-web-production.s3.amazonaws.com/sponsors/images/000/000/014/tiny/sponsor-logo-bristol-myers-squibb.png?1456406964" alt="Sponsor logo bristol myers squibb" />
</a><a target="_blank" href="http://www.abbvie.com/"><img src="https://liverpool-web-production.s3.amazonaws.com/sponsors/images/000/000/016/tiny/sponsor-logo-abbvie.png?1456407013" alt="Sponsor logo abbvie" />
</a></div>
</div>

<div class='editorial sponsors' id='sponsors'>
<div class='inner-wrapper'>
<div class='sponsors-title'>
EDITORIAL SPONSORS
</div>
<a target="_blank" href="http://www.easl.eu/"><img src="https://liverpool-web-production.s3.amazonaws.com/sponsors/images/000/000/017/tiny/EASL_logo_2015.jpg?1456407065" alt="Easl logo 2015" />
</a></div>
</div>


    <div class="footer">
  <div class="inner-wrapper">
    <div class="footer-left-column">
      <div class="footer-links">
        <a href="http://www.hep-druginteractions.org/cookie-policy">Cookie Policy</a>
        <a href="http://www.hep-druginteractions.org/privacy">Privacy Statement</a>
        <a href="http://www.hep-druginteractions.org/terms">Terms &amp; Conditions</a>
      </div>
        <p>Last Review: January 25, 2017</p>

      <p>Copyright © 2017 The University of Liverpool. All rights reserved.</p>
      <p>Designed and developed by the team at <a target="_blank" href="http://podmedics.org">Podmedics</a></p>
    </div>

    <div class="footer-right-column">

      <a href="https://www.liverpool.ac.uk/" target="_blank" class="footer-liverpool-logo"></a>

    </div>
  </div>
</div>

  </body>
  
</html>
